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Abstract 
   
 Milling has been the key unit operation in controlling particle size of 
pharmaceutical powders at scale. The work carried out in this thesis is a 
comprehensive study of the stability of pharmaceutical solids post-milling and upon 
storage, from molecular level up to bulk handling scale. It is an attempt to fill key 
gaps in knowledge with regard to the anomalous behaviour and physical instability of 
milled powder through the development of advanced novel techniques. 
 
The physical instability of milled or amorphous pharmaceutical powders often 
manifest in changes in derived powder properties. Moisture induced dimensional 
changes of amorphous lactose compacts were monitored by in-situ environmental 
controlled optical profilometry. The complex volumetric behaviour involves glassy-
rubbery phase transition followed by amorphous-crystalline transformation under the 
influence of water. These associated changes were not observed in physical aging of 
amorphous lactose compacts by measuring specific surface area.  
 
At the molecular level these physical changes are governed by relaxation 
processes. By operating within the linear viscoelastic region, low strain uni-axial 
indentation of small molecule organic glasses at a range of temperature generated 
master curves using WLF analysis. Viscoelastic behaviour of these materials were 
determined to be controlled by local -relaxation around the glass transition rather 
than globally for polymers. 
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At the bulk level, due to the non-equilibrium nature of milled and amorphous 
powders, their surface energies tends to be significantly higher than the equivalent 
crystalline forms. This can be detrimental as highly cohesive and poor flowing 
powders are difficult to process. The unconfined compression test was adapted to 
measure cohesion of small weak pharmaceutical powder compacts. More significantly, 
a positive relationship was confirmed between surface energetics and cohesion of 
modified D-mannitol. 
 
At the particle level, the mechanism(s) by which milling or micronisation 
creates low levels of amorphicity remains unclear. MOUDI fractionation of bulk 
micronised -lactose monohydrate and characterisation of fine fractions has clearly 
demonstrated that micronisation as well as mechanical particle size reduction also 
generates low levels of highly amorphous ultrafine particles within bulk crystalline 
powder which will have a significant effect on powder physical stability post-milling 
and upon storage. In conclusion, using the novel techniques developed here, 
significant progress has been towards understanding the physical behaviour of milled 
and amorphous pharmaceutical solids. 
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Tf Fictive temperature   
Cp Heat capacity   
E/G Modulus   
tan Dampling or phase lag   
 Strain   
T Temperature   
P/P0 Partial Pressure   
 Molecular relaxation time   
 Viscosity   
 Surface energy   
d Dispersive surface energy   
dm Change in mass   
 Stress   
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Abbreviations 
 
DPI Dry Powder Inhaler 
MDI (pMDI) Metered Dose Inhaler (pressurised) 
PSD Particle Size Distribution 
API Active Pharmaceutical Ingredient 
cGMP Current Good Manufacturing Practice 
FDA Food and Drug Administration 
QbD Quality by Design 
PAT Process Analytical Technology 
ICH International Conference on Harmonisation  
DSC Differential Scanning Calorimetry 
DMTA Dynamic Mechanical Thermal Analysis 
DVS Dynamic Vapour Sorption 
PXRD or XRPD X-ray Powder Diffraction 
WLF Williams-Landel-Ferry equation/model 
VFT Vogel-Fulcher-Tamann equation/model 
MRO Medium Range Order 
VdW Van der Waals forces 
RT Room Temperature 
SA Surface Area 
R&D Research & Development 
BET Brunauer-Emmett-Teller equation/model 
IMC Indomethacin 
FELO Felodipine 
MCC MicroCrystalline Cellulose 
MgSt Magnesium Stearate 
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OP Optical Profilometry 
TTM Through Transmissive Media 
VGI Vapour Generating Instrument 
RH Relative Humidity 
UCT Unconfined Compression Test 
MOUDI Micro-Orifice Uniform Deposit Impactor 
VAG Vilnius Aerosol Generator 
SEM Scanning Electron Microscopy 
IGC Inverse Gas Chromatography 
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Chapter 1 Introduction 
 
1.1 Introduction 
 
The development of modern pharmaceuticals has changed very little in the last 
fifty years. Oral solid dosage form(s) remain the preferred choice from both 
manufacturing and patient point of view [1]. This however maybe mainly due to the 
empirical nature of formulation science and the inclination to accept existing best 
practice versus innovation and adopting radical changes as well as patient compliance 
[2].  
 
According to the FDA, there are 111 distinct methods of drug administration 
or routes for drug delivery. Parenteral or intravascular is ideal and the preferred route 
in initial clinical trial studies (animal – phase 0) with 100% bioavailability but 
administration requires expert supervision. There has been growing interest in nasal 
and pulmonary therapeutics as the ability for direct systemic delivery which bypasses 
first pass metabolism and provides significant improvement in bioavailability 
compared to oral. It also enables alternative delivery of biological macromolecules 
e.g. insulin (Exubera). The lack of urgency in adopting the arrays of new novel 
technologies in synthesis, scale-up and manufacturing is due to the stricter regulations 
in approving new approaches as well as the willingness to follow traditional know-
how has meant that the industry is very much behind and playing catch up compared 
to other sectors such as medical devices/diagnostics, food/nutrition, fast-moving 
consumer/household goods etc. [3]. 
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Fig. 1.1.1 – Different Pharmaceutical Dosage Forms (from top left – clockwise, 
capsule, dry powder inhaler, tablet, metered dose inhaler) 
 
In terms of manufacturing, post chemical synthesis, more than 90% of 
marketed formulations contain the crystalline solid state form [4].  A powder is 
generally defined as a collection of individual solid particles surrounded by gas 
phases [5]. In order to achieve fit for purpose crystalline particles/powders, 
mechanical particle size reduction remains the only scalable method [6]. In terms of 
patient compliance, ‗round, white or off white tablets‘ still considered ultimately the 
goal of drug development (fig. 1.1.1) [7]. 
 
Comminution, which will be referred to as milling throughout due to the 
nature and scale applied, is the process by which size of particulate solids are reduced 
by mechanical means to achieve a desired average particle size (PS) [8]. This process 
is not to be confused with the shaping of metal and other solid materials [9]. It is a 
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key unit operation in the processing of pharmaceuticals and can significantly impact 
development time and final product performance [10]. Particle and powder physico-
chemical, mechanical and biopharmaceutical properties have been adversely affected 
by milling through different means in the process of achieving the primary goal of 
particle size reduction (fig. 1.1.2) [11]. 
 
 
Jet 
 
Air Impact 
 
Centrifugal Pin 
 
Air Classification 
 
Roll Crushing 
 
Jaw Crushing 
 
Rotary Crushing 
 
Hammer 
 
Fig. 1.1.2 – Mill Types (images courtesy of Sturtevant Inc.) [12] 
 
The main aim of pharmaceutical milling is to obtain the optimum PS in order 
to formulate a stable therapeutically adequate drug product [13]. PS may directly 
affect the product i.e. dry powder inhalation or indirectly i.e. powder flow and 
compaction [14-17]. The influence of milling on physical stability has been an 
industrial concern for many years as physico-chemical changes post-milling can lead 
to poor powder flow, particle segregation, inadequate solubility and dissolution which 
may lead to reduced bioavailability [18, 19]. Although particle size reduction has 
become an alternative method to deal with previously undevelopable poorly soluble 
compounds (Class II and IV, Biopharmaceutics Classification System) with increases 
in surface area improving the rate of dissolution [19-23].  Due to this unpredictable 
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nature, lack of control and costly batch to batch variation, milling may have to be 
repeated throughout development and manufacturing in order to maintain PS (fig. 
1.1.3) [24]. 
 
 
Fig. 1.1.3 – Breakdown of the Stages of Pharmaceutical Development [25]  
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1.2 Background 
 
Active pharmaceutical ingredients (API) predominantly exist as crystalline 
solid forms [26]. A crystalline solid by definition has to have an internal structure 
made up of unit cells with defined dimensions (a, b, c) and angles (α, β, γ), which 
repeat regularly and indefinitely in all three spatial dimensions. In addition there are 
defined planes of geometry, shape, orientation and volume [27]. They can be divided 
into 7 crystal systems , 14 Bravais lattices (14) and 230 space groups, all of which 
combine to produce the unique diffraction patterns for each crystalline material. Each 
material can also exist as different polymorphic forms, which have the same chemical 
composition but due to different molecular packing arrangements and/or 
conformations, have different physico-chemical properties [26, 28, 29]. The 
differences can dramatically affect the stability of a drug substance or product as 
demonstrated with the case of ritonavir (NORVIR®), a marketed protease inhibitor 
for the human immunodeficiency virus where during manufacture, a more stable  
polymorphic form (form II) was generated which required modifications to the 
original formulation in order to meet regulatory requirements [30, 31]. 
 
An amorphous solid is defined in a similar way to a crystalline solid except 
that the so called long range order resulting from regular molecular packing 
arrangements and conformations are absent [32]. Short range order may still exist 
between neighbouring molecules but can only be described by the randomness of 
conformations and lack of structure [33]. A crystal has a melting point, when the 
lattice is broken, which is absent in the amorphous form. It does however have a glass 
transition temperature (Tg) [34]. These differences cause marked changes in physico-
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chemical properties which have been exploited to improve solubility and dissolution 
rate [35]. 
 
It has been established that ―process induced structural disorder‖ (a number of 
other interchangeable terms have been coined) affects the overall crystallinity of the 
particulate solids concerned [11, 36-39]. This disorder is thought to contribute only a 
small percentage, normally <10% mainly on the surface using standard milling 
techniques, to the overall amorphous content but can lead to significant changes in 
physico-chemical properties and thermodynamic stability [40-43]. In consequence 
formulation and manufacture of final drug product becomes more difficult and 
unpredictable, affecting the overall control and assurance of quality. Secondary to 
that, it can also have a deleterious effect on both efficacy and safety [18, 19]. 
 
Milling as a physical process has been widely studied, particularly in the field 
of mechanical alloying and mineral processing [44, 45]. For powders, development 
has been focused on modelling and estimating the required energies for scale up 
efficiency. There are three well established models relating particle size to energy 
applied, Rittinger (1867), Kick (1885) and Bond (1952) [46-48]. Rittinger‘s Law 
assumes that the energy required for particle size reduction is directly proportional to 
the change in surface area. This is more appropriate for ultrafine grinding of powders 
as it takes into consideration significant increases in surface area. Kick‘s Law on the 
other hand assumes that the same energy required is directly proportional to the size 
reduction (in one dimension) ratio which is more appropriate for coarse crushing 
where surface area changes are less significant. Bond‘s Law is an intermediate of the 
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two which has been most useful as it can be applied to a much broader particle size 
range [49-51]. 
 
The problem however persists, why is particle size reduction efficiency much 
lower than predicted and what happens to all the energy that is applied to the 
particles? Anisotropicity of crystalline solids resulting in non-linear defects and 
dislocations may explain the fracture and breakage behaviour observed [52]. Several 
theories exist regarding the physical changes we observe, for example increases in 
surface area are expected but the contributions to physical change by different size 
fractions are unknown as they have yet to be isolated and characterised. Sub-micron 
particles may only account for a small percentage of the overall particle mass or 
number but contribute markedly to the increases in surface area. The cohesive and 
adhesive forces generated during milling means that there is usually rapid 
agglomeration of these sub-micron particles [53]. Leading to particle growth and 
decreases in surface area as the surface induced thin amorphous/disordered layer (40-
50nm thick) of neighbouring particles recrystallise (solid-solid bridges) [43, 54, 55].   
 
Historically, it has been shown that process induced structural disorder on the 
surface of milled particles tends to be restored via recrystallisation during controlled 
storage or accelerated ‗physical aging‘ (example condition being 40C/75% RH) in 
order to study physical stability, not to be confused with physical aging observed in 
amorphous solids and polymers [55, 56]. This was hypothesised to be as a result of 
the molecular mobility of amorphous material generated on the surface of particles 
during milling [38]. This amorphous material behaves viscoelastically, a property well 
studied for polymers [57]. Through stress relaxation induced by high temperature 
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and/or high relative humidity (RH), the ―partially‖ crystalline (amorphous) layer is 
―repaired‖ to the most thermodynamically stable crystalline form [34]. 
Experimentally it has been seen that there are substantial changes in the powder 
surface area measured by gas adsorption may be explained by changes in the primary 
particle size [55, 56]. An increase in particle size may be due to creation of high 
energy sites and amorphous zones on the surface which promote cohesion and 
agglomeration; with a decrease due to intra-particle crack formation, particle fracture 
and crack propagation [58-61]. 
 
As a physical model of particle interactions, milling has been thoroughly 
studied to understand, predict and control the milling behaviour, i.e. the energy input 
required, fracture index and optimal process parameters and environmental 
conditions. Novel methods such as  nanoindentation and single particle impact testing 
have helped to relate mechanical properties of particles to ―millability‖ [10, 62]. 
 
Current practice has relied upon the natural physical ―aging‖ of the post-
milled material under standard conditions until the most stable physical form has been 
obtained (―quarantine‖ which can be anywhere from months to years) which may 
require further milling for formulation purposes and is obviously both time-
consuming and inefficient. Regulatory requirements as set out in current good 
manufacturing practice (cGMP) guidelines specify PSD data as one of the key criteria 
for approval. For example in the current Code of Federal Regulations Title 21 Part 
314.50, applications for Food and Drug Administration (FDA) approval to market a 
new drug for human use, states that the documentation must include acceptance 
criterion relating to particle size, stability, sterility and crystalline form [63]. 
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Fig. 1.2.1 – QbD Cycle [64]  
 
As drug development moves into a new century, an industry-wide Process 
Analytical Technology (PAT) initiative has been rolled out with the aim to implement 
―a system for designing, analysing, and controlling manufacturing through timely 
measurements (i.e., during processing) of critical quality and performance attributes 
of raw and in-process materials and processes with the goal of ensuring final product 
quality‖ [65, 66]. For the critical process of milling, the aim is to maintain optimum 
PSD through on-line analysis and control with prior planning using quality by design 
(QbD) principles (fig. 1.2.1) in agreement with International Conference on 
Harmonisation of Technical Requirements for Registration of Pharmaceuticals for 
Human Use (ICH) Q6A [64, 67, 68]. 
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1.3 Aims and Objectives 
 
The aim of this project is to develop a number of novel physical 
characterisation techniques to detect and monitor the physico-chemical changes of 
milled and amorphous pharmaceutical solids. From which findings may be related to 
existing amorphous and viscoelastic theories in order to explain the possible 
mechanism(s) for anomalous physical changes observed post-milling and the impact 
on powder processing and performance.  
 
Scientific Objectives 
 
1. Detect and monitor the physical changes of model amorphous pharmaceutical 
solid(s) under controlled environmental conditions similar to standard 
pharmaceutical powder storage. 
2. Determine linear viscoelasticity of model amorphous pharmaceutical solid(s) 
by stress relaxation and relate behaviour to temperature dependence of 
viscosity (Williams-Landel-Ferry).  
3. Ascertain the impact of surface properties, which are significantly altered 
during milling, on inter-particle cohesive forces and powder performance.    
4. Elucidate mechanism(s) for physical changes by quantifying the amorphicity 
of sub-micron fine fractions of bulk milled pharmaceutical powders. 
 
The overall objective is to implement the methodologies developed in an 
industrial setting where the advanced understanding gained can help to predicti and/or 
control the impact of milling on powder stability. Providing the potential to expand 
the current QbD knowledge space and aid development decision making. 
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Chapter 2 Physicochemical Properties of Amorphous Pharmaceutical 
Solids 
 
2.1 Introduction 
 
The amorphous form of pharmaceutical solids is increasingly being considered 
as an alternative choice for solid-state development, particularly due to the unique 
properties, methods of preparation and solubility, dissolution and bioavailability 
advantages [35]. Previously always considered as detrimental or undesired due to 
thermodynamic instability, greater understanding is needed of the amorphous or 
glassy state, in order to manipulate and control the amorphous form [69]. With 
dwindling pipelines, pharmaceutical companies are increasingly interested in 
developing the solid state form(s) (fig. 2.1.1). The ability to enhance solubility and/or 
permeability opens up the possibility to numerous molecules formerly deemed 
‗undevelopable‘, although the anomalous behaviour caused by generation of 
amorphous character during processing and upon storage remain unanswered [70]. 
 
 
Fig. 2.1.1 – Pharmaceutical Solid State Forms (image courtesy of Solvias AG) 
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The amorphous form of a pharmaceutical solid can be prepared in a number of 
ways (fig. 2.1.2), by quench melting from solid, spray drying or freeze drying from 
solution, dehydration/desolvation of hydrates/solvates or polymorphic transformation 
through milling, granulation, dispersion etc. [35]. Characterisation of amorphous 
pharmaceutical solids focuses on structural determination (quantification is 
comparatively more difficult than for crystalline pharmaceutical solids), phase 
transitions/thermodynamic properties, kinetic stability i.e. crystallisation (or re-
crystallisation) and structural relaxation phenomenon [71, 72]. 
 
 
Fig. 2.1.2 – Routes of preparation for amorphous and partially amorphous solids [35] 
 
Current focus has been on stabilisation of the amorphous phase by the addition 
of excipients which inhibit re-crystallisation under normal operating environment, for 
example with the addition of polymers to form matrices that whereby drug release 
profiles can also be optimised [73-75]. The scope is therefore wide open in terms of 
improving understanding.  
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2.2 The Amorphous State 
 
The amorphous state, often also referred to as the glassy state (presence of a 
glass transition temperature up on heating) was first discovered around 50 BC by 
Phoenician merchants preparing glass around present day Syria [76]. It is a key solid 
physical sub-phase in materials science due to unique properties and despite its 
importance, definitive classification and characterisation remain elusive and 
understanding relies heavily on empirical data [32]. In order to define the amorphous 
state, it is often easier to first define the crystalline state, where by atoms or molecules 
are arranged in an infinite regular repeating pattern in all three dimensions with three 
ranges of order (short, medium and long) [26]. The amorphous state or non-crystalline 
state is the direct opposite where by disorder results in the lack of medium and long 
range order [33]. 
 
Fig. 2.2.1 – Crystalline vs. Amorphous (Encyclopaedia Britannica 1998) 
 
In the amorphous state, atoms and/or molecules lack medium and long range 
order, which is the unique feature of the crystalline state that has been well described 
[34]. A crystalline solid (fig. 2.2.1) by definition has an internal structure made up of 
unit cells with defined dimensions (a, b, c) and angles (, , ), which repeat regularly 
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and indefinitely in all three spatial dimensions. In addition there are defined planes of 
geometry, shape, orientation and volume. They can be divided into crystal systems 
(7), Bravais lattices (14) and space groups (230), all of which combine to produce the 
unique X-ray diffraction patterns whereby amorphous solids simply produce a general 
‗halo‘ at all angles of diffraction [26, 77, 78]. Structural packing of crystalline solids 
differs to amorphous solids with specific coordination and geometry as well as high 
packing efficiency (interstitial space  free volume) [27]. The lack of long range 
structural periodicity for amorphous solids also means that they are isotropic, as 
oppose to the anisotropicity observed for crystalline solids [79]. 
 
Fig.  2.2.2 – Crystalline and amorphous silica (image courtesy of NDE/NDT Resource 
Center) 
Short-range order which exists in all amorphous materials has often been 
classified as nano-crystallinity. For example in amorphous silica (fig. 2.2.2), the 
tetrahedral arrangement of SiO2 remains but the long-range structural ordering is 
missing [80]. Understanding of the properties of smaller and simpler metallic and 
inorganic glasses such as silica has been extended to organic small molecules (sugars 
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and drugs) and polymers (plastics and coatings), such as amorphous indomethacin 
which has been widely used as a model amorphous pharmaceutical solid in the study 
of physico-chemical properties [81]. Some of the universal behaviour such as physical 
aging, relaxation and viscoelasticity can be directly conveyed [82-84]. There is 
however a distinct gap in knowledge in the general due to the difficulty in quantifying 
amorphicity and classification compared to crystals/crystallinity [85, 86]. Only 
thermal and/or mechanical techniques are currently being implemented with respect to 
amorphous pharmaceutical solids but only provide enthalpic and modulus information 
with regard to glass transition and re-crystallisation of the amorphous phase [34, 54, 
69, 72, 83, 84, 87-101]. The free volume is fundamentally the best descriptor and 
classifier of the amorphous state. Free volume can be simply defined as equal to the 
specific apparent volume minus the specific occupied volume (fig. 2.2.3) [34].  
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Fig. 2.2.3 – Theoretical volume versus temperature relationship for amorphous and 
crystalline solids (y-axis can interchangeable i.e. to enthalpy) [32] 
Changes in temperature and pressure can enhance molecular mobility and 
configurational entropy leading to undesirable changes in physico-chemical properties 
[102]. The ‗lower‘ apparent melting point for amorphous solids is due to melting 
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occurring over a range of temperatures due to variation in bond strengths rather than 
sharp melting point for crystalline solids which bonds are of equal strength. 
Uncontrolled recrystallisation, solid state polymorphic transformation, particle 
agglomeration are just a few negative consequences associated with the amorphous 
form during processing and upon storage [55, 56, 60, 103, 104]. Amorphisation isn‘t 
always intentional (e.g. quench melting, spray drying and freeze drying) with a 
number of unit operations in pharmaceutical manufacturing (e.g. milling, drying and 
granulation) which may induce structural disorder resulting in low levels of 
amorphous content [37, 38, 55, 56, 105]. In order to develop a quality by design 
approach to the development of pharmaceuticals, greater understanding of amorphous 
phase and forms are required [106]. 
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2.3 Glass Transition 
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Fig. 2.3.1 – Tg, Tc and Tf (Tm) as determined by Differential Scanning Calorimetry (Tg 
– glass transition temperature, Tc – crystallisation temperature, Tm – melting 
temperature, Hc – enthalpy of crystallisation, Hf – enthalpy of fusion) [97] 
 
The glass transition or glass transition temperature(s) (Tg) is the key property 
in terms of characterising amorphous materials and was first critically considered to 
be of interest in the 1930s [107]. Due to the disordered nature of amorphous materials, 
only the glass transition, the range of temperatures at which the material changes from 
a non-equilibrium glassy state to an equilibrium rubbery state upon heating (or the 
opposite when cooling, rubbery to glassy) can be used to distinguish amorphous and 
crystalline material [108, 109]. The amorphous form is considered to be 
thermodynamically unstable, because of higher Gibbs free energy, entropy and free 
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volume compared to the crystalline form (fig. 2.3.1) [32, 110, 111]. In order to 
achieve the glassy state by cooling below the melting point (temperature at which the 
crystalline solid melts) through the second order phase transition (glass transition), the 
cooling rate needs to be sufficient to ‗freeze‘ the atoms/molecules in the disordered 
state, preventing any rearrangement or ordering leading to the crystalline form [34, 
35, 112].  
 
2.3.1 Thermodynamics 
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Fig. 2.3.2 – Volume, enthalpic and entropic changes during phase transitions for 
amorphous and crystalline solids (Tk – Kauzmann temperature, Tf – fictive 
temperature of amorphous solid at T‘, Tg – glass transition temperature, Tm – melting 
temperature) 
 
The super-cooled liquid behaves much like the stable liquid in equilibrium but 
has comparatively much higher viscosity [110]. On further cooling of this super-
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cooled liquid beyond the glass transition, a glass in the non-equilibrium state is 
formed whereby molecular relaxation and configurational entropy is reduced [113]. 
Tk or the Kauzmann temperature is a theoretical point below the glass transition 
during super-cooling of the liquid where molecular relaxation is considered to be at a 
minimum similar to the equivalent crystalline solid, i.e. zero entropic difference 
between the liquid and the solid [114]. The Tf or the fictive temperature is the 
temperature at which the theoretical equilibrium supercooled liquid has equivalent 
thermodynamic properties as the actual non-equilibrium glassy solid at T‘. Tf always 
lies between Tk and Tg (fig. 2.3.2) [84, 115, 116]. 
 
Although chemically the same as the crystalline form, the glassy form has 
much greater enthalpy and specific volume (fig. 2.3.2) which results in advantageous 
physical properties, particularly in terms of solubility and dissolution for 
pharmaceutical solids [117-120]. Due to the glassy state being a non-equilibrium 
state, the glass transition must be considered as kinetic driven phenomenon as oppose 
to a true phase transition such as melting which is thermodynamically driven to the 
equilibrium states (gas, solid and liquids) [121, 122].  
 
As stated previously, characterisation of amorphous solids focuses on the 
determination of the glass transition (Tg) [72]. In terms of thermal methods, this 
pseudo second order phase transition results in a step change in heat flow/heat 
capacity as a function of temperature which thermodynamically defined as a change 
in enthalpy at constant pressure [109]. The glass transition is considered second order 
as enthalpic and entropic changes are not equivalent with only continuous changes in 
heat capacity and pseudo phase transition (second order) as it is not ideal because of 
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continuous changes in heat capacity or thermal expansion coefficient and to a smaller 
degree entropic changes occur due to conformational changes during the glass 
transition. The reason being that greater energy is required for volume expansion 
(increase in free volume) to accommodate greater changes in molecular motion. 
Melting which on the other hand is a first order phase transition with comparable 
changes in both enthalpy and entropy and a significant discrete change during the 
phase transition i.e. the melting temperature (the melting point) [123]. 
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Fig. 2.3.3 – Effect of thermal history, different cooling conditions will generate 
different glasses with different glass transition temperatures. 
 
Glasses or amorphous solids have been traditionally prepared by thermal 
treatment. Therefore the thermal history of glass (fig. 2.3.3) as well as the 
fundamental physical properties (enthalpy, entropy and the summation of which, the 
free energy), chemical properties (molecular weight, water activity) and environment 
(temperature and pressure) combine to determine the non-equilibrium state and hence 
the overall stability of the amorphous solid [111]. In essence these factors also affect 
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the glass transition, the only current measurable parameter of amorphous solids which 
in itself has continuous incremental differences between forms compared to the 
equivalent crystalline form(s). These may be termed ‗polyamorphs‘ in a similar vain 
to the more well-known classification of crystalline solid forms but are not 
equilibrium thermodynamic forms [124]. More importantly as discussed earlier, 
partial amorphisation of crystalline solids during mechanical processing, resulting in 
undesirable changes in physical properties which are difficult to characterise by 
existing means. In addition there‘s a lack of understanding of the underlying 
mechanism(s) for partial amorphisation which will be discussed in further detail in 
Chapter 3 [11, 37, 39, 125-129]. 
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Fig. 2.3.4 – Examples of glass transitions (left) DSC – Cp, (right) DMTA – G‘ and 
tan 
 
There are a number of commonly used methods to determine the glass 
transition, such as differential scanning calorimetry (DSC) which uses relatively small 
amounts of sample (~5mg) and measures the heat flow and hence the heat capacity of 
the sample material as a function of temperature which undergoes abrupt discrete 
changes during any phase transition e.g. glass transition, crystallisation and melt. The 
difference being that the glass transition is a second order endothermic transition and 
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a step change in heat capacity is observed (fig. 2.3.4 – left, endo being positive in the 
y-axis) rather than a peak for first order exothermic transition (crystallisation), or first 
order endothermic transition (melt). This step also doesn‘t occur at a specific 
temperature, instead gradually over a small range depending on heating rate. 
Although often quoted in the literature as a single value, the methodology and sample 
preparation greatly affects Tg determination, fig. 2.3.5 shows how Tg is calculated 
using DSC data. 
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Fig. 2.3.5 – Tg determination using DSC (Tb is the beginning of Tg, T1 is the onset of 
Tg, T2 is the endset of Tg and Te is the end of Tg). N.B. endo is positive in the y-axis. 
   
Other techniques include dynamic mechanical thermal analysis (DMTA) 
which measures the change in modulus as a function of temperature whilst a 
sinusoidal stress is applied to the sample at a specific frequency and again, due to 
increased molecular mobility near, at and just beyond the glass transition, results in a 
rapid decrease in modulus (in this case can be considered to be equivalent to 
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viscosity), or a phase shift between the stress and strain, due to the viscoelastic nature 
of amorphous solids and the reduction in viscosity, as a result of heating (fig. 2.3.4 – 
right). 
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Fig. 2.3.6 – Determining RHTg using DVS [130] 
 
Dynamic vapour sorption (DVS), where mass changes (inflexion point in the 
rate of mass uptake similar to DMTA) is measured as a function of relative humidity 
(RH), or solvent vapour partial pressure, the glass transition can be calculated as a 
RHTg or P/P0Tg (fig. 2.3.6) [130]. This being due to greater molecular mobility 
enhancement as a result of water, or solvent molecules facilitating increased 
intermolecular interactions within the free volume of the amorphous, or partially 
amorphous solid (e.g. spray dried lactose) [87, 131, 132]. 
 
Tg can also be determined by dilatometry, where thermal expansion of the 
sample is directly monitored in terms of change in sample dimensions as a function of 
temperature [109]. As the glass begins to become rubbery, physical expansion occurs 
due to the asymmetric amplitude variations in thermal vibrations within the 
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amorphous solid (fig. 2.3.7 – physical expansion of amorphous solid as measured by 
dilatometry). Not only can Tg be determined based on changes in heat capacity, 
modulus, thermal expansion coefficient, but also isobaric expansivity and dielectric 
constant [123]. 
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Fig. 2.3.7 – Tg as measured by dilatometry (y-axis = linear expansion) [109] 
 
In terms of pharmaceutical processing, the Tg is inadequate in describing 
amorphous, or partially amorphous, solids as they are often not completely glassy 
[11]. There has been an abundance of research over the last two decades to quantify 
the ‗amorphicity‘ of crystalline solids as part of assessing physical stability [39, 41, 
133]. A range of techniques including powder X-ray diffraction, DSC, isothermal 
microcalorimetry, solution calorimetry, infra-red spectroscopy, Raman spectroscopy, 
solid-state nuclear magnetic resonance and DVS have been used to determine the 
relative amorphous content of pharmaceutical powdered solids [71]. The choice of 
analytical techniques and appropriateness will be discussed in further detail in 
Chapter 4.  
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2.3.2 Free Volume 
 
Free volume is the difference between the total volume and the occupied 
volume, and it is dependent on temperature but experimentally free volume cannot be 
accurately obtained as intermolecular pores are approximately 0.02-0.07nm
3
 [134]. 
Dilatometry measures the temperature dependence of occupied volume with only 
probe techniques involving X-ray or neutron scattering and positron annihilation 
capable of estimating the distribution of absolute free volume through direct 
interactions at the sub-atomic level [72]. Therefore due to this difficulty, theoretical 
models have taken precedence in terms of development in understanding. 
 
Free volume of a solid is defined as the specific volume of the solid minus the 
specific occupied volume of the atoms or molecules within the solid [135]. In terms of 
amorphous solids, this is considered the space available for molecular relaxation 
(returning to equilibrium) as a result of conformation changes such as rotational and 
translational movement. For the purpose of clarity, it essentially is the unoccupied 
void space between atoms or molecules. In a crystalline solid, free volume can be as 
considered as zero due to the efficient packing of atoms or molecules has reached an 
energy minima, no changes in volume will occur before the melt. In an amorphous 
solid, as temperature increases above the glass transition (in the rubbery phase), free 
volume also increases in parallel as well as the molecular mobility. Free volume 
decreases on cooling but below the glass transition, the atoms or molecules are 
trapped or frozen in motion, thus yielding excess free volume in comparison to the 
crystalline solid (or when the melt is cooled at a sufficient slow rate to allow for re-
crystallisation). Free volume can also be considered as the excess volume gained 
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which can move freely within the solid without any measurable changes in energy 
(enthalpy and entropy) [82, 102, 136, 137].    
Molecular relaxation time () is used to evaluate molecular mobility and free 
volume in amorphous solids. At the glass transition,  is typically in the order of 
~100s, increases below Tg where in the glassy state, short range order is maintained 
by rotational and translational molecular motion (α, β and  relaxation) and decreases 
above Tg and in the presence of water/solvent molecules where medium and long 
range order results from more complex intermolecular forces [138-140].  
 
Changes in physical properties at the glass transition can be related to the 
relationship between viscosity and free volume. Doolittle first defined the dependence 
of viscosity on free volume with an Arrhenius like relationship (equ. 2.3.1) [141]. 
 
     
   
   
 
Equ. 2.3.1 – Arrhenius equation, where k is the rate constant, A is the pre-exponential 
factor, Ea is the activation energy, R is the Universal gas constant (8.314 kJmol
-1
) and 
T is the absolute temperature in K 
 
      
 
  
 
Equ. 2.3.2 – Doolittle Equation, where  is viscosity, f is the fractional relative free 
volume ((specific volume – occupied volume) / occupied volume), A and B are 
constants 
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Equ. 2.3.3 – Adam-Gibbs equation, where  is viscosity, 0 is initial viscosity, C is a 
constant, T is absolute temperature in K and Sc is configurational entropy [142] 
 
The Arrhenius equation however is insufficient in explaining the non-
exponential relaxation of supercooled liquids or glasses and also the temperature 
dependence of α-relaxation time (). The Doolittle equation (equ. 2.3.2) predicts this 
temperature dependence based on the fractional free volume. Further development of 
this dependence was conducted by Vogel, Fulcher and Tamann to relate the 
temperature dependence of molecular motions taking into consideration the 
configurational entropy (Adam-Gibbs equ. 2.3.3) [142]. 
 
        
 
  
 
 
Equ. 2.3.4 – Vogel-Fulcher-Tamann (VFT) Equation, where  is viscosity, T is the 
temperature in K, T0 is the initial or reference temperature in K, A and B are constants 
 
When the configurational entropy (equ. 2.3.3) is considered as the integrated 
excess heat capacity (where Cp = k/T), the VFT equation is generated in the 
normalised form (equ. 2.3.4) [112].  
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Equ. 2.3.5 – Fractional free volume, where fg is the fraction at Tg, αf is the thermal 
expansion coefficient, T is the absolute temperature in K and Tg is the glass transition 
temperature in K  
 
       
         
           
 
 
Equ. 2.3.6 – Williams-Landel-Ferry (WLF) Equation, where aT is the shift factor, T is 
the temperature in K, Tr is the reference temperature in K, C1 and C2 are constants. T 
must be ±50K of Tr 
 
       
            
     (    )
 
 
Equ. 2.3.7 – Williams-Landel-Ferry (WLF) Equation where Tr equals Tg, where aT is 
the shift factor, T is the temperature in K, Tg is the glass transition temperature in K, 
C1 and C2 are constants. T must be ±100K of Tg 
 
When the Doolittle model (equ. 2.3.2) takes into consideration fractional free 
volume (equ. 2.3.5), the well-known WLF equation (equ. 2.3.6) to describe the 
temperature dependence of viscosity is formed and a universal relationship for 
polymers (equ. 2.3.7) has been empirically established [82, 102, 136, 137].  
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For the particular case of polymers, the Fox-Flory equation relates the glass 
transition and free volume further to the α-relaxation time  and molecular weight 
(MW) of the polymer [143]. This is not applicable to small molecule pharmaceuticals 
as the order in difference in MW and steric effects cannot be effective predicted (see 
fragility section). 
 
The free volume to viscosity relationship and subsequent bulk mechanical 
behaviour has been termed viscoelasticity, whereby molecular motions within an 
amorphous solid has been described to flow like a liquid under certain circumstances 
where on heating above the glass transition, viscosity rapidly decreases to be similar 
to a liquid during the rubbery phase [137]. 
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2.3.3 Kinetics 
 
As previously discussed, the glass transition not a true first order 
thermodynamic phase transition and is kinetically driven, with the temperature 
dependence related to changes in viscosity as well as the change in molecular 
relaxation, particularly in terms of α-relaxation [69]. This kinetic phenomenon can be 
further defined by the fact that the molecular relaxation times at the glass transition 
are of the same order as the experimental measurement time scale i.e. seconds. The 
temperature dependence and change in structural ordering is controlled by molecular 
dynamics which is the relative molecular motion and intermolecular interactions 
within the free volume [144]. Therefore heating and cooling rates greatly affect the 
properties of the amorphous solid, namely increasing the rate of heating or cooling 
will increase the glass transition temperature due to less time for molecular motion 
and structural reorganisation [145]. 
  
Heating Rate (ºC/min) Tg of Polystyrene 
5 100 
10 106 
20 108 
40 109 
80 111 
 
Tab. 2.3.1 – Effect of heating rate on Tg  of Polystyrene (MW 51,000) [145] 
 
Experimental results confirm this increase in Tg and more importantly from a 
processing and handling point of view, changes in Tg will greatly impact the physical 
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stability of an amorphous solid. The combination of temperature and time dependence 
of the phase transformation of the amorphous solid as a result of viscoelasticity is of 
great importance in the manufacturing and storage of amorphous pharmaceutical 
solids [100, 146]. Heating and cooling rates in characterisation methodology has been 
comparable to that of manufacturing processes e.g. spray drying and hot-melt 
extrusion in order to produce stable amorphous solids and formulations.  
 
The current problem the pharmaceutical industry faces is that passively, 
amorphous characteristics and content can be introduced into crystalline solids. This 
first leads to physical instability within the bulk starting material i.e. active 
pharmaceutical ingredient – API and excipients, as well the final dosage form e.g. 
tablet, capsule (granule) or dry powdered inhaler (DPI) pre-, during and post-
processing [39]. Then the unstable nature of amorphous solids can also be altered as a 
result of processing through milling (comminution – mechanical size reduction) 
drying and granulation [35, 147]. Finally upon storage, as current pharmaceutical 
manufacturing practice still remains largely batch based, instabilities can also occur 
through physical aging. At any stage during the manufacturing chain, the temperature 
and time dependency of viscoelastic behaviour of partially/fully amorphous solids can 
continue to contribute to batch-to-batch variability [58, 148]. There are several 
theories which have been hypothesised to explain the observed changes in 
physicochemical properties of amorphous solids but with limited evidence, with 
terminology such as process induced structural disorder, mechanical activation and 
surface amorphisation which will be discussed in more detail in Chapter 3 [37, 38, 
149-152]. 
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Fundamentally speaking, even when operating temperatures are below the 
glass transition temperature, amorphous solids have still been found to change 
physically as a result of molecular relaxation [69, 84]. Although the relaxation times 
are orders of magnitude greater, in days and months, this physical aging of amorphous 
solids can greatly impact its manufacturing and storage. The gap in knowledge 
remains in relating this kinetic phenomenon to actual bulk changes e.g. particle size, 
specific surface area and dissolution [56, 153, 154].  
 
2.3.4 Fragility 
 
Fragility is the ability of liquids to form glasses or amorphous solids, with 
which there are two general types, strong and fragile [155]. To be more specific, 
fragility describes how medium range order (MRO) changes within the liquids upon 
cooling. Strong glass formers such as silica which consists of mainly covalent 
bonding are resistant to changes in MRO due to the liquid having low configurational 
entropy and minimal changes in heat capacity at the glass transition. Fragile, or weak, 
glass formers which consists of weak intermolecular forces (ionic or VdW), have high 
configurational entropy and large change in heat capacity at the glass transition [32, 
156-159]. 
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Fig. 2.3.8 – Fragility of glass formation [155] 
 
In addition and more importantly, organic materials such as amorphous 
pharmaceutical solids fall into the fragile category whereby the temperature 
dependence of viscosity follows a non-Arrhenius relationship as discussed earlier, 
compared to strong glass formers (according to Angell, fig. 2.3.8). Fragility can also 
explain the extent to which molecular relaxation is reduced, due to cooling, as the 
liquid approaches the glass transition. Strong amorphous solids have a broader glass 
transitions due to ‗stronger‘ MRO compared to weaker, or more fragile, amorphous 
solids, which have narrower glass transitions. Fragility is directly related to the 
stability of pharmaceuticals [98, 160]. 
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2.4 Viscoelasticity 
 
 
Fig. 2.4.1 – Stress relaxation of polystyrene with temperature (adapted from Cowie) 
[57] 
 
 
Viscoelasticity is a phenomenon commonly observed in polymers with which 
the amorphous state exists, as typical elastic and plastic deformation does not occur 
upon unloading stress. A viscoelastic material displays both viscous and elastic 
behaviour in that it‘s initially elastic (glassy – AB) but as temperature increases 
near the Tg and greater molecular mobility, it becomes more viscous (leathery – 
BC) until a plateau phase (rubbery – CD), followed by flow (rubbery flow – 
DE) pending the final viscous state (EF) [57]. 
 
Although viscoelastic behaviour is typical of polymers, partially crystalline 
solids with amorphous regions should theoretically display some similar properties 
[109]. As mentioned previously, milling can induce amorphisation/vitrification of 
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crystalline organic particulate solids [55]. Stress relaxation due to viscoelasticity of 
the material may explain the physic-chemical changes we observe [161]. 
 
Viscoelasticity has been thoroughly studied in the compression and 
compaction of pharmaceutical powders during tabletting [162-166]. Conventional 
mechanical testing can involve tablet hardness testing with diametral compression 
(radial tensile strength), transverse compression (axial tensile strength) to determine 
tablet properties [167-169]. Unloading and post-compression studies using a rotary 
tablet press has proved successful but can only provide limited understanding [170-
172]. None of which distinguish between the viscoelasticity of the powder or the 
ensemble (tablet).
 
 
Radebaugh et al. developed a novel non-destructive technique to measure the 
three empirical parameters of viscoelasticity, namely elastic modulus, viscous 
modulus and damping as a function of strain, rate of strain, composition (the material, 
its properties and compression characteristics). The elastic modulus is the elastic 
energy stored upon deformation, whereas the viscous modulus is the energy lost 
through flow (viscous dissipation). Heckel plots of these parameters for 
microcrystalline cellulose (MCC) compacts provided insights on the interparticle and 
intraparticle interactions due to viscoelasticity. For highly crystalline pharmaceutical 
solids, elastic deformation is strictly dependent on crystalline constraints, however if 
amorphicity is generated through processing, they become more dependent on Van 
der Waals interactions and hydrogen bonding. This shift in dependency to weak 
intermolecular interactions means that temperature and relative humidity (partial 
pressure in solvent systems) can greatly affect thermodynamic stability and 
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polymorphic transformations. One important caveat with this type of mechanical 
testing is that variation in sample preparation can lead to poor reproducibility. A 
number of factors need to be considered including conditioning before and after 
compaction (T, RH), degree of consolidation, packing fraction, voids, tendency for 
brittle fracture and fragmentation [173].  
 
Malamataris et al. extended their research to study the viscoelastic properties 
of pharmaceutical powders by using six materials (starch, calcium phosphate, 
paracetamol, aspirin) with different physicochemical properties (crystallinity, particle 
size etc.). They found that apparent viscosity and elastic compliance (total compliance 
minus plastic component) differ significantly between highly and partially crystalline 
powders [174]. Increasing the loading rate increased the apparent viscosity of all the 
materials but did not have such effect on elastic compliance, which they suggest may 
be due to particle fragmentation in highly crystalline materials. Earlier studies have 
shown that as apparent viscosity increases, elastic compliance decreases [175, 176]. 
This general trend does not however consider material properties, for example 
calcium phosphate has high apparent viscosity and low elastic compliance because 
elastic strain is relieved through brittle fracture, but starch on the other hand has low 
apparent viscosity and high elastic compliance because of its ability to relieve elastic 
strain by undergoing plastic deformation. Crystalline paracetamol relieves elastic 
strain through consolidation (particle fragmentation) and aspirin has a combination of 
both plastic deformation and particle fragmentation [177, 178]. 
 
It has been shown that particle size reduction has the opposite effect to 
increasing loading rate, in that apparent viscosity decreases and elastic compliance 
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increases. This can be explained in a number of ways, smaller particles have greater 
packing (density) and fewer dislocations to allow for brittle fracture which increases 
elastic compliance. The lack of brittle fracture also means that it allows for plastic 
flow which reduces apparent viscosity. It is believed that sufficient porosity exists in 
these finer systems allows for plastic flow to relieve elastic strain [179].  
 
The general conclusion from these studies has been that no single universal 
parameter is appropriate for describing the viscoelastic behaviour of pharmaceutical 
powders in terms of tabletability (hence post-milling stability). In order to fully 
understand a material, designs of experiments need to consider all the variables 
(packing fraction, loading rate, particle size, yield pressure etc.).  
 
One aspect yet to be fully explored for pharmaceuticals is utilising the WLF 
model to relate physical instability to changes in molecular relaxation and 
viscoelasticity of amorphous and partially amorphous pharmaceutical solids [82]. As 
stated above, the non-equilibrium metastable amorphous state allows for glassy and 
rubbery flow to exist depending on preparation and environment. Stress through 
milling generates amorphicity/disorder which may play a significant role in initiating 
and propagating the physical changes through stress relaxation.  
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2.5 Interaction with the crystalline state 
 
 The amorphous form(s) is always considered as the most unstable non-
equilibrium form; therefore when sufficient molecular mobility is acquired within the 
system, crystallisation will take place. The rate of crystallisation of an amorphous 
solid is highest between the Tg and Tm (i.e. Tc) [180]. 
 
Crystallisation can occur in all amorphous pharmaceutical preparations (spray 
dried, freeze dried, hot-melt extrusion, milled/micronised etc.), particularly when the 
external environment is altered which enhances molecular mobility, i.e. increase in 
temperature and relative humidity. Water causes plasticisation of the amorphous solid, 
reduces Tg and significantly increases rate of crystallisation which is normally 
dependent on the difference between material temperature and Tg [181, 182]. 
 
 
Amorphous 
 
Crystalline 
 
 
Fig. 2.5.1 – Amorphous-Crystalline Phase Transformation 
 
Although it has been found that molecular mobility remains significant up to 
50K below Tg [69]. Others, however, have found that whilst this molecular mobility 
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exists it remains insufficient in causing crystallisation [183]. Therefore these factors 
still need to be considered when controlling the crystallisation of amorphous solids 
(fig. 2.5.1). It also offers an alternative route to conventional crystallisation methods 
such as cooling, evaporation and anti-solvent with potential for novel forms and 
characteristics to be crystallised and stabilised, e.g. spherical crystalline lactose 
particles produced from re-crystallisation of amorphous spray dried lactose [184-187]. 
 
2.6 Preparation 
 
 
Preparation Technique Temperature Range Starting Material 
Hot melt extrusion >RT Solid 
Rapid precipitation – 
spray drying, spray 
freeze drying  
 
> RT 
<0 
Liquid 
Freeze drying <0 Liquid 
Doping – crystallisation 
inhibitors 
RT Liquid 
Anti-solvent RT Liquid 
Quench melt >RT Solid 
Dehydration/Desolvation >RT Liquid 
Comminution RT Solid 
 
Tab. 2.6.1 – Methods of preparation of amorphous solids [35] 
 
Preparation of amorphous solids is dependent on the ability to form glassy 
solids, i.e. the fragility of the material which has been discussed in detail earlier. This 
can be understood in terms of thermodynamics, whereby there is a difference in 
stability, or disorder, between the crystalline and amorphous form. Smaller 
differences in stability or greater disorder, (or tendency for disorder with weak 
packing or greater configurational entropy) results in good glass formers. Conversely 
in terms of kinetics, rate of crystallisation determines the glass forming ability, slower 
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kinetics means molecular mobility within the ‗liquid‘ melt can be reduced easily 
(frozen or vitrified). 
Inadvertent mechanical and chemical stresses such as milling/micronization, 
granulation, drying, mixing during the preparation and processing of crystalline 
pharmaceutical solids can also generate varying levels of amorphicity. This being the 
main motivation of this project, as often undesired partial crystalline-amorphous 
transformation can occur with detrimental effects on physical (particle size, surface 
area) and chemical (polymorphic form) stability, of the initial, predominantly 
crystalline, powder. There is a growing need to understand the mechanism, but more 
importantly stabilisation strategies, in order to deal with the instability, particularly 
with dry powder inhaled formulations. 
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2.7 Characterisation 
 
Characterisation Technique 
Amorphous Content 
Detection Limit 
Amount of Sample 
Required 
Powder X-ray Diffraction 
(PXRD) 
10% 300mg-400mg 
Differential Scanning 
Calorimetry (DSC) 
5% 4mg-10mg 
Isothermal MicroCalorimetry 
(IMC) 
0.5% 20mg-300mg 
Solution Calorimetry (SC) 1% 10mg-70mg 
InfraRed Spectroscopy (IR) 1%-2% 5mg-50mg 
FT-Raman <1% 2000mg 
Solid State Nuclear Magnetic 
Resonance Spectroscopy 
(ssNMR) 
0.5% 500mg-700mg 
Dynamic Vapour Sorption 
(DVS) 
<5% 10mg-150mg 
Positron Annihilation 
Lifetime Spectroscopy 
(PALS) 
Unknown 100mg-200mg 
 
Tab. 2.7.1 – Techniques in quantifying amorphous content of pharmaceuticals 
(adapted from Shah et al.) [71] 
 
There are a number of ways to characterise amorphous solids including 
dilatometry, calorimetry and mechanical analysis, but more specifically for 
amorphous pharmaceutical powders, industry and academia remain focused on a set 
of core techniques (tab. 2.7.1) in order to quantify and understand amorphous content 
and amorphicity. Each technique is however limited in terms robustness of application 
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and vary in levels of detection. For example, PXRD is only appropriate for simple 
detection purposes as all amorphous solids will produce a broad halo over a wide 
range diffraction angles [78].  
 
Whilst calorimetry can provide enthalpic and phase transition information, 
none except PALS can relate amorphicity to free volume, which is the only true 
descriptor to amorphous materials [135]. Development and utilisation of this 
technique, particularly for small molecule organic pharmaceutical solids, determine 
whether the phenomena of ‗polyamorphism‘ truly exists and finally allows for the 
effective classification of amorphous phases, as evidence is already clear that there 
are subtle differences between amorphous forms prepared through different routes 
[35, 85, 124]. 
 
In terms of characterising the specific amorphous phase, i.e. extent of 
molecular relaxation (-relaxation or Johari-Goldstein relaxation), ssNMR, DSC as 
well as dielectric relaxation spectroscopy, thermally stimulated depolarisation current 
and scattering techniques can be utilised [98, 188-195]. 
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Chapter 3 Milling of Pharmaceutical Solids  
 
3.1 Introduction 
 
Milling or grinding to reduce powder or grain size by mechanical means has 
existed for thousands of years, predominantly in an agricultural or mining context 
(fig. 3.1.1) [196]. Whilst the process is well developed, implementation remains 
mainly empirical, with increasing demand from food and pharmaceutical regulators 
for higher understanding and control to ensure quality, safety and efficacy [67]. 
 
 
 
Fig. 3.1.1 - Schematic of a windmill 
 
Comminution is the general term to describe the bulk size reduction process 
by which mechanical breakage of particles, or aggregates (agglomerates), is used to 
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produce powders of desired particle size distributions. The physical action by which 
particle size is reduced can vary from grinding, milling, cutting, chopping, crushing, 
micronising etc. and the choice is dependent on the feed material properties, size 
reduction requirements and type of equipment available [5]. The bulk starting material 
may require coarse crushing as a pre-treatment for fine grinding. For pharmaceuticals, 
the starting material generally tends to be crystalline solids in the form of particles or 
aggregates suitable for fine grinding, milling or micronisation to achieve a smaller 
size and narrower particle size distribution in order to meet requirements for 
formulation, dissolution and manufacturing. The complexity of a milling operation 
can be seen in fig. 3.1.2 [197]. 
 
 
Fig. 3.1.2 – Example of comminution circuit with online particle sizing 
(adapted from Malvern Instruments) 
 
Processing methods in particle technology can be divided into constructive 
and destructive in terms of their effect on particle properties, both physically and 
chemically. Milling has been classified as destructive because the initial coarse bulk 
solid is broken down by applying significant energy to produce smaller discrete 
particles with greater surface area (surface area being inversely proportional to 
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particle size). Growing evidence however, particularly in mechanical alloying and co-
milling, has shown that simple methods like planetary ball milling can be constructive 
in initiating reactions to improve mechanical properties and fabricating nanoparticles. 
 
3.2 Comminution 
 
 
Fig. 3.2.1 – Different types of mechanisms by which stress can be applied to particles 
in milling (adapted from Rhodes) [5] 
 
Particle size reduction by milling can be generalised through three physical 
mechanisms: compression, attrition and impact which may act independently or in 
combination (fig.3.2.1). They vary in their ability to apply energy into the powder 
system and are chosen based on efficiency and requirement. A recent review by 
Nakach et al. describes two of the most common types of mills used in the 
pharmaceutical industry, jet/‖pancake‖ and impact. Milling pressure and feed rate 
were found to be the key operating parameters in obtaining desired PSD. The main 
Stress applied between two surfaces (left and 
middle – compression, right – compression and 
attrition)
Stress applied between at a single surface (left – 
impact [particle-surface], middle – impact and 
attrition, right – impact [particle-particle] )
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conclusion was that depending on the requirements and cost of operation, distinct 
subtypes are most appropriate. (N.B. both jet and impact mills are based on impact 
breakage mechanisms – jet milling relies on particle-particle collisions, whereas 
impact infers particle-surface collisions) [198]. 
 
As stated above there is an increase in surface area (SA) as a result of particle 
size reduction. This increase in SA enhances the rate of pharmacokinetic processes 
which are key in drug delivery by various routes (the FDA recognises 111 distinct 
routes of administration). Another physical phenomenon that can be caused by 
variation in PSD is segregation, as differences in particle sizes, density, shape, 
roughness and particle resilience promote the disturbance of a well-dispersed system 
during processing [199-201]. Particle size is by far the most important and the 
limiting factor for ideal mixing [202]. Sedimentation, another problem commonly 
encountered in topical formulations and oral suspension, has also been found to be 
driven by particle size [203]. 
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Fig. 3.2.2 – Particle size requirements for effective deposition and therapy for 
pulmonary drug delivery (Bloomberg OpenCourseWare Image Library) 
 
With the advent of more complex dosage forms e.g. orally disintegrating 
tablets and dry powder inhalers (DPI), fine particles with narrower PSD are required. 
The term ―micronisation‖ was coined to emphasise the increasing development of 
techniques to produce micron or sub-micron sized API particles [204]. DPI 
formulations for instance are usually based on a blend of coarse (100-200m) and fine 
(<10m) lactose with API particles (<5m) attached to the coarse carrier lactose 
[205]. All three components require tight size distributions in order to meet strict 
performance guidelines based on aerodynamic PSD and fine particle fraction (FPF) 
(fig. 3.2.2 – % penetrating vs. aerodynamic diameter). Optimisation of particle size 
enables targeted delivery to specific regions of the human respiratory system. 
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Rasenack & Müller have reviewed the current methods for micronisation, 
dividing the topic into two main themes, mechanical comminution and particle 
engineering. The conclusions were that a number of properties shape/morphology, 
flow, surface properties, PSD and agglomeration behaviour can be dependent on the 
size reduction technique. Milling is more common, but has less control over the 
resulting product. Spray drying, supercritical fluids and solvent precipitation can 
provide the control but have drawbacks in terms of being costly, both in time and 
initial investment. Also scale-up for these controlled techniques are not often 
achievable. Great effort in R&D has been extended to utilise these novel techniques to 
enable development of previously poor candidates, initially rejected due to poor 
permeability and/or solubility. Increased efficiency in the delivery of these smaller 
particles produced by particle engineering, will also improve bioavailability and side 
effect profiles [206].
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Fig. 3.2.3 – High Attrition during Pharmaceutical Research & Development [207] 
 
At present, milling remains the method of choice but the question regarding 
lack of control of physical properties post-milling, in particular batch-to-batch 
variability and differences in final product performance. This ―fouling‖ of material 
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over time may be due to the energies applied during milling and the resulting damage 
or disorder could combine to contribute to the high attrition rate (fig. 3.2.3) for drug 
candidates during the initial phases of clinical trials, with only 8% completing the 
entire development process [207, 208]. 
 
3.3 Particle Fracture Mechanisms 
 
Milling is an extremely energy intensive process, particle size reduction 
accounts for approximately 5% of the World‘s annual electricity consumption 
(~5,000TWh). Particulate products contribute nearly $1 trillion annually to the US 
economy but milling efficiency at industrial scale is around 1%. Although particle 
engineering technologies have improved significantly, milling (‗micronisation‘ for 
sub-micron particles) remains the mainstay for achieving desired PSD [5]. 
 
In order to explain particle fracture, only well-defined crystalline solids are 
considered in this case. Fracture therefore occurs when applied stress exceeds the net 
attractive intermolecular forces that hold atoms/ions/molecules/lattices together and 
results in crystal fracture and will tend to shear along crystal planes. The balance 
between attractive and repulsive intermolecular forces obey Hooke‘s Law in terms of 
linearity, as strain is directly proportional to stress with this proportionality being the 
Young‘s modulus of the crystalline solid. The applied stress needs to exceed the 
elastic limit or reach the yield stress in order for plastic deformation to occur and to 
‗break‘ the crystal. Linear breakage models have been presented to predict the applied 
stress required based on knowledge of intermolecular forces which understandably are 
limited and result in underestimation and overestimation [5]. 
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In addition, the total applied stress is not completely utilised to cause breakage 
with significant amounts stored within the crystals as strain energy. This energy is the 
area under the curve in a stress strain graph between the origin and elastic limit. Strain 
energy however isn‘t equally distributed throughout the crystal but concentrated in the 
defects within the crystals [197]. 
      √
 
 
 
Equ. 3.3.1 – Inglis Factor 
 
The Inglis stress concentration factor, K, describes the extent at which strain 
energy is concentrated, where L is the half the length of the defect, R is the defect 
width. In order for crack initiation and propagation to occur, Griffith in addition 
proposed that there must be a known breakage mechanism for stress distribution with 
a critical defect size. Constant applied stress concentrated at the defects generates 
sufficient strain energy for breakage. This strain energy must be greater than energy 
of the new surface(s) created [209]. 
 
To further understand the milling process, Gilvary predicted the PSD of milled 
solid using the idea of different individual flaws/vacancies (volume, facial and edge) 
which are randomly distributed within the solid with crack propagation occurring 
upon removal of the applied stress. In addition Evans considered that depending on 
shape, compressive stress exceeding the fracture strength of the solid is sufficient to 
cause breakage without the presence of defects. For milled crystalline solids, it is 
important to consider the number of comminution steps and the process of defect 
formation and propagation (process induced structural disorder) on PSD post-milling 
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and upon storage. Finally there is a critical particle size at which no further breakage 
and occur due to the increase in fracture strength as particle size decreases with only 
elastic deformation is possible [210].  
 
3.4 Energy Relationships 
 
As touched upon in the introduction, there are three well-known related 
empirical models which have widely used to predict the energy requirements for 
effective particle size reduction. There is a general breakage law which considers 
energy, particle size, material and mechanism (equ. 3.4.1). 
 
  
  
      
Equ. 3.4.1 – General Breakage Law 
 
Rittinger first proposed in 1867 that energy requirement is direct proportional 
to the change in surface area (in this case it is the increase in surface area per unit 
volume or mass due to reduction in particle size) as shown in equ. 3.4.2, where E is 
the energy required, CR is the constant of proportionality (Rittinger‘s constant), L1 is 
the initial particle size and L2 is the final particle size and in the differentiated form 
(equ. 3.4.3) gives that greater energy is required linearly in order to achieve a smaller 
final particle size, L2 [46].  
    (
 
  
 
 
  
) 
 
Equ. 3.4.2 – Rittinger‘s  
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Equ. 3.4.3 – Differentiated Rittinger‘s 
 
Experimentally it has been found that Rittinger‘s Law is more suitable for the 
grinding of fine powders where significant surface area increase occurs as a result of 
particle size reduction. This is due to energy contribution in creating new surface is 
greater. In reality this is often a considerable underestimation as particle breakage is 
entirely due to creating new surfaces (sum of the surface energies of the new surfaces 
created is less than the input strain energy for breakage).  
 
     (
  
  
) 
 
Equ. 3.4.4 – Kick‘s 
 
In 1885, Kick suggested modification of the Rittinger‘s Law in order to 
consider that energy required is directly proportional to the size reduction in one 
dimension (size reduction ratio) in equ. 3.4.4, where E is the energy required, , C is 
the constant of proportionality, L1 is the initial particle size and L2 is the final particle 
size and in the differentiated form (equ. 3.4.5) where L is starting particle size with 
energy requirement being proportional to the change in particle size [47]. 
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Equ. 3.4.5 – Differentiated Kick‘s 
 
Kick‘s Law also greatly underestimates the energy requirements as only the 
linear particle size reduction ratio in one dimension is considered and this makes more 
suited for coarse crushing where particle size reduction has a relatively small 
contribution to increase in surface area per unit mass. 
 
      (
 
√  
 
 
√  
) 
 
Equ. 3.4.6 – Bond‘s 
 
  
  
   
 
    
 
 
Equ. 3.4.7 – Differentiated Bond‘s 
 
An intermediate between Rittinger‘s Law and Kick‘s Law was developed by 
Bond in 1952 (equ. 3.4.6 and equ. 3.4.7), both surface area increase and particle size 
reduction ratio are considered and can be applied for infinitely large initial particle 
size and minimum final particle size of 100m. As can be seen in the differentials of 
all three laws, they can be considered as one universal equation (equ. 3.4.8) where the 
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power of the particle size term (N) varies (Rittinger = 2, Kick = 1, Bond = 1.5) which 
is analogous to the general breakage law (equ. 3.4.1) [48, 50, 51]. 
 
  
  
   
 
  
 
 
Equ. 3.4.8 – Universal Breakage Law where L is initial particle size 
 
Application of these laws is dependent on requirement and previous 
understanding of industrial processes. The extent to which they can be used is 
summarised in fig. 3.4.1. 
 
 
Fig. 3.4.1 – Energy requirements as a function of particle size requirements [5] 
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3.5 Predicting Milling Behaviour 
 
As a physical model of particle interactions, milling has been thoroughly 
researched, to try to understand, predict and control the milling behaviour, i.e. the 
energy input required, fracture index and optimal conditions. Novel methods like 
nanoindentation (fig. 3.5.1a) and single particle impact testing (fig. 3.5.1b) have come 
a long way in helping to understand the inherent properties of the individual 
components of solid dosage forms and aid scale-up and mass production [10, 62].  
 
 
 
Fig. 3.5.1a – Nanoindented Sildenafil 
Citrate [62]
 
Fig. 3.5.1b – Schematic of Single Particle 
Impact Testing Setup [10] 
 
Milling kinetics can be predicted based on the rate of breakage, which is a 
function of the milling parameters (e.g. type of mill, milling conditions, feeding rate) 
and material parameters (e.g. mechanical properties, hardness, Young‘s modulus, 
input particle size). Particle breakage behaviour has been well studied, particular in 
the breakage of agglomerates, but has not taken into consideration the variation of 
powder mechanical properties which govern ‗millability‘ of a material [211, 212]. 
DEM and population balanced based modelling has also been utilised to better 
understand milling behaviour [213, 214].  
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3.6 Amorphisation and Polymorphic Transformation 
 
The physical changes that milling can generate are well established, with 
pronounced effects on physico-chemical properties and solubility, temperature effects 
on phase transformations, and significant changes in surface energy relating to water 
adsorption and wettability, which can alter the overall solid state stability of 
pharmaceuticals solids. The cracks/disorder/defects generated can be visualised, but it 
is yet unclear how these modifications result in amorphisation [215-218]. Zografi et 
al. have published extensively on assessing the level of disorder to quantify the so 
called disruptions and activation of the crystalline structure and attempt to relate these 
changes to the molecular mobility of amorphous materials [11, 34]. It is well known 
that a number of parameters can be altered during and post-milling, e.g. feed rate, 
milling rate/speed, temperature, relative humidity, the provision of gases (to aid 
milling or for safety) and system pressure all play a part but with varying significance 
in amorphisation (fig. 3.6.1) [38]. 
 
Fig. 3.6.1 – Polymorphic transformations during pharmaceutical processing [38] 
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The influence of temperature has been thoroughly studied, with the glass 
transition temperature (Tg) considered to be a critical factor that governs the 
thermodynamic stability. Tg is defined as the temperature at which an amorphous 
material changes state, below which it exists as a glassy solid and above which it 
exists as a rubbery/viscous liquid. In the rest of this discussion, when stating the role 
of Tg, it refers to the Tg of the amorphous form of a crystalline solid. Descamps et al. 
have described that milling well below the Tg can result in direct vitrification which 
generates a different form compared to the typical melt quench process. On the other 
hand, milling well above the Tg can induce polymorphic transformations to metastable 
forms. In addition milling just below the Tg can lead to transformations which are 
dependent on the milling intensity, which when high, results in amorphisation and 
when low, results in polymorphic transformation [219]. This ―inverse‖ relationship 
can be rationalised by the idea that at milling temperatures well below Tg, the system 
does not have sufficient kinetic input for molecular motion to restore the crystalline 
equilibrium [220].  
 
The explanation for the polymorphic transformations when milling above Tg is 
that both temperature and milling raises the energy state above even the metastable 
forms, so the most favourable conversion would be to an initial step to a less energetic 
metastable state before further conditioning can generate the most stable form. Otsuka 
et al. confirmed that milling leads to conversion of indomethacin to the metastable 
form from an initially unstable amorphous intermediate at a temperature just above Tg 
and conversion to a stable amorphous form at just below Tg [221]. These metastable 
conversions are seen in a number of pharmaceutical solids including lactose, 
trehalose, budesonide, sorbitol and mannitol [219, 222-225]. 
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In contrast Pirttimäki et al. have reported that milling can have the opposite 
effect with caffeine with quantitative XRPD analysis demonstrating that grinding and 
compression induced the transformation from the metastable form (I) to the stable 
form (II) [226]. Chieng et al. have also shown this can be true for ranitidine 
hydrochloride which is also believed to convert to a more stable form. However they 
reason that this may not be a simple polymorphic transformation. It is suggested 
instead that process induced structural disorder causes formation of an amorphous 
intermediate which through further milling generates nuclei of a different polymorph 
followed by growth and the subsequent conversion. At lower milling temperatures, 
this pseudo-transformation does not occur as an original polymorph nuclei present in 
the sample can lead to recrystallisation of the amorphous intermediate back to the 
original form. They also suggest that Tc may play a role in controlling these observed 
transitions. In this case when form I of ranitidine hydrochloride was milled below Tc, 
the amorphous form was created; when milled close to Tc, some amorphous drug was 
present, but predominantly form II was present indicating transformation; and finally 
when milled above Tc, transformation was faster with no amorphous form detected, 
possibly due to recrystallisation in the presence of form I nuclei [227]. 
 
Direct cooling of the milling process also confirmed the role that temperature 
can play in amorphisation. Feng et al. have shown that cryogenic milling induces 
amorphisation (crystal defects) rather than vitrification (amorphous regions), 
demonstrating that the bulk thermal properties of organic solids are linked to the 
propensity for amorphisation. Also to note, using Raman analysis they suggest that 
generating crystal defects and the amorphous form are two distinct events which may 
occur during mechanical processing [38]. Cryogenic milling can also be beneficial in 
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producing stable amorphous forms (e.g. ranitidine hydrochloride) as a novel technique 
to develop formulations for poorly soluble API [227]. Further work by Chieng et al. 
has shown that co-milling of complementary (mechanisms of action) crystalline APIs 
can also form stable amorphous systems to improve solubility. This binary system 
enhances amorphous stability through a reduction in free volume, which increases the 
Tg, thus delaying recrystallisation [228]. 
 
The mechanical stresses induced which affect ―local molecular organisation‖, 
is proportional to the milling intensity and at high intensity results in de-vitrification 
to a metastable phase, due to the high energy and disorder imparted into the system, 
which is similar to milling well above Tg. Whereas at low intensity, milling drives the 
―local molecular reorganisation‖ of any disorder back to the crystalline state [229]. 
Further studies have shown that the direct transformations induced by milling are 
independent of the initial state, controlled solely by the milling temperature. Also the 
so called ―duality‖ between amorphisation and polymorphic transformation occurs 
within a narrow range of temperatures just above and below the Tg [126]. 
 
Analysis of sulfamerazine showed that heating the original material using 
DSC causes irreversible transformation from form II to form I between 51C to 54C. 
When this was repeated with milled sulfamerazine (milled for 120 minutes), the 
temperature for this transition decreased slightly. XRPD showed that milling only 
reduced peak intensities and broadened the pattern, suggested to be an effect of 
reduced particle size and crystallinity with no polymorphic changes. Milling for a 
longer period (180 minutes) however resulted in complete transformation (in both 
directions – form I  form II and form II  form I) [230]. In summary it is difficult 
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to define a universal temperature derived relationship with regard to polymorphic and 
phase transformation characteristics of organic solids induced by milling. Establishing 
the Tg and Tc however can provide important information relating to the relative 
stability. The milling induced changes observed must be multi-factorial involving Tg, 
Tc, melting temperature (Tm), crystallisation kinetics, degree of weak intermolecular 
interactions (hydrogen bonding, van der Waals and electrostatic), molecular and 
crystal symmetry [219]. 
 
Relative humidity (RH) is another key factor in controlling the observed 
changes [54]. During milling the liberation of bound water i.e. from a hydrate, can 
increase free volume and enhance molecular mobility [87]. This is due to water‘s 
ability to act as a plasticiser by being dissolved in the amorphous solid, reducing 
hydrogen bonding between neighbouring molecules and lowering the Tg, which drives 
recrystallisation of amorphous/disordered regions created by milling [55]. This 
decrease in energy threshold for recrystallisation has been shown to be the direct 
result of mechanical activation. This has shown that Tg can be manipulated by a 
number of means, namely managing the effect of water plasticisation (RH control) 
and also the degree of molecular disorder generated by processing i.e. milling. By 
reducing Tg below operating temperatures through milling, model amorphous solids 
transformed from the glassy to the unstable rubbery state, immediately followed by 
crystallisation [87, 126]. A number of dynamic vapour sorption (DVS) studies, which 
generate RH using precise mass flow control have shown that all the transformations 
mentioned can be related to quantitative material specific mass changes and that the 
thermodynamically activated surfaces (by mechanical activation)  can be detected by 
the same technique [105, 231, 232]. 
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Ohta and Buckton have suggested that milling not only causes amorphisation 
but preferentially exposes hydrophilic groups (carbonyl). Inverse gas chromatography 
(IGC) studies have shown that acidic/basic nature (KD/KA) of surfaces provides a 
better correlation with the process induced crystallinity changes than the standard 
dispersive surface energies (DS). As RH increased, the exposed acidic hydrophilic 
groups on the surface of amorphous regions led to a decrease in basicity due to 
shielding by adsorbed water molecules. This dramatic alteration of surface pH 
presents another mechanism for the effect of moisture and further evidence for the 
importance of controlling RH during processing and storage of pharmaceutical solids 
[233]. 
 
Milling can generate molecular disorder or amorphous content which 
enhances the effect of water on solid state behaviour but it can also have impact on 
any further processing. Mechanical properties (relative density, tensile strength and 
Young‘s modulus) of both API and excipients can be affected by the presence of free 
water molecules. Gupta et al. found that moisture facilitated rearrangement and 
deformation of particles to influence the characteristics of the final dosage form [234]. 
Mosharraf et al. proposed that the specific effect of RH can also be linked to the 
solubility as this parameter is known to be distinctive for crystalline and amorphous 
phases. Upon storage at high RH the solubility of model materials decreased which 
they concluded was due to the re-crystallisation of disordered/amorphous structures 
on the surface of particles [235]. 
 
As well as RH studies, the use of organic DVS has enabled the study of the 
effect of partial pressure of various organic solvent on amorphous material. This 
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refinement of DVS allows for the sorption studies without the presence of water 
which as previously suggested plays a number of roles in driving recrystallisation. It 
also aids in the understanding of the change in surface chemistry as a result of process 
induced disorder. Whilst avoiding desorption difficulties when using water, which 
may become bound to the parent molecules through hydrogen bonding [236]. 
 
Li et al. have reported that the crystal defects generated through milling relate 
directly to the mechanism of transformation. A ―random nucleation and growth‖ 
(Avrami-Erofe‘ev) correlates with the post-milling kinetics observed. Also water can 
promote transformation even in hydrophobic systems by catalysing nucleation 
through binding/bridging defects which increases molecular mobility to drive 
transformation [237]. 
 
The actual milling time and residence time can also have a significant effect 
on the transitions observed. Zhang et al. showed that increasing the milling time of 
sulfamerazine can lead to complete transformation, rather than simply decreasing 
crystallinity (or increasing crystal defects) [230]. Increasing temperature drives the 
crystallisation kinetics resulting in reduction in milling time required for 
transformation [227]. Gupta et al. have suggested the milling time required may be 
related to the melting point as time for complete amorphisation was much lower for 
ketoprofen (4-6 hours) than naproxen, indomethacin and progesterone (18-24 hours) 
which have considerably higher melting points [238]. 
 
As well as looking at the effect of cryogenic milling, Feng et al. also found 
that crystalline and amorphous mixtures were inadequate in simulating process 
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induced crystal defects in the Griseofulvin model [38]. This is just one of many 
arguments against describing amorphous systems by quoting percentage content, 
derived from these mixtures. A recent study by Chamarthy et al. dispute the nature of 
disorder induced by milling, as the general consensus is that it must be amorphous – 
i.e. destruction of the crystal lattice must result in complete disorder. Their 
observations with two common API (griseofulvin and felodipine) have shown that 
there are little similarities between the milled and amorphous forms, leading them to 
postulate that the problematic changes in properties and behaviour are due to 
continuous defects or partial disorder in the crystal lattice proportional to milling 
intensity rather than the discrete classification of amorphous regions on the surface 
[37]. 
Chikhalia et al. found that the crystal morphology (habit) also influences the 
level of disorder. Milling caused partial conversion of -Succinic acid to the α-form 
but this did not contribute to the observed decrease in enthalpy of solution (Hsol) as 
the levels present detected by solution calorimetry was <2% w/w. It is suggested that 
in addition to milling-induced disorder, morphology has a significant effect as plate 
like crystals were more prone to disorder than needle like crystals. This was suggested 
to be due to the greater decrease in heat of solution for milled plate like crystals (ball 
milled or jet milled) and the reduction in crystallinity is thought to be directly related 
to the reduction in Hsol. As predicted, jet milling produced a finer material with 
greater surface disorder. The efficiency at which this type of milling imparts stress 
and causes fracture also means that tighter control of conditions are needed to prevent 
any undesirable changes in material properties [239]. 
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Brodka-Pfeiffer et al. have shown that grind pressure is the most important 
parameter in order to minimise amorphous content (crystal defects) generation whilst 
achieving optimum PSD. Insufficient pressure cannot produce the required size 
reduction and excess pressure can increase amorphous content on the surface without 
any effect on PSD. This extra energy input is stored and remains latent but over time 
and through stress relaxation can lead to further negative changes in PSD. At the same 
time, the influence of feed rate on crystallinity has been found to be insignificant. The 
increase in feed rate led to an increase in powder concentration in the grinding 
chamber which reduced the ―inter-particulate acceleration distance‖, resulting in 
coarser particles compared to lower feed rates [150]. 
 
Wildfong et al. have put forward a comprehensive model encompassing a 
number of parameters mentioned above with the aim to understanding the post-
milling behaviour. This model takes into consideration the changes in free energy 
required for lattice incorporation of a ―critical dislocation density‖. To determine the 
―critical dislocation density‖, the physical properties of the material are required e.g. 
elastic shear modulus, Burgers vector magnitude, molar volume, Tm, enthalpy of 
fusion (Hfus). The predictions are based on the fracture limit which when exceeded 
forces the lattice to accommodate dislocations (occurs during natural crystal growth 
when atoms are not spaced in set positions within the crystal lattice). When the 
―critical dislocation density‖ is reached, its energy state is equivalent to the 
amorphous form. Although there are a number of assumptions in this model, 
empirical data has shown that the amorphisation potential prediction were successful 
with six out of the seven materials [240, 241]. 
 
88 
 
To summarise, a number of important factors have been shown to affect the 
polymorphic transformation of amorphous and crystalline powders. Crystal defects 
and molecular mobility appear to be crucial to the physical stability irrespective of 
storage temperature and humidity, which facilitate any post-milling phase changes 
[126]. Also the characteristic changes observed have been compound specific, 
therefore greater understanding on the impact of milling is required in order to predict 
post-milling stability [242]. 
 
3.7 Milling Mechanisms and Post-Milling Behaviour 
 
Most modern comminution techniques rely on impaction/collision of particles 
and particle impact testing has given insight into the breakage mechanism and post-
breakage behaviour by studying the effects of particle size, impact velocity, impact 
angle, fatigue etc.  
 
Samimi et al. explored the effects of relative humidity, temperature, particle 
size, impact velocity, impact angle and fatigue on the breakage behaviour of 
agglomerates using particle impact testing. Plastic deformation was observed and 
suggested to be due to the elongation and rupture of strong ―inter-particle solid 
bridges‖ (50-200kcalmol-1), particularly with increasing RH which facilitates the 
process by increasing molecular mobility and weakening the agglomerates. Reducing 
RH (moisture desorption) i.e. dehydration, strengthens the agglomerates by 
solidifying these bridges. Reducing the temperature also increased deformation as 
cryogenic conditions led to brittle fracture, whilst at room temperature (RT) and just 
above RT (45
o
C) resulted in partial brittle failure by shear deformation [243]. 
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The Rumpf theory states that particle breakage occurs when adhesion forces 
are displaced by the applied separation force.  This net gain results in the fracture of 
all the inter-particle bridges along the ―rupture plane‖ (slip plane) [244]. Kendall 
however believes that this overestimates the total required energy for breakage. 
Proposing that nucleation of existing cracks/defects must also be considered [245]. 
Coury et al. attempted to investigate the validity of these two theories using two 
agglomeration processes (filtration cake removal and dry granule crushing). Their 
results suggest that for filtration cake removal, Rumpf‘s theory is more appropriate as 
the peeling process primarily concerns the displacement of adhesion forces between 
the cloth and the cake. Conversely for dry granule crushing, Kendall‘s theory is better 
as it takes into consideration, crack propagation as well as particle cohesion [246]. 
 
Subero et al. meanwhile have tried to classify and understand the patterns of 
agglomerate breakages. They observed two distinct types of breakages, one which 
resulted in localised damage by generating fines and minor aggregates (1-3 particles). 
This was termed localised disintegration (―standard‖ fragmentation) as 
defects/damage only occurred within the impact site. The other being localised 
disintegration combined with fracture and crack propagation. Fracturing of 
agglomerates can be subdivided into internal and interfacial. Internal fractures occur 
at inter-particle bridges between defined boundaries, resulting in ―clean‖ surfaces 
similar to the preference of paracetamol form I crystal to expose facet 010 on 
cleavage (milling). In order to determine or predict the pattern of breakage, thorough 
understanding of the complex variation in surface and bulk structure is required [52, 
247]. 
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Analysis of agglomerates obviously deals with much larger ―particles‖ but this 
retrospective approach in terms of steps within the manufacturing process has enabled 
insights into the underlying mechanisms. Sub-micron inhaled particles are inherently 
more difficult to examine, evidence has shown that post-milling, they have a greater 
propensity to agglomerate through fusion re-crystallisation of process induced 
amorphous regions [55]. The ―inter-particle bridging‖ concept helps to explain the 
empirical increase in particle size and decrease in BET surface area [56]. 
 
Omelczuk et al. have shown that micronised particles (jet-milling) display 
greater particle cohesion and higher particle-bonding index compared to other 
comminution processes. Therefore have a greater tendency to aggregate/agglomerate, 
leading to increase in PSD and decrease in SA upon post-milling storage. The surface 
energy of particles is also greatly altered as a result of milling [53]. Buckton et al. 
have shown that different comminution techniques can have a profound effect on 
surface energy, and consequently proportional to the efficiency of milling (energy 
input). In addition, further comminution did not greatly affect the initial change in 
surface energy which was suggested to mainly provide particle size reduction [217]. 
 
Newell et al. utilised inverse gas chromatography (IGC) to study the effects of 
milling on surface energy of lactose. They found that, as predicted there was a 
significant difference in surface energy between crystalline (0% amorphous content) 
and amorphous lactose (100% amorphous content). For milled lactose however, with 
only approximately 1% amorphous content (determined by amorphous/crystalline 
mixture and DSC), surface energy changes were similar to the complete amorphous 
lactose. This result indicates that although the increase in amorphous content may be 
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minor post-milling. The location rather than degree of disorder seems to play a greater 
role in determining surface energy as well as any interactions with other phases and 
surface energy is weakly associated to the bulk nature of powders [58]. 
 
Chen et al. have investigated the relationship between milling mode and 
Rittinger and Kick Laws. Using ball-milling, two modes were observed, impaction 
whereby the ball traverses between each end of the milling chamber and rolling 
whereby the ball rolls across the powder bed. Impaction, which mainly involves 
fragmentation, occurs with high frequency and smaller sample size, generating 
particles that follow Rittinger‘s model of energy vs. size reduction. Rolling however 
involves predominantly ―chipping‖ and attrition occurs with low frequency and larger 
sample size, more closely correlating with Kick‘s model. This study emphasises the 
need to take into consideration the size reduction mechanism as it may have a 
profound effect on type and level of defects and any further changes (polymorphic 
transformation, recrystallisation and vitrification) [248]. 
 
Most studies reviewed focus on the post-milling changes; de Vegt et al. sought 
to assess the effect of inherent crystal flaws on the breakage/fracture behaviour. Four 
samples of sodium chloride with increasing flaw density were jet-milled and the 
results showed that flaw density was proportional to the extent of fracture. This single 
variable study highlights the importance of existing defects but crucially, the authors 
reiterate the significance of initial particle size and the need for a holistic approach to 
understanding milled materials [249]. 
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Mechanical activation is another term coined to describe process by which 
milling alters stability of particulate systems. A number of studies have shown the 
correlation between milling-induced amorphicity and mechanical activation which 
influences polymorphic transformations, thermodynamic stability and functionality 
[54, 150, 240, 248, 250, 251]. 
 
As stated above Joshi et al. found that post-micronisation storage of 
budesonide (inhaled corticosteroid) led to substantial increase in specific SA (BET). 
This increase in SA was accompanied by other changes in porosity (increase in total 
pore volume and positive skew in pore size distribution), decrease in PSD and 
increase in surface rugosity/roughness, all enhanced by an increase in temperature 
(i.e. kinetic input). The explanation for these observed changes are based on the 
display of stress relaxation behaviour within organic solids. Residual stress (not 
released during fracture) accumulates within the areas of damage (defects – 
cracks/disorder/amorphous/partially-crystalline/chipping) and eventually over time 
causes extension/propagation of existing defects or creating new defects. Often these 
post-milling changes lead to formation of smaller secondary particles (minor 
agglomerates) which contribute toward the increase in SA. Increases in temperature 
and RH can often induce further agglomeration and particle growth which may 
explain any negative skew of PSD and decrease in SA [56]. 
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Fig. 3.7.1 - Mechanical activation of crystalline material followed by recrystallisation 
driven by T or RH [252] 
 
Brodka-Pfeiffer et al. have shown that these changes can be manipulated to be 
advantageous in controlling particle growth by post-milling conditioning. Effective 
control of temperature and RH will ensure complete re-crystallisation of any 
Mechanical Activation (Process Induced Structural Disorder)
Increase in T and/or RH
Molecular mobility drives transformation to a more thermodynamically 
stable state
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amorphous or crystal defect/disorder by mechanisms explained above. A critical 
temperature RH combination can be determined to minimise particle growth whilst 
maintaining or even enhancing overall stability [251]. 
 
Ng et al. have shown that post-milling, PSD can be manipulated depending on 
the storage conditions. PSD reduction can be attributed to the ―localised 
disintegration‖ where smaller particles break off from the disordered outer layer of the 
milled particles. Milling only disrupted weak van der Waals forces and ―interlocking 
or solid bridges‖. This breakage process supports the idea that the changes seen are 
due to stress relaxation, whereby excess stress applied through the milling process is 
stored and released over time, causing the particle breakages and a reduction in PSD. 
When the storage conditions were kept just above the critical relative humidity, the 
particle size remained relatively unchanged but increasing temperature led to re-
crystallisation, agglomeration and particle size enlargement [60]. 
 
Roberts et al. have recently reported the use of atomic force microscopy in 
order to determine the millability of pharmaceutical solids by relating the changes in 
mechanical (hardness, Young‘s modulus and their ratio) properties and surface energy 
of single particles. Milling/micronisation was found to clearly increase surface energy 
for all three polymorphs of carbamazepine and more importantly surface energy 
decreased upon storage for four weeks [253]. 
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Chapter 4 – Materials and Methods 
 
4.1 Materials 
 
 
 
Fig. 4.1.1 – Pharmaceutical Development Cycle (image courtesy of B. Glasser) 
 
Model material selection is particularly important in order to gain further 
understanding of physicochemical properties and behaviour through effective 
characterisation. Not only must the model material be relevant for application but 
have the appropriate properties in terms of preparation, handling and availability in 
order to achieve the aims and objectives of characterisation. In these studies, a 
number of chemical compounds have been prepared in a number of different ways to 
achieve the necessary solid-state properties to establish the physical stability of post-
milled pharmaceutical solids and also the underlying mechanism(s) for previously 
observed anomalous behaviour. The following sections will discuss in further detail 
the model compounds, preparation techniques and characterisation methods.
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4.1.1 Lactose 
 
 
 Lactose is a common excipient found in pharmaceutical formulations, usually 
as a bulking agent or filler to improve for example, compressibility and flowability. It 
is a major component and most important carbohydrate in mammalian milk. Its 
versatility in the solid state has resulted in a number of processed forms (sieved, 
milled, spray dried, granulated and anhydrous) in varied applications (wet 
granulation, dry granulation, direct compression, capsulation and powder blends) 
within pharmaceutical development. Of most interest in these studies is the use of 
lactose as carrier particles and adherent particles (‗glue‘) in dry powder inhaled 
formulations. Lactose has been widely studied in terms of solid state physicochemical 
properties and therefore presents an ideal relevant compound for study, particularly 
due to availability and lack of handling issues [254]. 
 
 Lactose (milk sugar – molecular formula, C12H22O11), a disaccharide (IUPAC 
name – -D-galactopyranosyl-(1→4)-D-glucose), is a dimer made up of two 
monosaccharides, galactose and D-glucose. It was first discovered by Fabriccio 
Bartoletti, in Bovine milk, in 1619 and classified as a sugar by Carl Wilhelm Scheele 
in 1780 with its faint flavour giving the slight sweetness to milk. Lack of digestive 
lactases has resulted in a large human population who are lactose intolerant. Whilst in 
the young, during infant development, this intolerance results in general indigestion 
which has been traditionally described as colic [255]. 
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Fig. 4.1.2 – Lactose (2D structural formula) 
 
 
Fig. 4.1.3 – Lactose (3D structural formula) 
 
The monomers, galactose and glucose are joined together by a -1→4    
glycosidic/glucosidic linkage created by simple condensation of the two hydroxyl 
groups (
1
C of galactose and 
4
C of D-glucose). Lactose has two isomers, α and β which 
differ in the orientation (facing or away) of hydrogen and hydroxyl group on 
1
C of D-
glucose. In solution there is a constant conversion of  to  and  to  which is 
termed mutarotation, the rate of which is dependent on pH, temperature and 
concentration until equilibrium at room temperature a ratio of 40%:60%. This key 
factor needs considered in working with lactose in terms of controlling crystallisation 
and physicochemical properties. These isomers are also diastereomers which rotate 
planar polarised light by different angles depending on relative concentrations. In 
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addition there is a critical temperature for lactose crystallisation from aqueous 
solution (93.5C), below which crystalline -lactose forms are made and above which 
crystalline pure anhydrous -lactose is made.  
 
   
-lactose monohydrate -lactose spray dried lactose 
Fig. 4.1.4 – Lactose forms 
 
Lactose exists in four primary distinct solid state crystalline polymorphs: -
lactose (anhydrous – stable and unstable which is hygroscopic), -lactose 
(anhydrous), -lactose monohydrate (the most stable and most prevalent) and -
lactose monohydrate (unstable – mutarotates to ). -lactose monohydrate is the 
commercial crystalline form (hard and brittle) which is monoclinic (space group P21 – 
tomahawk shaped) prepared usually by cooling an aqueous supersaturated solution at 
low temperatures followed by centrifugation and drying. Pure -lactose (space group 
P21 – kite shaped) is anhydrous and more brittle than -lactose monohydrate and 
usually prepared acidic alcoholic refluxing. Industrial anhydrous lactose used for 
direct compression filler-binder contains 80% -lactose and 20% -lactose and is 
prepared by roller drying highly concentrated lactose solutions [256].  
 
Non-crystalline lactose is commonly prepared by spray drying and freeze 
drying. On an industrial scale, highly concentrated aqueous lactose solution is rapidly 
dried to produce anhydrous amorphous lactose particles (as determined by XRPD, 
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DSC and DVS) which are usually spherical in shape with size being controlled by 
liquid droplet size (by controlling nozzle size and feed rate), carrier gas flow rate and 
drying temperatures. Spray dried lactose contains both -lactose and -lactose 
(40%:60%) and is hard but not brittle like the crystalline forms, has good flow 
properties and plastically deforms well, therefore highly suitable as an excipient for 
direct compression formulation [184]. 
 
4.1.2 Spray Drying 
 
Spray drying is a widely used industrial (food, pharmaceuticals, fast moving 
consumer goods) scalable process for particle formation and drying through rapid 
precipitation. It is versatile and can be made continuous in the preparation of powders 
and granules. Generating the solid state form and removal of water from 
liquids/solutions/emulsions help to improve physical stability and increase shelf-life, 
with the added advantage of reduced volume and weight for transportation. 
 
The process begins with atomising of a single or multiple liquid feed using a 
carrier gas feed into a fine spray or mist of liquid droplets, droplet size can be 
controlled by nozzle diameter and feed rate, which will also determine the shape, size 
and physical properties of the spray dried powder product. The product itself can be 
crystalline, partially crystalline or amorphous depending on drying rate and post-
drying processing.  
 
Droplet generation can be achieved through four distinct methods: 
pressurisation, bi-fluid impingement, rotary atomisation and ultrasonic agitation in 
100 
 
order to disperse the liquid feed; the dispersion energy being inversely proportional to 
particle size. Particle formation occurs when the liquid droplets come in contact with 
hot gas in a drying column/chamber/bed. Effective heat and mass transfer is required 
to produce high quality spray dried product and there are three flow regimes: co-
current, counter-current and combined flow to ensure mixing of the spray and drying 
gas. Evaporation occurs rapidly at the saturated vapour film layer on the surface of the 
droplet, due to an osmotic gradient and high contact surface area. Contact time which 
is dependent on dryer design should be sufficient (residence time) to result in 
complete evaporation of water or other solvents from the droplets and the formation 
of dry, spherical particles, yet minimises thermal degradation. Separation of the spray 
dried product from drying gas occurs initially at the base of the drying 
column/chamber/bed, followed by further cooling through usually a cyclone before 
final collection [257].  
 
1. Air inlet 
2. Heater 
3. Inlet temperature 
4. Flow through drying 
column/chamber/bed 
5. Outlet temperature 
6. Cyclone 
7. Product collection 
8. Aspirator with HEPA filter 
 
Fig. 4.1.5 – Schematic of standard bi-fluid co-current cyclone spray dryer (image 
courtesy of Büchi) 
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4.1.3 Micronisation 
 
Fig. 4.1.6 – Schematic of a jet mill (microniser) [12] 
 
Micronisation is the particle size reduction process (comminution) by which 
fine powders in the order of microns are produced, mainly to reduce particle size 
(tighten PSD), increase surface area to improve solubility, dissolution, formulation 
and bioavailability of drug compounds. The breakage mechanism is predominantly as 
a result of particle-particle interactions where stress results primarily in fracture 
through mechanical impact, fluidised energy impact and some attrition. Micronisation 
or jet-milling usually involves introducing dry feed powders at higher pressure 
(Venturi pressure) into a ring of converging air Jetstream at lower pressure (Ring 
Pressure). Pressure differential is created by Venturi effect to fluidise the particles and 
provide sufficient mechanical energy for particle collisions and breakage.  Larger 
particles begin at the outer perimeter of the ring and as size is reduced, move towards 
the centre of the ring due to centrifugal effect, and eventually discharge into a 
collecting chamber or classifier. Micronisation is normally utilised in the 
pharmaceutical industry to provide particles between 1m to 30m using samples 
from 0.2g to industrial scale [206]. 
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4.1.4 Indomethacin 
 
Fig. 4.1.7 – Indomethacin (2D structural formula) 
 
Indomethacin is an orally active compound classified as a non-steroidal anti-
inflammatory drug (NSAID – e.g. aspirin, ibuprofen, diclofenac, ketoprofen etc.) 
which has anti-inflammatory, analgesic and anti-pyretic properties. Its main 
mechanism of action is non-specific inhibition of cyclooxygenases (COX-1 and COX-
2), enzymes which control the synthesis of prostaglandin, a major proponent of 
inflammation. Due to relative potency and side-effects, it has been reserved for the 
treatment of chronic inflammatory conditions such as arthritis and gout. It is a BCS 
class II compound (poorly soluble, highly permeable). 
 
Crystalline indomethacin exists in five distinct polymorphs, , , ,  and  
with  being the thermodynamically most stable form. The melting points (Tm) of the 
five are 152C – 156C, 158C – 161C, 158C – 162C, 148C and 134C 
respectively. The glass transition temperature (Tg) of indomethacin being 
approximately 42C. Amorphous indomethacin can be prepared by quench cooling a 
melt using liquid nitrogen or natural cooling a melt to room temperature. Crystalline 
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indomethacin powder is an off-white powders, upon melt, produces an intense 
fluorescent yellow glass [258-260]. 
  
4.1.5 Felodipine 
 
Fig. 4.1.8 – Felodipine (2D structural formula) 
 
Felodipine is an orally active pharmaceutical compound classified as a 
calcium channel antagonist (blocker, of the dihydropyridine class e.g. amlodipine, 
nifedipine, lercanidipine etc.) primarily used in the control of hypertension (elevated 
blood pressure). The mechanism of action is reversible block of voltage-gated calcium 
channels in the cardiac smooth muscle (heart and blood vessels), which leads to lower 
intracellular calcium concentration resulting in reduced muscular contractions. It is 
normally given in combination with other anti-hypertensives for the treatment of heart 
disease and related co-morbidities. 
 
Crystalline felodipine exists in five distinct polymorphs: I, II, III, IV and V 
with V being the thermodynamically most stable form. The melting points (Tm) of the 
five are 133.9C, 140C – 142C, 144.9C, 137.6C and 147.1C respectively. The 
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glass transition temperature (Tg) of felodipine being approximately 44C. Amorphous 
felodipine can be prepared by quench cooling a melt using liquid nitrogen or natural 
cooling a melt to room temperature. Crystalline felodipine powder is an off-white 
powders, upon melt, produces a clear translucent glass. It is also a BCS Class II 
compound [261]. 
 
4.1.6 Quench Melting 
 
   
 
Fig. 4.1.9 – Trehalose Dihydrate Melt Formation, example of a small molecule 
organic glass prepared by room temperature melt without quench cooling (initial 
dehydration followed by melt and significant reduction in volume) 
 
Quenching melting is a common method to prepare glasses and amorphous 
solids by rapid cooling the liquid melt. The heating and quenching rate greatly affects 
the properties of the glass (fragility, see chapter 2) and results in ‗polyamorphism‘. 
Quenching the melt prevents re-crystallisation by minimising opportunity for medium 
and long range order to be established, the molten liquid becomes ‗supercooled‘, 
usually by liquid nitrogen, the rapid heat transfer and dissipation, freezes the liquid, 
minimises molecular motions and reduces potential intermolecular interactions. 
Viscosity of the liquid rapidly increases continuously during cooling, ‗continuous 
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hardening‘, resulting in the glass/amorphous solid. This is opposite to crystallisation 
of the melt where there is a sudden increase in viscosity, ‗discrete hardening‘, as 
nucleation and growth occurs. Cooling rate must be sufficient to prevent 
crystallisation. The critical cooling rate qc necessary for glass formation, which is also 
knowns as vitrification is: 
    
      
   
 
Equ. 4.1.1 – Critical Vitrification Cooling Rate [262] 
 
Where 1n is the induction/nucleation time at Tn, Tm is the melting temperature 
and Tn is the nominal final temperature. Usually the maximum cooling rate that can 
be achieved is in the order of 10
7
 Ks
-1 
but in thin films it is possible to reach 10
14
 Ks
-1
 
[111].  
 
4.1.7 Mannitol 
 
 
Fig. 4.1.10 – D-mannitol (2D structural formula) 
 
D-mannitol is a common compatible excipient used in the pharmaceutical 
industry, mostly to improve caking, mouth feel and non-sugar sweetening agent. 
There are three known polymorphs of D-mannitol,  (orthorhombic – P212121),  
(orthothrombic – P212121) and  (monoclinic – P21), with Tm of 166C, 166.5C and 
106 
 
155C respectively and a Tg of approximately 12.6C. D-mannitol is usually obtained 
by hydrogenation of fructose and can be crystallised from aqueous solution by 
controlled evaporation, low moisture melt and spray dried. It has been selected due to 
the ease of surface functionalisation via reflux silanisation to manipulate the 
dispersive surface energetics. Large numbers of free hydroxyl (-OH) functional 
groups on the surface allows for dispersive surface energy, acid-base character and 
surface chemistry to be altered [263-265]. 
 
Fig. 4.1.11 – Macroscopic D-mannitol Crystal [265] 
 
4.1.8 Silanisation 
 
Fig. 4.1.12 – Mannitol Silanisation Mechanism (hydrophilic surface hydroxyl groups 
modified to hydrophobic methylsiloxyl groups) 
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 Silanisation is the process by which surfaces can be modified through self-
assembly with the use of alkoxysilane molecules which themselves have been 
functionalised with organic functional groups. A hydrophilic starting surface (organic 
or inorganic) is required and in the case of pharmaceutical solids, macroscopic 
crystals or crystalline powders can be modified by refluxing in a suitable solvent with 
pre-functionalised alkoxysilanes (-SiO2R-). Nucleophilic attack (substitution) of 
surface hydroxyl groups of the crystal enables covalent bond (O-Si-O) to form which 
can have different properties depending on the functionalised silane (-R e.g. -CH3, -
NH2, -Cl, -C6H5) used [266].  
 
In the case of pharmaceutical powders, Ho et al. have shown with D-mannitol, 
the ability to manipulate the surface properties (surface energy, hydrophobicity) of 
both macroscopic crystal and crystalline powder in order to further understand the 
role of surface properties on high shear wet granulation [265]. Other more industrious 
purposes include controlling the adhesion/bonding of coatings to inorganic materials 
such as minerals, glass and metal oxides. 
 
4.1.9 Powders for Cohesion Testing 
 
4.1.9.1 Microcrystalline Cellulose 
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Fig. 4.1.13 – Microcrystalline Cellulose (2D structural formula) 
Microcrystalline cellulose (MCC) is an excipient/additive prepared from 
refined wood pulp and has many uses, particularly in pharmaceutical formulations to 
improve binding, flowability, compactability, density, mouthfeel, granulation, 
compression etc. It is a naturally occurring cellulosic polymer first marketed by FMC 
Biopolymer as Avicel (American Viscose Cellulose), it is composed of D-glucose 
monomers linked by a 1-4 -glycosidic bond to form linear chains which are then 
bundled together as water insoluble microfibrils in plant cell walls. The microfibrils 
contain crystalline and amorphous regions, the crystalline regions being used to 
prepare MCC. MCC in powder form is an off-white crystalline powder (see fig. 
4.1.14) which is highly hygroscopic, with PSD altered depending on application 
[267]. 
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Fig. 4.1.14 – Powder X-ray Diffractogram of Avicel PH-101 
 
 
 
 
 
 
4.1.9.2 Starch 
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Fig. 4.1.15 – above) amylose, below) amylopectin (2D structural formulae) 
 
Starch is a polysaccharide based polymer made up of D-glucose repeating sub-
units linked by 1-4 -glycosidic bonds and exist in -helices as amylose (15% - 30%) 
and cross-linked -helices as amylopectin (70%- 85%). It is produced by plants as an 
energy store and in consequence has become the main carbohydrate based energy 
source for humans in the form of wheat, maize, rice and potatoes. Starch is also an 
off-white powder that is practically insoluble in water at room temperature. It is a 
commonly used bulking agent in the pharmaceutical industry as well as disintegrant 
(swelling upon on contact with water), lubricant, glidants and in pre-gelatinised form 
[268]. 
 
4.1.9.3 Magnesium Stearate 
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Fig. 4.1.16 – Magnesium Stearate (2D structural formula) 
 
Magnesium stearate, also known as magnesium dioctadecanoate 
(Mg(C18H35O2)2) is another off-white powder, insoluble in water. The stearic acid salt 
of magnesium has a Tm of approximately 120°C and considered by the FDA as 
generally recognized as safe (GRAS) with inactive ingredient maximum potency in 
tablet formulation being 400.748mg. 
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4.2 Methods 
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Fig. 4.2.1 – Key Development Factors of Pharmaceutical Solids 
 
Characterisation methods differ from analytical methods due to the nature of 
the query. In analytical methods, the ideal result is usually known and generally the 
hypothesis is clearly defined. They are mainly carried out for quality control or 
validation purposes. Characterisation methods differ in that a property, behaviour or 
phenomenon is not well understood and can‘t be ‗analysed‘ as part of a standard test, 
instead based on theory and available techniques, a property is measured or 
determined in order to explain the behaviour or phenomenon. Therefore it is 
important to not only understand the objectives of characterisation when designing the 
experiments but also to carefully select techniques and consider their limitation in 
order to carry out effective characterisation. The following sections will discuss in 
further detail the characterisation methods, their development and implementation. 
113 
 
4.2.1 Optical Profilometry 
 
 
 
 
Fig. 4.2.2 – Schematic of Optical Profilometer (adapted from Wyko Technical 
Manual 1999) 
 
Optical profilometry is a non-contact, interferometric technique commonly 
used in surface metrology. Due to rapid data acquisition through the usage of a 
charged coupled device (CCD), high resolution and signal-to-noise ratio, it provides 
an excellent tool for quality control and surface analysis in solid state electronics and 
materials science.  
 
Fig. 4.2.3 – Interferences Fringes 
(constructive – white vertical band, 
destructive – black vertical band, sample – 
paracetamol crystals) 
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The technique is based on interferometry and was first developed by Albert 
Abraham Michelson and Edward Williams Morley in 1887 in the famous Michelson-
Morley experiment (fig. 4.2.2). A source of light, usually from a white light emitting 
diode (LED), is split into two beams, a test/sample beam and a reference beam by a 
beam-splitter (two triangular glass prisms), a height measurement is made by 
determining the optical path difference between the test/sample beam (which is 
reflected from the sample surface) and the reference beam (which is reflected from 
the reference surface), constructive and destructive interference occur when these two 
beams are combined and the path difference of the two light beams is within a few 
wavelength, with well-defined interference fringes at the focal point (fig. 4.2.3).  
 
 
 
Fig. 4.2.4 – Comparison of Mirau and Michelson objectives 
 
The main difference between the two objectives is that in the Mirau objective 
the reference mirror sits in-line with the optical path rather than ninety degrees to the 
optical path in the Michelson. The reason being that large FOV (low magnification) 
requires a large reference mirror which cannot be placed in-line with optical path due 
to light obstruction (fig. 4.2.4). 
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4.2.2 Through Transmissive Media Objective 
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Chamber (VGI)
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Fig. 4.2.5 – Through Transmissive Media Objective Schematic (adapted from WYKO 
Surface Profilers Technical Reference Manual, September 1999) 
 
Due to issues with aberrations and dispersion when analysing enclosed or 
packaged samples, a compensatory Michelson objective was developed. The 
reference beam is ‗compensated‘ for by being passed through essentially the same 
material as the test/sample beam (same material as enclosure with the same 
thickness). To reduce the effect of dispersion at higher magnification, an additional 
light box is added. This setup enables the monitoring of sample in-situ which can be 
combined with a relative humidity and temperature controlled cell (SMS VGI2000M). 
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Fig. 4.2.6 – VGI Schematic 
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4.2.3 Stress Relaxation 
 
Stress relaxation is the measure of the decrease in stress required to maintain 
constant strain in a material kept at constant temperature. By measuring stress 
relaxation in the linear viscoelastic region (elastic rubbery region, at relatively low 
strain – see Chapter 3), molecular relaxation and viscoelastic behaviour of the 
material can be determined. It can also be determined by a creep test, whereby 
inversely, the increase in strain is measured whilst constant stress is maintained at 
constant temperature. Stress relaxation is usually measured by applying compressive 
force to the sample and measuring the counter-force using a load cell at the set 
temperature. It can also be measured in tension mode where by force is exerted 
continuously or intermittently as the sample is stretched/sheared (equ. 4.2.1). The aim 
of stress relaxation experiments is to determine the relaxation modulus of the material 
through a number of short experiments at different temperatures above and below the 
glass transition temperature of the material. This can only be done at low strains 
where modulus is independent of strain (equ. 4.2.2). This is termed the linear 
viscoelasticity region as stress applied to proportional to the strain [109, 209]. 
t t
ε ζ
 
Fig. 4.2.7 – Stress relaxation (left - strain vs. time, right - stress vs. time) 
 
G(t, 0)  (t)/0 (t)  G(t)0 
Equ. 4.2.1 – Shear relaxation modulus Equ. 4.2.2 - Linear viscoelasticity 
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4.2.4 Isothermal Low Strain Uniaxial Indentation 
 
  
 
Fig. 4.2.8 – Isothermal Low Strain Uniaxial Indentation Setup 
 
Low strain (<10%) indentation of pharmaceutical glasses at constant 
temperature was chosen as the technique to understand the viscoelastic behaviour of 
amorphous pharmaceutical solids. Stress relaxation curves generated at various 
temperatures below and above the glass transition temperature can be utilised to 
construct a master relaxation curve to describe the molecular relaxation behaviour of 
the material over time. In addition the superposition required to construct the curve is 
based on Boltzmann‘s principle and the shift factors calculated empirically can be 
used to describe the linear viscoelasticity of the amorphous pharmaceutical solid 
based on Williams-Landel-Ferry (WLF) model (see Chapter 2 and 6). This enables 
prediction of relaxation times as well as physical stability of the material as a function 
of temperature and/or relative humidity [109, 269]. 
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4.2.5 Unconfined Compression Test 
 
Platen
Strain 
Gauge
Load
Loading Frame
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Fig. 4.2.9 – UCT schematic 
 
Unconfined Compression Test (UCT) was first developed by Jenkins in 1932 
as a simple laboratory test to determine the strength and mechanical properties of 
soils. The undrained shear strength is a function of the unconfined compressive 
strength measured (Su = c / 2). By measuring compacted soil at different loads and 
extrapolation to zero compaction, soil cohesiveness can also be determined. The test 
involves preparation of cylindrical consolidated samples and measuring the uniaxial 
load behaviour. This provides information in terms of strength, effect of water 
content, mineral composition and overall soil quality. The standard method utilises a 
loading frame (fig. 4.2.9) whilst an autographic method also exists (both in BS and 
ASTM standards). A modified version of the UCT was developed using a load cell 
based mechanical tester (texture analyser) in compression mode, taking into 
consideration the requirement height:diameter ratio of 2:1 after preparation (Tf = 
tan + c where Tf is the shear strength,  is the normal consolidation stress,  is the 
angle of internal friction, the y-axis intercept c is cohesion) [270].  
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 4.2.6 Ultrafine Particle Fractionation 
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Fig. 4.2.10 – Schematic of Ultrafine Particle Fractionation System (MOUDI – Micro-
Orifice Uniform Deposit Impactor) 
 
 Existing powder characterisation techniques have struggled to deal with the 
presence of fine particles or ‗fines‘, i.e. those less than 5m in terms of nominal 
particle size and more importantly sub-micron particles termed ‗ultrafines‘ present in 
the bulk powder at low levels but contribute significantly to specific surface area, 
aerosolisation and physical changes. At present these particles exist between true 
nanoparticles, defined as those less than 100nm and the detectable range of laser 
diffraction instruments commonly used in pharmaceutical development. Light 
scattering provides higher resolution but requires wetting of the powder in diluent. In 
addition difficulties remain in determining other physico-chemical properties of fines 
and/or ultrafines. Thus this technique, ultrafine particle fractionation was developed in 
order to separate the fines from the bulk powder to enable analysis by conventional 
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means and to understand the role they may play in the physical behaviour of powders 
post-processing and more specifically, to measure the amorphicity of fines and 
ultrafines and ascertain their contribution to the physical instability of milled powders. 
 
4.2.7 Micro-Orifice Uniform Deposit Impaction (MOUDI) 
 
 
 
Fig. 4.2.11 – Schematic of MOUDI stages (MSP NanoMOUDI-II 125B Manual 2010) 
 
 The micro-orifice uniform deposit impactor was first developed by Marple et 
al. in the early 1990s as an improvement on inertial impactors with aim for the size 
selective capture and collection ultrafine particles. It is based on the simple 
mechanism that when powder dispersed in air is passed through nozzles, and the jets 
of particles are directed at a vertical cascade of impaction plates, the larger particles 
with greater inertia/mass will impact and collect on the upper plates, whereas the 
smaller particles will remain in the jet of air and circumvent the upper plates and 
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collect on the lower plates. This size selectivity is not absolute and is heavily 
dependent on sample preparation, dispersion and the particle size itself is not the 
physical dimension but a more complex parameter – mass median aerodynamic 
diameter which takes into consideration the density of the material as well as shape 
and porosity. The MOUDI utilises very small nozzles at low air pressures and rotating 
stages which has significantly improved collection efficiency and size selectivity 
[271]. 
 
4.2.8 Vibrating Turbine Aerosol Generation 
 
Powder dispersion and aerosolisation is vital in the effective ultrafine particle 
fractionation. The aerosol generator used in this case is unique in that three processes 
are controlled with feedback to generate the required powder aerosol. First of all, 
powder is fed into the sample chamber and agitated by a rotating turbine, rotation is 
generated by jets of pressurised air (1.5bar). Secondly to aid deagglomeration and 
dispersion of the powder, a vibrating cam is also agitating the powder. Thirdly, 
additional pressurised air is fed after the sample chamber to form the aerosol. 
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Fig. 4.2.12 – Schematic of Vilnius Aerosol 
Generator (Courtesy of EMMS – 
http://www.electromedsys.com/) 
 
This aerosol is then passed through a laser diffraction based measuring device 
which determines the powder concentration within the aerosol, the device is also part 
of the feedback control loop, so when concentration falls below threshold, it can 
increase the rotational speed of the turbine and aerosol generation air flow via a valve 
as well as increasing the speed of the vibrating cam. 
 
4.2.9 Other Characterisation Techniques 
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Fig. 4.2.13 – Physical Characterisation Methods (B. Hammouda, NIST) 
 
 
There are numerous characterisation techniques available to the modern 
materials scientist. The challenge is to first define the objectives of characterisation 
and then to select the appropriate techniques to enable understanding and further 
development. Broadly speaking, they can be categorised into the six key classes of 
techniques, namely, microscopy, calorimetry, chromatography, scattering, 
spectroscopy and sorption (fig. 4.2.13) which captures the majority of well understood 
physicochemical properties and characteristics of materials. Limitations have to be 
considered in selection in terms of sample size required, resolution. In order to 
achieve successful characterisation, almost always more than one technique is 
required with complementary techniques allowing for a more definitive conclusion. 
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4.2.10 Dynamic Vapour Sorption 
 
 
 
 
Fig. 4.2.14 – Schematic of Dynamic Vapour Sorption instrument (Courtesy of SMS) 
 
 
 Dynamic vapour sorption (DVS) is a gravimetric technique which measures 
the uptake or loss of water or other organic solvents of solid materials such as 
powders, fibres and membranes at controlled temperature and atmospheric pressure. 
The kinetics of gravimetric uptake or loss is determined by varying relative humidity 
(RH) or solvent partial pressure (PP) over set time.  
 
 Standard DVS systems utilise a microbalance with a mass resolution of 
±0.1g with sample range between 10mg – 150mg, RH/PP control of ±1% and 
temperature range of 5ºC - 60ºC (±0.5ºC). In this study, DVS has mainly been used to 
determine the amorphous content of amorphous or partially amorphous powders by n-
octane sorption [236]. Aside from this, there are a wide range of applications 
including moisture uptake, physical stability, hygroscopicity, surface energy, specific 
surface area, deliquescence, phase transition, hydration and dehydration, surface 
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adsorption and bulk absorption studies etc. can be carried out with the same 
instrument.  
 
4.2.11 Powder X-ray Diffraction 
 
 
 
 
Fig. 4.2.15 – Schematic of X-ray Powder Diffractometer 
 
 
X-ray powder diffraction (XRPD or PXRD) is a solid state characterisation 
technique mainly used to identify crystalline material in the form of finely powdered 
solids and to quantify the degree of crystallinity as well as the ability to determine 
unit cell dimensions.  Crystalline solids diffract monochromatic characteristic X-rays 
(K radiation generated with a Cu source is 1.54184Å) which match the atomic-
spacing of the internal crystal lattice. X-rays are generated by accelerating through 
high voltage, electrons produced from a heated filament in a vacuum cathode ray tube 
and fired at a metal target. The collision that occurs generates Brehmsstrahlung 
(‗braking radiation‘) and when electrons acquire sufficient energy through 
acceleration, the collisions can knock out outer electrons of the metal atoms, electrons 
at higher energy level will fill the vacancy and in the process release X-ray photons.  
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When the incident X-ray, lattice spacing and angle of diffraction obey Bragg‘s 
Law (nλ = 2dsinθ), constructive interference occurs and strong intensity peaks of 
radiation can be observed and recorded in the form of a diffractogram. The number, 
relative intensity and position (2) of these peaks can be used to describe the 
crystallinity of the powder. In modern XRPD, the powder sample is scanned at all 
angles of 2 using a goniometer arrangement and also rotates in order to take into 
consideration every possible orientation of crystal [272]. 
 
4.2.12 Differential Scanning Calorimetry 
 
Differential scanning calorimetry (DSC) is a thermal calorimetric technique 
commonly used to establish the physicochemical properties of pharmaceutical solids. 
By measuring the heat flow characteristics between the reference and sample with 
temperature and time, exothermic or endothermic changes and phase transitions can 
be determined qualitatively and changes in heat capacity and enthalpic information 
acquired quantitatively.  
 
 
          
 
Equ. 4.2.3 – Relationship between enthalpy and heat capacity 
(dH/dt = Cp dT/dt + C, where H is enthalpy, Cp is heat capacity, T is 
temperature and C are the thermal events) 
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Standard measurement parameters for solid state pharmaceuticals include 
glass transition temperature (see Chapter 2), crystallisation temperature and melting 
temperature, enthalpy of crystallisation and fusion etc. Other physical changes and 
chemical reactions involving change in heat such as polymer cross-linking (curing), 
oxidation or decomposition can also be measured. The main applications of DSC have 
been for identifying composition, establishing thermal and oxidative stability, analyse 
purity and assess degree of crystallinity of solid materials [273]. 
 
 
 
Fig. 4.2.16 – Schematic of Differential Scanning Calorimeter (www.anasys.co.uk) 
 
 
 
4.2.13 Scanning Electron Microscopy 
 
Scanning electron microscopy (SEM) is a microscopy imaging technique 
which utilises an electron beam to scan the surface of a solid material and provides 
high resolution two dimensional images with detailed topographical and 
morphological information and can be used qualitatively to measure particle size and 
128 
 
dimensions. Characteristic X-rays generated can also be used to determine chemical 
composition quantitatively (energy dispersive X-rays or EDX). SEM provides a much 
greater magnification range (typical up to 30,000X) and spacial resolution (typically 
between 50nm – 100nm) compared to light microscopy with further improvement 
depending on the type of detector.  
 
 
 
Fig. 4.2.17 – Schematic of Scanning Electron Microscope (ITG – UIUC) 
 
Electrons are usually generated from an electron gun by heating up a tungsten 
filament with an accelerating voltage between 0.2KeV to 40KeV and focused into a 
fine beam by a series of condenser lenses/apertures to a defined spot size. 
Bombardment of these electrons with different kinetic energy at the solid surface and 
subsequent deceleration generates a number of signals which can be used to form the 
image. Common signal/detector combination include backscattered electrons (BSE) in 
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which the incident electrons are deflected slightly beneath the surface and 
‗backscattered‘ at an angle (elastic scattering), secondary electrons (SE) which are 
lower in energy, the incident electron knocks out an electron from the outer shell of a 
surface atom (inelastic scattering). Much like XRPD, displacement of this electron 
will result in an electron from a higher level to fill the vacancy and simultaneously 
release a X-ray photon, the energy of which is characteristic to the atom and 
transition. SE collected by the detector can be further accelerated to emit light when 
passed through a scintillator (cathodoluminescence). 
 
4.2.14 Inverse Gas Chromatography 
 
 
Fig. 4.2.18 – The difference between conventional GC and IGC (Courtesy of SMS) 
 
 Inverse gas chromatography (IGC) is a solid state characterisation technique 
developed from gas chromatography (GC) to determine the surface properties of 
solids through the study of the interaction between the known gas probe molecules 
and the unknown solid surface. In that sense it is completely opposite to conventional 
GC where the packing is known and the sample in gaseous form is which is unknown 
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is passed through it. The retention time and volume whilst within the packing is 
characteristic of the sample.  
 
      
        
  
 
     
  
 
     
 
Equ. 4.2.4 – Schultz equation to determine dispersive energy based on retention 
volume (VR) 
 
IGC also utilises retention time and volume as the primary measurement 
parameters but instead of a single unknown gas sample, a range of specific apolar and 
polar probes are injected at varied flow rates, pulsatile or at constant concentration in 
order to understand the surface properties of the unknown solid packing, which can be 
in the form of powders, beads or fibres. The retention properties of the probe are 
defined by how strongly or weakly the intermolecular interactions are at the surface of 
the solid. Once the probe is eluted through the glass column packed with solid 
material (stoppered by silanised glass wool). It is usually detected by the flame 
ionisation detector, the same as a GC and therefore many known systems have been 
converted from standard GCs with the addition of a column oven. Thermal 
conductivity detector can also be used but are limited when thermal conductivities of 
different probes are too similar. There are an abundance of application for IGC, the 
most common being measuring the powder surface energy, polar or acid/base 
properties, phase transitions, diffusion and permeability. In this work, IGC has been 
utilised to relate the dispersive component of surface energy which consists of weak 
non-polar Van der Waals interactions that govern many of the phenomena observed in 
pharmaceutical powder behaviour [106].  
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Chapter 5 - Physical Volume Changes during Recrystallisation of 
Spray Dried Amorphous Lactose 
 
5.1 Measuring Physical Volume Changes in Recrystallisation of Amorphous 
Spray Dried Lactose 
 
The characterisation of amorphous pharmaceutical solids, including physical 
stability under the influence of temperature and relative humidity and subsequent re-
crystallisation behaviour, remains a major industrial challenge. This concern is 
particularly true for materials with low levels (≤10%) of ‗amorphicity‘ which can 
have a significant effect on final drug product stability [40]. A number of bulk 
techniques including gravimetric dynamic vapour sorption (kinetic related mass 
change – uptake or loss), differential scanning calorimetry (thermal phase transitions) 
and X-ray powder diffraction (structural order) have been used to study amorphous 
pharmaceutical solids and to establish stability profiles for the development of solid 
dosage forms [71]. They are all integral to current industrial methodology in solid 
state form screening but have limited ability to understand milling induced amorphous 
solids, and provide only some qualitative insight into the external physical changes 
associated with internal amorphous to crystalline structural transformation.  
 
It is generally assumed that for milled powders, any resultant process induced 
structural disorder, particularly on the surface of particles, will be susceptible to the 
same humidity/temperature/time facilitated re-crystallisation as the equivalent bulk 
solid during controlled storage [38, 43, 90]. This behaviour is hypothesised to be due 
to the viscoelastic nature of the amorphous particles, and their enhanced molecular 
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mobility once they have been plasticised by water [34, 90]. Substantial changes in 
physical properties of milled pharmaceutical powders have been observed with time, 
especially changes in particle size and specific surface area [55, 56]. An increase in 
particle size and decrease in specific surface area may be due to the creation of high 
energy sites and/or amorphous zones on the surface which promote particle cohesion 
and agglomeration [58, 59, 251]. A decrease in particle size and increase in specific 
surface area were also observed, though less often, attributed to intra-particle crack 
formation, particle fracture and crack propagation [60]. 
 
The aim of this study was to investigate the volumetric behaviour related to 
when small compacts of milled powders are exposed to elevated environmental 
conditions that induce morphological changes during amorphous-crystalline phase 
transitions.  The work carried out utilises a new and novel experimental concept based 
on optical profilometry (OP). This dilatometric approach quantifies the dimensional 
changes of powder compacts, initially associated with water sorption in sample 
compacts made from a known model amorphous powder and tracks the subsequent 
amorphous re-crystallisation [274, 275]. 
 
The novel aspect of this approach relies on white-light non-contact optical 
surface profilometry, which determines the optical path difference between the 
reflected test/sample beam and the reflected reference beam. Constructive and 
destructive interference (coherence) can occur when these two beams are combined, 
with well‐defined interference fringes at the focal point where precise height 
measurements (x/y resolution is ~0.5μm and z resolution is ~2nm in vertical scanning 
interferometry mode) are made [276, 277]. This system has an optional through-
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transmissive-media interferometric objective (Michelson), which consists of an 
optical compensator (with a cover glass of same thickness as the environmental 
chamber, parallel to the reference mirror) to enable in-situ analysis of samples of 
interest under controlled temperature and relative humidity [278]. 
 
This new instrumentation configuration has not been previously reported and 
not only offers high dimensional resolution, but could also be employed when only 
small amounts of material are available to assess physical dimensional stability of 
solids or to evaluate the performance of thin coatings and films on tablets. 
 
5.2 Materials and Methods 
 
5.2.1 Materials 
 
Amorphous lactose was prepared by spray drying. Crystalline α-lactose 
monohydrate (L3625-5kg, reagent grade, ~0.01% D-glucose, ~4% β-lactose, Sigma-
Aldrich, Gillingham, UK) was dissolved in deionised water (ELGA Ultra Pure) at a 
concentration of 10%, w/v. The solution was spray dried (Pro-C-epT 4M8 Spray 
Dryer, Zelzate, Belgium) using a medium cyclone with a 0.4mm bi-fluid nozzle 
(1.5bar pressure and 3L/min flow rate) at an inlet temperature of 150C, 2ml/min feed 
rate, nozzle air flow rate of 0.3m
3
/min, cooling air flow rate of 0.25 m
3
/min and 
cyclone pressure difference of 25mbar. To ensure the spray dried lactose was 
sufficiently dry before analysis, the sample was placed above phosphorus pentoxide 
(Sicapent with indicator – VWR, Lutterworth, UK) in a glass desiccator for 1 week. 
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5.2.2 Optical Profilometry 
 
Approximately 50mg of sample was compressed into 5mm diameter, 0.8mm 
thick cylindrical compacts at 20kN using a 5mm stainless steel evacuable die and 
manual tablet press (Specac Ltd. Slough, UK). The sample compact was then placed 
on a glass slide in a temperature and relative humidity controlled environmental cell 
(VGI2000M, Surface Measurement Systems, London, UK). An optical profilometer 
(Wyko NT9100, Bruker-Nano, Tucson, USA) was then operated in the vertical 
scanning interferometry mode with a 10X true transmissive media objective and a 
0.55X field of view objective. Primary scan parameters were set at 0µm backscan, 
1000µm scan length, 1X scan speed and 1% modulation threshold. The height of the 
top surface of the sample compact was monitored at the same exact sample area 
(2300µm by 1700µm) over a 10 hour period with a range of temperatures and relative 
humidities, with an initial one hour of 0% RH drying to ensure no surface/bulk 
changes as a result of residual moisture left from spray drying. The compact height 
measurements were made using Bruker VISION® software with both relative surface 
height changes measured (with respect to initial height H0) and absolute overall 
compact height changes (step measurement between glass slide and top of compact). 
 
5.2.3 Dynamic Vapour Sorption 
 
 
 
Gravimetric Dynamic Vapour Sorption (Surface Measurement Systems DVS-
1, London, UK) measurements were carried out to measure the water sorption 
behaviour and the bulk re-crystallisation kinetics. The Cahn recording microbalance 
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has a mass resolution of ±0.1g with a sample range between 10-150mg. Relative 
humidities were generated by mixing water saturated vapour and dry air using mass 
flow controllers at a standard total gas flow of 200sccm. The sample (~50 mg) was 
initially dried at 0%RH for 8 hours to remove any residual moisture, and then exposed 
to various relative humidities (±1.0%) for 10 hours whilst the temperature was 
controlled (±0.1C). 
 
5.2.4 X-ray Powder Diffraction 
 
X-ray powder diffraction (PANalytical X‘Pert PRO X-ray diffractometer, 
Almelo, The Netherlands) was used to assess the crystallinity of the different sample 
compacts pre/post exposure to changes in relative humidity. Samples were scanned 
(Ni filtered Cu-α radiation at 40kV, 40mA) using a standard 5-60 (2θ) method 
(0.016
 
step size, 2s count time) and data converted using PowDLL. 
 
5.2.5 Nitrogen Gas Adsorption 
 
Nitrogen gas adsorption (Micromeritics Tristar 3000, Norcross, GA, USA) 
was used to determine the change in BET specific surface area of amorphous spray-
dried lactose (ASL) and crystalline α-lactose monohydrate (CLM) compacts during 
in-situ physical aging at different conditions (25°C 0% RH and 25°C 60% RH). 20 
compacts (as prepared in OP experiments) were placed in 3/8-in OD glass sample 
holders and degassed at 25°C under helium flow for 3 hours prior to analysis.  
136 
 
5.3 Results and Discussion 
 
5.3.1 Reproducibility 
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Fig. 5.3.1 – Change in surface height of crystalline -lactose monohydrate compacts 
(H) as a function of time at 0% RH and 25C (n = 3) 
 
The data shown in Fig. 5.3.1 was used to validate the precision and long term 
stability of height measurements of powder compacts. Surface height as measured by 
this OP setup was found to be highly reproducible using a crystalline -lactose 
monohydrate compact prepared in the same way as a standard. Error in measurement 
was found to be approximately ±0.02m (0.0025%) with a similar stability over a 10 
hour period. This high level of quantitative precision of a dilatometer can only be 
achieved by use of an OP based system. It corresponds to a stability of ~25ppm in 
sample dimension measurement for this reference sample. A key feature of the 
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approach reported here is the ability to provide full 2-D topographical mapping as a 
function of time. 
 
5.3.2 Measurement Parameters 
 
 
Fig. 5.3.2 – Compact dimensions and measurement parameters 
 
Compact measurements were made in x, y and z directions (fig. 5.3.2). Only z 
direction data (compact height) are reported due to significant changes (increases) 
measured during controlled physical conditioning. Overall net change in x and y 
directions were approximately 0.5m (0.01% of compact diameter). This may be due 
to the compaction process, where x and y diametral confinement in the tablet die 
results in greater powder densification around the circumference of the compact 
which limits volumetric expansion in those regions thus constraining physical changes 
induced by moisture. Expansion or shrinkage in the z or vertical direction was not 
constrained and therefore more significant and hence the focus of this study. 
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5.3.3 Gravimetric Dynamic Vapour Sorption 
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Fig. 5.3.3 – DVS profile of amorphous spray dried lactose at 25C. Samples were 
dried for 480 minutes then exposed various RH steps as indicated above 
 
Gravimetric DVS (fig. 5.3.3) of amorphous spray-dried lactose at different 
RHs showed that crystallisation only occurred when RH was above 51% at 25ºC, with 
rapid water sorption as mass increases dramatically followed by water loss due to re-
crystallisation (: polymorphic mixture confirmed by PXRD in fig. 5.3.9 – second 
curve from X axis with peaks at 10.5º 2 and 12.5º 2). The difference in kinetics 
between 55% RH and 75% RH is due to more rapid moisture uptake, greater 
plasticising effect which drives the re-crystallisation process [130, 274].  
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5.3.4 Compact Height 
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Fig. 5.3.4 – Compact height of amorphous spray dried lactose compacts (n = 3) as a 
function of time at 35% RH 25C 
 
When measuring overall compact change (H0 + H), it was observed that at 
35% RH (fig. 5.3.4), no significant changes were observed over the entire duration of 
the experiment with compact height remaining at approximately 830m±5m. Once 
RH exceeded the critical for amorphous spray dried lactose re-crystallisation in the 
presence of water at 25ºC (51% RH), substantial increases in dimensions were 
observed [130]. Compact height increases began first at 75% RH (~60 minutes, fig. 
5.3.6) followed by 55% RH (~100 minutes, fig. 5.3.5). This was due to the higher rate 
of moisture uptake which was confirmed by DVS (fig. 5.3.3). 
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Fig. 5.3.5 – Compact height of amorphous spray dried lactose compacts (n = 3) as a 
function of time at 55% RH 25C 
 
Overall compact height increases however was greater for 55% RH, this 
difference was attributed to the rapid absorption of water into the bulk of the compact 
resulting in crystallisation, at which point volumetric expansion reduces as moisture 
uptake ceases and water is released due to hydrate formation [279]. The net change in 
compact height observed at 55% RH of 90m versus at 75% RH of 40m was due to 
the slower sorption kinetics, the slight delay enabling overall higher water uptake 
(AUC in DVS plot – fig. 5.3.5 and fig. 5.3.6). 
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Fig. 5.3.6 – Compact height of amorphous spray dried lactose compacts (n = 3) as a 
function of time at 75% RH 25C 
 
Higher moisture content at 55% RH as well as presence of water not involved 
in crystallisation led to more pronounced compact volume expansion by extending the 
process of water sorption, plasticisation and rubbery flow resulted in greater increases 
in compact height. It must be noted that in this measurement, no compacts had true 
linear z or vertical expansion due to variations in local density and/or porosity within 
the compact from compression and viscoelastic relaxation [280]. Height 
measurements were taken as an average over the scan area analysed and repeated (n 
=3). Therefore greater errors in expansion kinetics were observed at 55% RH and 
75% RH, with average height values indicating greater overall expansion at 55% RH 
and faster kinetics at 75% RH (fig. 5.3.5 and fig. 5.3.6) [281]. 
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5.3.5 Specific Surface Area 
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Fig. 5.3.7 – Physical Aging of Amorphous Spray-dried Lactose (ASL) and  
Crystalline -Lactose Monohydrate (CLM) compacts (n = 20) 
 
 Another area of interest in this study was whether there was any change in 
compact surface area during these aging experiments. The compact diameter of 5mm 
used in this part of the study was chosen to allow direct BET analysis of intact 
compacts. The physical aging study of amorphous spray dried lactose (ASL) and 
crystalline -lactose monohydrate (CLM) as measured by N2 gas adsorption. BET 
specific surface areas were calculated using full isotherms. Fig. 5.3.7 shows the 
detailed aging study of compact surface areas for range of conditions over seven 
weeks. In all cases there were no significant variations (>5%) in surface area, 
suggesting that the overall structure and morphology of the compacts do not change 
significantly due to either water sorption or crystallisation. This is in contradiction to 
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work by Sebhatu et al. which inferred significant changes (>80%) in sample surface 
area under conditions identical to those reported here with only 15% amorphous 
spray-dried lactose in compacts. In this case, whilst specific surface area remained 
low but typical of crystalline pharmaceutical powders, no noticeable changes in 
compact surface area could be detected by N2 gas adsorption. Complete amorphous-
crystalline transformation of compacts used was confirmed by XRPD (fig. 5.3.9), and 
whilst theory and literature suggests that local structure and porosity changes should 
occur upon re-crystallisation, this null result indicates that subtle dimensional changes 
due to moisture uptake and phase transformation in these compacts cannot be 
measured by conventional approaches such as DVS, DSC or XRPD [282].  
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5.3.6 Surface Height 
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Fig. 5.3.8 – Averaged surface height of amorphous spray dried lactose compacts (n = 
3) as a function of time for a series of different humidity profiles at 25C. 
 
Significant increases in sample surface height were observed once the RH at 
25C was raised above the critical RH of 51% for amorphous spray dried lactose (fig. 
5.3.8). Minor fluctuations in surface height at 35% RH (<5m) were attributed to 
surface moisture sorption, leading to minimal changes in surface topography. Also 
bulk amorphous phase re-crystallisation has been found to be limited by surface 
kinetics, which in this case at 35% RH is only sufficient in affecting the free surface 
water. At the two higher RHs (55% and 75% RH) rapid bulk moisture sorption (fig. 
5.3.8) led to local material structural changes, which manifest themselves in small 
initial decreases in surface height. This decrease was then followed by significant 
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increases in surface height due to the moisture induced re-crystallisation of the 
amorphous spray dried lactose.  The data in fig. 5.3.8 shows greater induction time at 
55% RH compared to 75% RH.  Overall, the surface height changes remained 
nominally the same when RH was elevated above critical.  
 
At 35% RH (25°C), a very small, <5μm in 800μm, total increase in compact 
height was observed. This corresponds to an overall dimensional change of 0.6%. 
Accompanying this small dimensional change, DVS data (fig. 5.3.3) shows that 35% 
RH will result in a ~6% increase in sample mass due to moisture sorption. Otsuka et 
al. have examined the moisture induced volume expansion of amorphous lactose 
tablets at 30°C for a similar range of RHs [283]. For 35% RH, Otsuka et al. reported a 
5% mass increase, in line with the data summarised here, but with a much larger, 4% 
volume expansion. It has been established that the condition of 35% RH at 25 °C is 
below the critical conditions under which amorphous lactose will pass through its 
effective Tg. Haque and Roos reported that for a moisture content of 6%, the Tg onset 
for amorphous spray dried lactose is ~35°C [284]. 
 
Hölck et al. meanwhile have studied gas sorption in glassy polymers and 
found that for carbon dioxide and methane, in two different glassy polymers, the 
percentage sorbed solute or mass of sorbent was ten to twenty times the percentage 
volume change in the sample as measured by dilatometry [285]. Gotthardt et al. also 
measured carbon dioxide sorption in a range of glassy polymers and established that 
for an approximately 2.5% mass uptake of carbon dioxide per unit mass of polymer, 
volume changes were in the range of 0.3 to 0.6% volumetric change [286]. It is 
therefore concluded that the volume changes observed here for 35% RH of 0.6% 
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(associated with a 6% mass change due to water sorption – volumetric change being 
10% of mass uptake) for amorphous spray-dried lactose are fully consistent with 
water sorption by lactose in a glassy state [101]. 
 
A more complex pattern of compact surface height changes was observed for 
55% RH, which is above the critical RH (51%) at 25ºC for amorphous spray‐dried 
lactose where crystallisation will ensue [274]. The initial observation was a decrease 
in compact surface height of 2.5%, and therefore overall compact volume, despite the 
sorption of up to 12% of moisture per unit mass (fig. 5.3.3). This initial compact 
shrinkage in the z direction was observed in all six compacts tested at both 55% RH 
and 75% RH. Hygroscopic amorphous solids which obtain sufficiently high moisture 
content will pass through its effective Tg and as such will creep due to viscoelastic 
behaviour, due to significant lowering of the compressive moduli in response to the 
internal stresses present within the compacts as a result of initial uniaxial 
compression. In the relaxed state, the rubbery compact occupies a smaller volume 
than the initial glassy amorphous compact due to the creep governed loss of inter-
particle volume [287].  
 
This identical trend was first observed by Otsuka et al., although only 
approximately 0.8% volume decrease was reported [283]. This difference is attributed 
to fact that internal stresses within the compact was lower as compaction loads were 
five times lower (196MPa versus 1018MPa). Due to smaller compact dimensions, 
data reported here reached equilibrium typically after 8 hours in a 10 hour 
experimental run whereas Otsuka et al. experiments required more than 30 hours to 
achieve equilibrium [283]. The difference is consistent with the larger compact size 
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with ten times more sample (500mg versus 50mg), three times larger compact 
diameter (16mm versus 5mm). 
 
After the initial sample shrinkage at both 55% RH and 75% RH, the compacts 
then exhibited significant monotonic dimensional expansion of 120μm±3μm over the 
next 10 hours corresponding to a 15% increase in compact height. Volume expansions 
were found to be highly reproducible with all six compacts having relatively small 
standard error in the surface height measured. These changes can be associated with 
initial water sorption into the amorphous, but now rubbery particles, followed by 
subsequent crystallisation. Vapour sorption into rubbery materials is well known to 
cause large volumetric changes as measured by dilatometry due to enhanced 
molecular mobility [87]. In this case, the increase in molecular mobility resulted in 
direct crystallisation – hydrate formation [281]. Similar behaviour at faster kinetics 
was also observed at 75% RH. Longer induction time was observed at 55% RH 
compared to 75% RH due to higher rate of moisture uptake (fig. 5.3.3). Overall 
though the final equilibrium surface height changes remained nominally the same at 
different RHs, indicating that net volumetric change is governed by amorphous-
crystalline transformation rather than the rate of moisture uptake. 
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Fig. 5.3.9 – X-ray Powder Diffraction (PXRD) of lactose forms 
 
Though it is well understood that crystallisation can only occur with sufficient 
depression of Tg due to water sorption and molecular mobility enhancement, the 
compact dimension changes shown in fig. 5.3.8 show a continuous and smooth 
transition in sample height. This data is in contrast to gravimetric vapour sorption data 
shown in fig. 5.3.3, which shows two clear separate events; (I) the initial rapid 
sorption of water into the amorphous phase and (II) a subsequent delayed mass 
decrease following nucleation and crystallisation. It was not possible with the optical 
dilatometry data to differentiate between the kinetically driven dimensional changes 
associated with event (I) and (II). In comparison, although Otsuka et al. obtained 
significant increases in tablet volume at both 78% RH and 94% RH at 30ºC, with 
reported higher moisture concentration, only ~9% height increase was observed. They 
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did however observe a clear relationship between tablet volume change and mass loss. 
This step change in measured tablet volume was linked to lactose crystallisation, 
though the larger dimensions used their study and consequently much slower kinetics 
may explain the slight difference in observations at equilibrium. 
 
The overall type of behaviour reported here has been well documented with 
water acting as a plasticiser to lower the glass transition temperature (Tg for dry 
amorphous lactose is ~110°C) as amorphous lactose transitions from the glassy state 
to the rubbery state, increasing molecular mobility which in turn promotes 
crystallisation [288-290]. Water sorption also leads to macroscopic changes with 
increased compact permeability, loss of macro-pores and a more open structure upon, 
increased compact volume and finally re-crystallisation resulting in the volumetric 
changes and height increases observed [291]. Langrish and Wang have extensively 
reviewed the literature in this area with a focus on stability of food powders [288]. 
 
The physical behaviour of the amorphous spray-dried lactose compact upon 
exposure to above critical RH (51%) 25°C resulting in dimensional changes have 
been reported as follows [274, 275, 282, 288-291]: 
 
1. Initial water sorption into the glassy compact with minimal external 
dimensional changes 
2. Effective Tg depression due to sorbed water plasticising the glassy phase 
3. Transition of glassy into rubbery flowing phase due to the decrease in Tg 
4. Possible physical contraction of material ensemble if amorphous solid is 
within a mechanically highly constrained situation i.e. in a compact 
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5. Proceeding on to the complete rubbery phase which exhibits an even higher 
water sorption rate and net water content, with greater dimensional changes 
relative to the glassy phase 
6. Once the critical molecular mobility has been exceeded in specific regions of 
the rubbery phase, then nucleation within those specific regions will result in 
crystallisation, which in the case of lactose is hydrate formation, causing 
ejection of excess water from the crystalline phase 
 
The critical issue which unexplained by the sequence of events above is 
whether compact dimensional changes are governed by initial moisture swelling of 
the rubbery phase or controlled by the act of re-crystallisation. Burnett et al. have 
reported the crystallisation kinetics of amorphous spray-dried lactose in the kinetic 
driven region between 50% RH and 60% RH 25ºC where a two‐step crystallisation 
mechanism was in operation. The first step being autocatalytic crystal nucleation 
initiated by water sorption, and the second step which was three-dimension diffusion 
limited with water diffusing out of the crystallised lactose. Above 60% RH 25ºC only 
the first step occurred. This analysis however only focused on crystallisation and 
removal of water  and did not consider the impact of rate of water sorption and water 
content in the moisture swollen phase before crystallisation [274]. Currently there are 
no reports on the effect of moisture on the rubbery phase of amorphous solids. In 
order to fully appreciate the significance of volumetric behaviour in amorphous 
compacts during re-crystallisation, the kinetics of swelling process also need to be 
understood.  
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To summarise, the result of this study re-emphasises the important effects of 
water on physical changes in powder properties with moisture sorption and 
crystallisation causing significant volumetric expansion of amorphous compacts 
[283]. Crucially at scale these changes may lead to adverse effects in terms of 
processing and handling in the manufacturing of partially amorphous and amorphous 
pharmaceutical solids. With potential problems such as particle agglomeration, 
caking, poor powder flow, anomalous changes in particle size and specific surface 
areas. In addition, this novel approach has demonstrated the use of OP to study 
powder behaviour with high resolution.  
 
5.4 Conclusions 
 
It has been shown for the first time that small powder compacts made from 
substantially amorphous spray-dried lactose particles can exhibit up to 15% volume 
expansion at the free surface due to water sorption under conditions associated with 
the glass transition. At 35% RH 25ºC, amorphous spray-dried lactose compacts 
showed dimensional stability, but when RH was raised above the critical for moisture-
induced crystallisation (51% RH 25ºC), significant volume changes were observed. 
The compact volumetric behaviour is complicated as during water sorption, shrinkage 
and expansion both occurred with a multitude of water interactions with amorphous 
spray-dried lactose. The observations however are consistent with three different 
water sorption phenomena occurring in order with sorption in glassy and rubbery 
phases followed by amorphous-crystalline transformation. The resultant dimensional 
changes are attributed to all three phenomena, and therefore difficult to distinguish 
when linking to the volumetric changes measured. 
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Furthermore it has been shown that optical dilatometry can be used to assess 
the physical stability of amorphous materials by measuring compact dimensions, in-
situ under controlled environmental conditions with sub-micron resolution. This 
approach may be used to improve understanding of solution or vapour mediated re-
crystallisation of amorphous powders where subtle differences between surface and 
bulk physicochemical properties can impact processability and physical stability. 
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Chapter 6 Determining Viscoelasticity of Pharmaceutical Glass Melts 
by Stress Relaxation 
 
6.1 Linear Viscoelasticity of Pharmaceutical Glasses 
 
 
The amorphous state is of enormous interest for the pharmaceutical industry 
due to potential improvements in solubility, bioavailability and absorption of small 
organic molecules which are limited in the solid crystalline state. Especially as ~40% 
of drug compounds in development have been found to be poorly soluble (BCS class 
II) and even more in the earlier phases of drug discovery [21, 292].  
 
The actual enhancement in solubility and/or permeability (and thus 
bioavailability) between the amorphous and crystalline state is substantial but has 
been found to be less than predicted, due to amorphous forms being non-equilibrium 
metastable forms with a strong tendency to re-crystallise depending on storage and 
handling conditions [111, 117, 293].  Amorphous forms can be developed through 
‗amorphisation‘ by methods such as spray drying, freeze drying, vapour deposition 
and quench melting etc. They can be stabilised through API-polymer solid dispersions 
(hot-melt extrusion), complexation and co-milling (molecular alloying) to inhibit 
crystallisation and maintain advantageous properties of the amorphous form [35]. 
Nevertheless the intrinsic physicochemical instability of the amorphous phase remains 
the major stumbling block in their development and widespread adoption into existing 
formulation strategies. Further constraints are additional capital costs associated with 
scale-up and manufacturing of amorphous dosage forms [294]. 
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Fig. 6.1.1 – Volume versus temperature relationship for amorphous and crystalline 
solids [32] 
Amorphous forms are inherently unstable as a result of how they are formed. 
For example, as melt is cooled to near its glass transition temperature (dependent on 
the cooling rate), viscosity increases dramatically and molecular relaxation processes 
become infinitesimally slow as a result. Cooling (rapid or slow) prevents extensive 
molecular rearrangement and ultimately crystallisation but produce structurally 
different amorphous forms. Therefore the thermal history is vital to controlling the 
physicochemical properties of amorphous materials and has been manipulated for 
stabilisation and enhancement [34]. During pharmaceutical processing however, 
increase in temperature and/or relative humidity can lead to undesirable changes in 
physical stability [55]. 
 
Characterisation of amorphous pharmaceutical solids focus on empirical 
studies to determine the glass transition temperature and measuring the enthalpy of 
crystallisation using thermal techniques or vapour sorption using gravimetric 
techniques [71]. In this study, the linear viscoelasticity of pharmaceutical glasses was 
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measured by stress relaxation experiments with small sample strain (10%) and 
±10C of the Tg and this allowed the determination of constants for the William-
Landel-Ferry (WLF) model which provides the basis for predicting the mechanical 
relaxation behaviour of small molecule amorphous pharmaceutical solids [82, 295, 
296]. 
  
Global and local relaxation processes within amorphous solids are dependent 
on the cooperative mobility of molecules and result in the time and temperature 
dependent physicochemical properties observed experimentally. In order to 
characterise these relaxation processes, relaxation times need to be determined 
directly or indirectly. In this study, low strain normal stresses are applied to glassy 
amorphous solid cylinders uni-axially, to measure the stress decay profile which is a 
function of the relaxation time. Ultimately relaxation times are governed by the 
heterogeneous metastable structure formed from the super-cooled liquid and the 
resultant relative free volume which directly affects the relaxation processes [109, 
269].   
 
The temperature dependence of relaxation as the amorphous phase is initially 
cooled is dominated by -relaxation processes (global) where relaxation times 
increases do not follow Arrhenius behaviour. This tendency is due to significant 
structural relaxation as the system attempts to explore the energy landscape through 
molecular diffusion over long time periods which exceed plausible experimental time 
frames. Local or -relaxation occur over shorter time periods and usually below the 
glass transition and are related to local relaxation such as molecular motion of side 
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groups of branched polymers. As temperature approaches Tg, -relaxation tends to 
merge with -relaxation into one complex event/process. Although there is a clear 
relationship between these local and global processes, the underlying molecular 
mechanisms for -relaxation and -relaxation processes in amorphous solids are not 
well-defined. At temperatures just above the Tg, the temperature dependence of 
molecular relaxation is Arrhenius in nature by following the Vogel-Tammann-Fulcher 
(VTF) or Williams-Landel-Ferry (WLF) models [111, 188, 297]. 
 
6.2 Theoretical Background 
 
 
 The relaxation modulus in stress relaxation is defined as the ratio of set strain 
to the time dependent reduction in stress required to maintain the set strain (equ. 
6.2.1). Usually the relaxation modulus decreases with increasing temperature, as the 
time required for applied stress to equilibrate at set strain decreases exponentially. 
 
 
Equ. 6.2.1 – Relaxation modulus 
 
As eluded to earlier, in the Arrhenius behaviour range of temperatures just 
above and below the Tg, the temperature dependence of relaxation times can be 
described by the VTF or WLF equations (equ. 6.2.2) [109].  
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Equ. 6.2.2 – Standard Williams Landel Ferry Equation (Tr = reference temperature) 
 
 
 
Equ. 6.2.3 – Williams Landel Ferry Equation for polymers with universal C1 and C2  
 
Equ. 6.2.3 is the classic universal WLF equation based on experiments with 
polymers (e.g. polystyrene and polyisobutylene) and between Tg±50 has been 
applied to other polymer solutions, organic and inorganic amorphous solids and 
glasses. As conventional pharmaceuticals remain dominated by small organic 
molecules with much lower molecular weight compared to polymers, analogy has 
been made to observations with organic glasses such as glucose, dimethylthianthrene 
and abietic acid have been reported, where upon cooling to near the Tg, the super-
cooled liquid has marked increase in viscosity and relaxation times [82]. Relaxation 
times as expected are quite different with a much narrower distribution compared to 
polymers of much higher molecular weight. The temperature dependence of 
relaxation processes however very much exists, as confirmed by viscometry and 
dielectic spectroscopy [93, 298].  
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Fig. 6.2.1 – Time Temperature Superposition (TTS) Principle [299] 
 
 
 It is with this prior understanding that this work aims to measure relaxation 
modulus through mechanical stress relaxation in order to construct a master curve 
(fig. 6.2.1) by time shifting for known glass forming drug molecules. From which 
specific WLF equations can be formulated as a means to predict relaxation times 
under specific conditions and effectively their physical stability [109]. 
 
6.3 Materials and Methods 
 
6.3.1 Material  
 
Indomethacin (≥99% TLC) and felodipine were purchased from Sigma 
Aldrich (Gillingham, Dorset, UK) as off-white crystalline powders and used as 
received. Both compounds were chosen due to extensive previous work as model 
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amorphous pharmaceutical solids and both having relatively low Tg close to ambient 
temperature which maybe exceeded during processing and manufacturing.  
 
6.3.2 Slow Cooled Quench Melt 
 
Amorphous indomethacin (IMC) and felodipine (FELO) were prepared via 
slow quench melting in aluminium weight boats (round dish – 13mm diameter, 
3.5mm depth, VWR 12577-062, Lutterworth, Leicestershire, UK) using a hotplate 
(IKA RH-KT C), by heating up to ~160C and ~145C respectively for 5 minutes 
followed by slow cooling to ambient temperature (25C).  
 
6.3.3 X-ray Powder Diffraction  
 
Amorphous and crystalline forms of indomethacin and felodipine were 
confirmed using a PAnalytical (Almelo, the Netherlands) X‘Pert Pro X-ray 
diffractometer (Ni filtered Cu- radiation at 40kV, 40mA) with a standard 5-60 (2) 
method (0.016 step size, 2s count time) and data analysed using PowDLL, 
 
6.3.4 Differential Scanning Calorimetry 
 
Amorphous crystalline forms of indomethacin and felodipine were confirmed 
using a TA instruments (Newcastle, DE, USA) Q2000 differential scanning 
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calorimeter, ~5mg of sample were placed in standard Tzero pans and crimped. Each 
sample was heated from 20ºC to 200ºC (beyond Tm) at 10ºC/min and data was 
analysed using TA Universal Analysis. 
 
6.3.5 Stress Relaxation 
 
 
 
Fig. 6.3.1 – Schematic of stress relaxation setup (flat probe uni-axial compression – 
probe (blue), sample (white)) enclosed in temperature and relative humidity 
controlled chamber. 
 
Stress relaxation experiments (fig. 6.3.1) were performed using a TA.XT2i 
texture analyser (Stable Micro Systems, Godalming, Surrey, UK) with a 6mm 
diameter flat cylindrical stainless steel probe and a 5kg load cell (±0.1g force 
sensitivity) using a hold until time compression mode. Each sample (fig. X) post pre-
conditioning was indented at 10% strain for 36000 seconds (10 hours). Temperature 
(Fluke 50 Series II thermometer) and relative humidity (Rotronic S1 hygrometer) was 
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monitored throughout. The texture analyser itself was situated in a Borolab incubator 
with temperature control (5C – 60C±1C) and RH was monitored at 5%±1%. 
 
6.4 Results and Discussion 
 
6.4.1 Amorphous Forms 
 
Ambient glasses were prepared from as received crystalline forms and 
confirmed by both X-ray powder diffraction and differential scanning calorimetry. 
For indomethacin, the initial crystalline form was the most thermodynamically stable 
-form with a melting temperature of 161.5C and highly crystalline with a range of 
well-defined high intensity peaks between 10-30 2 (fig. 6.4.1). Amorphous 
indomethacin glass had a Tg onset of 42C, recrystallisation between a broad range of 
temperatures (100C – 150C) and a melting temperature of 158.5C (fig. 6.4.2) 
[258]. 
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Fig. 6.4.1 – X-ray diffractogram of IMC forms 
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Fig. 6.4.2 – DSC traces of indomethacin forms 
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For felodipine, the initial crystalline form was the most thermodynamically 
stable form III with a melting temperature of 147.5C and crystalline with a range of 
well-defined high intensity peaks between 10 – 35 2 (fig. 6.4.3). Amorphous 
indomethacin glass had a Tg onset of 40C, recrystallisation between a broad range of 
temperatures (90C – 130C) and a melting temperature of 137.5C indicating it is 
most likely the form known as Im which is formed from recrystallisation of the glassy 
melt (fig. 6.4.4) [261]. Ambient glasses were prepared instead of quench cooling with 
liquid nitrogen as the excess strain made it impossible to perform further stress 
relaxation experiments. The ambient glasses were stored over a week over P2O5 
(Sicapent) at ambient temperature in a glass desiccator to release any remaining 
strain within the glass.  
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Fig. 6.4.3 – X-ray diffractogram of felodipine forms (N.B. form III of 
crystalline felodipine) 
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Fig. 6.4.4 – DSC traces of felodipine forms (N.B. form III of crystalline felodipine) 
 
 
6.4.2 Stress Relaxation 
 
Deformation of prepared glasses at 10% strain (within the linear viscoelastic 
region) generated raw stress relaxation plots with good reproducibility for both 
materials, for example amorphous indomethacin glass (AIMC) at 40C in fig. 6.4.5 as 
well as modulus (E) plots (fig. 6.4.6) at temperatures above and below the known Tg. 
As previously discussed, because of the low molecular weight, indomethacin being 
~358gmol
-1 
and felodipine being ~384gmol
-1
 the range of temperature dependence is 
fairly narrow for organic glasses as compared to high molecular weight polymers.   
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Fig. 6.4.5 – Stress relaxation plots (Force vs. Time) (n = 3) 
 
The feasible temperature range for each glass was established experimentally 
to be 40C to 50C for both indomethacin and felodipine. Below the lower limit of the 
stated temperature range, relaxation processes are predominantly based on local, less 
significant -relaxations, which become difficult to characterise in realistic time 
frames and fall into the risk of auto-re-crystallisation. Above the upper limit of the 
temperature range, relaxation processes of small MW organic amorphous solids occur 
faster than the accurate response time of the load cell [300]. 
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Fig. 6.4.6 – Stress relaxation plots (Modulus vs. Time) (n = 3) 
 
A master curve can be constructed from the relaxation modulus over time 
plots of the chosen temperatures range to obtain the full scale of the relaxation 
behaviour over a much longer time period. This curve is as a result of the Boltzmann 
superposition principle which states that stress is a function of the strain history, 
therefore the net effect of a number of contiguous strain experiments is the same as 
the linear addition of a number of separate strain experiments under the same 
conditions.  In this specific case, experiments must operate within the linear 
viscoelastic region, where stress relaxation is a function of deformation 
characteristics, obtainable from multiple deformation steps, each of which have 
independent contribution to the deformation history, the linear sum of which equals 
the total net deformation [269]. 
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6.4.3 Indomethacin 
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Fig. 6.4.7 – Modulus curves of AIMC (40C-50C), Tg = 42C-47C 
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Fig. 6.4.8 – Master curve of AIMC (40C-50C), Tg = 42C-47C 
168 
 
T-T
g
 (
o
C)
-4 -2 0 2 4 6 8 10
lo
g
a
T
-3.0
-2.5
-2.0
-1.5
-1.0
-0.5
0.0
0.5
1.0
AIMC experimental shift factor (Tg = 42
o
C)
AIMC WLF shift factor (Tg = 42
o
C)
Experimental linear fit curve (R
2
 = 0.9729)
WLF linear fit curve (R
2
 = 0.9973)
   
Fig. 6.4.9 – Comparison between experimental and WLF Shift Factor of AIMC 
(40C-50C), Tg = 42C-47C 
 
In terms of relating the stress relaxation results to temperature dependent 
models (VTF/WLF), master curves were successfully constructed for both model 
materials. For indomethacin, individual stress relaxation modulus curves at different 
temperatures (fig. 6.4.7) were manually shifted using tracing paper to construct the 
master curve (fig. 6.4.8) and obtain shift factor values (tab. 6.4.1). There was good 
linear fit of experimental shift factors for indomethacin (fig. 6.4.9) (R
2
 = 0.9729) but 
better for the universal WLF derived shift factors (R
2
 = 0.9973). 
 
  
169 
 
6.4.4 Felodipine 
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Fig. 6.4.10 – Modulus curves of AFELO (42C-50C), Tg = 43C-49C 
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Fig. 6.4.11 – Master curve of AFELO (40C-50C), Tg = 43C-49C 
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Fig. 6.4.12 – Comparison between experimental and WLF Shift Factor of FELO 
(40C-50C), Tg = 43C-49C 
 
 
Material Temperature (C) Experimental logaT WLF derived logaT 
Amorphous 
Indomethacin 
40 0.25 0.70 
42 0.00 0.00 
44 -1.00 -0.65 
46 -1.50 -1.25 
48 -1.75 -1.81 
50 -2.50 -2.34 
Amorphous 
Felodipine 
40 1.50 1.47 
42 0.50 0.70 
44 0.00 0.00 
46 -0.25 -0.65 
48 -0.75 -1.25 
50 -1.10 -1.82 
 
Tab. 6.4.1 – Comparison between shift factors determined experimentally and derived 
from universal WLF equation 
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For felodipine, the master curve (fig. 6.4.11) was constructed in the same way 
manually using individual stress relaxation modulus curves at different temperatures 
(fig. 6.4.10) and with shift factor values quoted in tab. 6.4.1. Experimental shift 
factors for felodipine (fig. 6.4.12) also provided reasonably good linear fit (R
2
 = 
0.9527) but the universal WLF derived shift factor curve had a better linear fit (R
2
 = 
0.9969). 
 
WLF parameters (Tr/Tg, C1 and C2) for indomethacin and felodipine were 
obtained from experimentally determined shift factors with the following WLF 
equations with the reference temperature being the glass transition temperature: 
 
       
           
            
 
  
Equ. 6.4.1 – Experimentally determined WLF equation for amorphous indomethacin 
(slow melt) 
 
       
        
        
 
 
Equ. 6.4.2 – Experimentally determined WLF equation for amorphous felodipine 
(slow melt) 
 
 The shift factor at the temperature 2ºC above and below the Tg were chosen to 
determine the C1 and C2 using simple simultaneous equations. 
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No logarithmic decay in relaxation (shift factor) was observed as the 
temperature range (T-Tg) of the experiment was very narrow (~Tg+5ºC) compared to 
the full universal WLF range (Tg+100ºC). The linearity is a consequence of the 
narrow temperature range as well as the low molecular weight nature of the organic 
glass, which essentially behaves like a dilute solution of very low molecular weight 
polymer. The Arrhenius behaviour suggests predominantly local -relaxation rather 
than global -relaxation, with a lack of long range structural relaxation processes as 
usually obtained for polymer and macromolecules. This observation is consistent with 
the smaller MW nature of the model amorphous pharmaceutical solids studied here 
[188]. 
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6.5 Conclusions 
 
This study is the first known attempt to quantify viscoelasticity by directly 
measuring stress relaxation of amorphous pharmaceutical materials that normally 
exists as small molecular crystals. Experimental stress relaxation results over a range 
of temperatures for amorphous indomethacin and felodipine were used to construct 
master curves for both materials, as classically carried out for polymers. This data was 
then successfully analysed using the WLF model, with WLF parameters (C1 and C2) 
determined for both materials in a narrow range of temperatures above and below 
their glass transition, thus confirming the viscoelastic behaviour of these amorphous 
pharmaceutical glasses. As hypothesised, the viscoelastic driven mechanical transition 
observed were due to local -relaxation based processes rather than global -
relaxation based processes expected for macromolecular polymers. 
 
Under low strains, amorphous forms of small organic molecules in the solid 
state behave within the linear viscoelastic region through Arrhenius relaxation. More 
work is required at wider temperature ranges and amorphous pharmaceutical materials 
with higher glass transition temperature to further understand the universal 
applicability of WLF to amorphous pharmaceuticals and quantitatively define their 
stability. With the growing interest in the amorphous form, it provides an opportunity 
to understand the fundamental molecular relaxation mechanisms of different 
amorphous forms that control physicochemical properties and product stability. 
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Chapter 7 Establishing the Relationship between Surface Properties 
and Adhesion and Cohesion of Pharmaceutical Powders 
 
7.1 Unconfined Compression Testing of Loose Pharmaceutical Powder Compacts 
 
Powder cohesion or cohesiveness (―stickiness‖) remains a major challenge in 
the manufacturing of pharmaceuticals. The phenomenon of cohesion relates to a 
number of practical industrial issues where particles interact under low load 
conditions (such as internal self-loading with minimal external loading from 
container). Powder cohesion plays a key role in controlling active powder flow which 
has been well studied [301-304]. This current work focuses on static particulate 
systems which relates directly to the behaviour of stored powder and the 
aerosolisation and entrainment of inhaled carrier/active particles ensembles [305].  
 
The difficulty remains in measuring the weak intermolecular attractive forces 
between individual particles. Currently atomic force microscopy has been used for 
single particle measurements of cohesion and adhesion [306]. The practical use 
however of this approach is limited for routine industrial troubleshooting. For bulk 
ensembles, shear cell and angle of repose tests have standards for decades, whilst 
more recently powder rheometry experiments have been in vogue [307-309]. The 
focus of interest in this thesis is in measuring the cohesive inter-particle forces present 
in weakly compressed compacts where there is no active powder flow and where the 
normal contact stresses are low. This relates to the industrial post-filling of high 
surface energy micronised powders in dry powder inhaler capsules, where cohesion is 
directly related to the end-product performance (therapeutic effect) [310]. 
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Powder cohesion normally refers to the dry inter-particle adhesion which is 
predominantly due to long range Lifshitz-Van der Waals forces i.e. London dispersion 
forces. These are physical inter-particle forces which are uni-directional and present 
in all scales and states. In some cases very long range electrostatic forces can also be 
present in addition to Lifshitz-Van der Waals forces, for example during processing of 
powders through triboelectric charging [305]. 
 
It is particularly important in the pharmaceutical industry as cohesion is 
deemed to be inversely proportional to powder flowability, which is a key physical 
limiting factor to powder processability. The approach presented here is a simple 
method using existing equipment based on the undrained unconfined compression test 
first developed for soil mechanics with a number of standards including ASTM 
D2166, BS 1377:Part 7:1990:7.2 and BS 1377:Part2:1990:7.3 [270]. 
 
  
176 
 
7.1.1 Introduction 
 
A number of defined powder properties have been categorised in terms those 
fundamental to the individual constituent particle and those derived to the collective 
of particles referred to as a powder. Chemical composition, molecular structure, 
physical size/dimensions, shape, particle porosity, bulk density and surface texture are 
considered by Heywood as fundamental to the intrinsic particle [311]. Derived 
properties of the powder ensemble which are dependent on the fundamental properties 
but influenced by the preparation, processing and environmental conditions include 
particle size distribution (where size is often considered as the Feret diameter), 
powder specific surface area, flowability (e.g. Hausner ratio), cohesiveness, moisture 
content, powder porosity, compressibility (e.g. Carr‘s index), dilatancy etc. [312]. 
 
Cohesiveness and flowability are interrelated as a free flowing powder has low 
inter-particle cohesion and adhesion to the wall/surface of the container, whereas a 
highly cohesive powder has poor flowability with a tendency to adhere to equipment 
surfaces and result in caking [308].  Cohesive pharmaceutical powders can be very 
problematic industrially, as formulating a drug product consists of a number of unit 
operations involving many processing and handling steps. In addition powders are 
usually manufactured in batches and of high value, due to high potency, complexity in 
synthesis and scale-up [313].  Processing issues as a result of cohesiveness not only 
affect production also the direct performance of final drug product, for example in 
inhalation powder aerosolisation by the patient when using dry powder inhalers 
(DPIs) [15]. DPI capsules contain only a physical blend of API and carrier, so the 
blended powder properties and aerosolisation characteristics must be optimised with 
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the delivery device, which currently provide dose delivery efficiency around 10-15% 
(Advair - GlaxoSmithKline Diskus device, Salmeterol – 12%, Fluticasone – 15%), 
making it crucial to control cohesiveness of the powder blend in processing and upon 
storage [314]. 
 
As existing powder cohesion/flow tests such as annular shear test and powder 
rheometry requiring relative large powder samples in the order of hundreds of grams 
and also cannot measure very low unconfined yield strength [313]. There is a clear 
need to develop a rapid and robust method which can measure the cohesiveness of 
small (<1g) weak (<1kPa) pharmaceutical powder compacts, thus simulating the DPI 
capsule powder conditions. This work aims to modify and adapt the traditional 
unconfined compression test used in soil mechanics to measure cohesiveness of small 
loose pharmaceutical powder compacts and in addition relate cohesion parameter in 
terms of dispersive surface energy of the powders. 
 
  
178 
 
7.1.2 Powder Flow Properties 
 
The movement or flow of powder is essential in the manufacturing of solid 
state pharmaceuticals. Therefore it is essential to establish the flow properties of the 
desired powder. Undesirable effects of flow mechanism include segregation, risk of 
explosion on discharge, agglomeration and/or caking etc. Powder flow is part of the 
intrinsic nature of the bulk arrangement of particles and is a result of the fundamental 
properties and environmental conditions. Flow when described in terms of bulk solids 
can be fairly qualitative and relate to the container (e.g. silo) and dispensing device 
(e.g. hopper) and good and poor flow to this degree of precision can be easily deduced 
with the angle of repose test by pouring powder into a funnel and measuring the angle 
of the resultant powder heap (fig. 7.1.1). This can then help in the design of the 
hopper to ensure good flow [315]. 
 
Fig. 7.1.1 – Angle of Repose Test 
  
Flow can however be quantified further more directly when the stresses on the 
powder are taken into consideration. Under the confinement of the container and 
gravitational load of neighbouring particles, there can be significant stresses exerted 
on the powder. Flow can only occur when those stresses are exceeded i.e. above the 
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elastic limit resulting in plastic deformation and flowability is the measure of this 
required force. Microscopically, intermolecular forces govern the interaction between 
particles and the inner surface of the container, and between the particles themselves, 
these phenomena are termed adhesion and cohesion respectively. Adhesion is 
dependent on the powder properties as well as the container material, surface 
properties and environmental conditions (temperature, pressure and relative humidity). 
Cohesion is dependent mainly on the powder itself irrespective of whether the 
container is a silo or a capsule [305]. 
 
Fig. 7.1.2 – Mohr‘s stress circle  
 (where  is the shear stress,  is the consolidation or normal stress, T is the tensile 
strength, C is cohesion, UYS or c is the unconfined yield strength, MCS or 1 is the 
major consolidation stress or major principal stress a t steady flow and e is the angle 
of internal friction) 
 
In order to determine cohesion or cohesiveness of the powder, only two 
aspects of stress are taken into account, to be acting on the powder. The container 
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wall is considered to be frictionless and therefore only normal stress is acting 
vertically on the powder and in consequence, leads to stress being applied 
horizontally against the container wall (the ratio of the two is known as K or ), with 
shear stress occurring even at rest with no external mechanical influence. Therefore in 
the situation of the unconfined compression test, cohesiveness or force required for 
flow would be the shear stress required to break the powder compact and by 
extrapolating to zero consolidation stress, the intrinsic cohesion can be quantified. An 
important caveat for calculating cohesion in this manner is that only a one 
dimensional shear stress plane is considered whereas stress exerted on a particle in a 
powder is three dimensional. This can be represented by Mohr stress circles from 
shear elements which reflect the shear angle and the equilibrium between normal and 
shear stresses (fig. 7.1.2). In addition to cohesion, flowability can also be determined 
with the flow function which is the ratio of the consolidation stress and the 
unconfined yield stress and larger the ratio, the more free flowing the powder [5, 270]. 
Current methodology for measuring powder cohesion and flow involve ring shear 
cells and powder rheometry whereby shear forces through a powder bed are measured 
after initial consolidation based on Mohr-Coulomb failure criterion. 
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7.1.3 Materials and Methods 
 
7.1.3.1 Materials 
 
Powders of microcrystalline cellulose (Avicel PH-101), α-lactose 
monohydrate (Lactohale 210), starch (Starch 1500), dibasic calcium phosphate 
(DBP) (dihydrate, 04231, Sigma-Aldrich, Gillingham, UK) and magnesium stearate 
(MgSt) (26454, Sigma-Aldrich, Gillingham, UK) were used as received.  
 
7.1.3.2 Unconfined Compression Test 
 
Powder 
Compact
Uniaxial 
Compression
 
 
Fig. 7.1.3 – Schematic of unconfined uniaxial compression test 
 
1g of each excipient powder was weighed out and compacted in a 10 mm 
diameter evacuable pellet die (Specac, Slough, UK) to 10 N at 0.1 mm/s compaction 
speed using a TA.XT2i texture analyser (Stable Micro Systems, Godalming, UK). 
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The compacts varied in height depending on bulk density but height was maintained 
to be greater than the diameter. The deformation orientation was uniaxial. Cohesion 
tests were performed with a 36 mm diameter cylindrical aluminium probe and a 5 kg 
load cell using a set displacement compression mode with test speeds of 0.01 mm/s 
(fig. 7.1.3). Before each experiment, the texture analyser was calibrated for force, 
height and frame stiffness (compliance). Yield stresses were determined using the 
method above at different compaction loads (10N, 20N and 30N). Yield stress was 
plotted against compaction stress, cohesion being the y-axis intercept and angle of 
internal friction being the gradient of the curve. 
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7.1.4 Results and Discussion 
 
7.1.4.1 Unconfined Compression Test 
 
  
Fig. 7.1.4.1 – Weak cylindrical compact during unconfined yield stress test (left), 
compact post-yield (right). 
 
As shown in fig. 7.1.4.1, an aspect ratio of powder compact of at least 1:1, 
whereby the cylindrical compact height is greater than the diameter must be 
maintained in order to generate reproducible fracture/yield values. The top stainless 
steel pellet used in the compact preparation was removed during the ejection process, 
whilst the bottom pellet remains for transport from die to texture analyser platform 
and acts as the bottom platen for the experiment [270, 316]. 
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Fig. 7.1.4.2 – Shear failure modes, (a) dry soil – fracture failure, (b) wet soil – plastic 
flow [317] 
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Fig. 7.1.4.3 – Yield curves for common pharmaceutical excipients 
 
This simple test proved to be robust at measuring the yield stress of a number 
of common pharmaceutical excipients, some which have become problematic with 
other techniques (shear cell etc.). For example, when measuring cohesion powder 
blends using shear cells, the lubricant properties of magnesium stearate leads to lower 
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than expected cohesion values. This is advantageous for powder compaction purposes 
but undesired when determining cohesion. Fig. 7.1.4.3 shows the range of yield 
curves for the different powders chosen which have a variety of yield values and yield 
characteristics. Although they differ in terms of yield, all have an initial elastic 
deformation phase, followed by the yield point (peak force) at which shear fracture 
occurs. As the compacts are brittle, angular shear planes (45 to normal) were 
observed due to multiple fracture planes (fig. 7.1.4.1 & fig. 7.1.4.2) [317]. 
 
7.1.4.2 Yield Stress 
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Fig. 7.1.4.4 – Yield Stresses of Excipient Compacts (n = 6) 
 
Reproducible unconfined yield stresses were determined for all the powders 
(fig. 7.1.4.4), with accuracy dependent on load cell resolution which in this case was 
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±0.05N. Variability was due to using powder as received, this choice being intentional 
to test the robustness of the methodology. As expected, magnesium stearate, a 
common lubricant and glidant had low yield stress compared to other excipients. 
Starch 1500, a proprietary modified form of starch – partially pre-gelatinised starch 
(Colorcon) also had low yield stress which enables it to be used in direct compression 
formulations and negates the need for additional lubricants and glidants. Avicel PH-
101 had much higher yield stress as a result of a reported residual moisture level of 
3.0% - 5.0% which increases the compact strength. Lactohale 210 (LH-210, Friesland 
DOMO) having similar yield stresses but lower % error compared to dicalcium 
phosphate dihydrate (DCPD – Sigma-Aldrich) as LH-210 is an industrial grade milled 
and sieved fraction of lactose with much more narrow particle size distribution 
compared to a standard pharmaceutical reagent grade of DCPD. 
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Fig. 7.1.4.5 – Elastic Modulus of Excipient Compacts (n = 6) 
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Fig. 7.1.4.5 shows the elastic moduli of the different pharmaceutical powders. 
The trend is in agreement with the role of the different excipients. Starch 1500 
(Colorcon) being a pre-gelatinised version of the common bulking agent. Low elastic 
moduli are required in order to improve compressibility. Starch has the added benefit 
of being hydrophobic and results in swelling of the tablet on wetting and acting as a 
disintegrant. Magnesium stearate values being even lower as it acts as lubricant or 
glidant to improve flow, aiding dilatancy. DCPD being more difficult compress 
means that it is often used in sustained release formulations and finally lactohale 210 
being a milled and sieved -lactose monohydrate used as a DPI carrier, so 
compressibility is not so important.  
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Fig. 7.1.4.6 – Elastic Potential Energy of Excipient Compacts (n = 6) 
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Fig. 7.1.4.6 shows the elastic potential energies of the different pharmaceutical 
powder compacts. Whilst there is no clear correlation with elastic modulus, these 
values give an indication of the strength of compacts at the same consolidation stress. 
Starch 1500 (Colorcon) being lowest most likely due to large particle size and its 
inherent hydrophobicity. Magnesium stearate, DCPD and Lactohale 210 were similar 
in average energies and as expected the smallest particle size, Avicel PH-101 
(~50m) having the highest elastic potential energy. In addition microcrystalline 
cellulose is fairly hygroscopic so in preparation it is possible minimal moisture uptake 
could have further strengthened the compacts which were tested as prepared with no 
storage or conditioning and stored in zero RH ambient environment. 
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Fig. 7.1.4.7 – Dispersive Surface Energy of Excipient Compacts (Literature Values by 
Contact Angle Measurement) 
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 A comparison of dispersive surface energy of these powders as measured by 
sessile drop contact angle on powder compacts (fig. 7.1.4.7) showed no correlation 
with compact mechanical properties discussed above as determined by unconfined 
compression tests. This may be due to the powder dispersive surface energy 
measurement as it is an average equilibrium value dependent on surface roughness, 
surface asperities and minimal absorption of contact angle probes into the bulk of 
powder compact. More modern techniques such as atomic force microscopy and 
inverse gas chromatography provide much more reliable measurements of powder 
average surface energy [106, 318-320]. 
 
7.1.4.3 Cohesion 
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Fig. 7.1.4.8 – Shear stress at failure (f) versus normal stress (n) of common 
pharmaceutical excipient compacts 
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Excipient Cohesion (Pa) Angle of Internal Friction () 
Avicel PH-101 2962 1.472 
Starch 1500 1255 0.304 
DCPD 24567 1.673 
Magnesium Stearate 735 0.004 
Lactohale LH210 20137 1.151 
 
Tab. 7.1.4.1 – Summary of Common Pharmaceutical Excipients 
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Fig. 7.1.4.9 – Cohesion of Excipient Compacts 
 
 Cohesion were determined by linear extrapolation of yield stress best fit line at 
different consolidation stresses (fig. 7.1.4.8) and with angle of friction being a 
function of the gradient of the best fit line (tan
-1). Cohesion and angle of internal 
191 
 
friction values for the different excipients were in good agreement with elastic 
modulus values and the role of the excipients. Although the trend for angles of 
internal friction was different to cohesion in one case, with Avicel PH-101 which had 
significantly lower cohesion than Lactohale 210 (2962Pa versus 20137Pa).  
 
7.1.4.4 Comparison with Existing Techniques 
 
 
Cohesion, cohesiveness or cohesivity is influenced by numerous factors such 
as primary and secondary particle size, particle shape and density, moisture content, 
bulk consolidation pressure, storage time, container material and design. Cohesion 
can be measured in a number of ways ranging from uni-axial compression, ring and 
annular shear cell to powder rheometry, however cohesion values obtained can be 
quite different due to the shearing mechanism. The most common, so called 
‗universal‘ test has been the Jenike shear cell test (ASTM D6128-06) which utilises a 
bi-axial shear cell which deforms the consolidated sample in opposite directions at 
constant speed to obtain the frictional resistance between the particles and against the 
wall of the cell. It requires significant amount of sample and expertise to generate 
reproducible results. 
 
Part of the aim of this work was to develop a simple empirical test in similar 
vain to other flowability tests such as angle of repose, bulk density based Hausner 
ratio or Carr‘s index which does not require additional proprietary equipment such as 
the Jenike shear tester or the Schulze shear tester. Additionally, shear cells have been 
shown to be unable to detect the unconfined yield strength when the consolidation 
stress is low (~100Pa) [321]. Ramachandruni et al. have reported cohesion values for 
Avicel PH-101 which varied greatly depending on shear cell design modifications 
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(from 0.09kPa up to 0.68kPa) but under very different conditions to those reported 
above (30-100g of powder, consolidated for 15-20 minutes into a powder bed) [322]. 
The cohesion value using the UCT was approximately 3kPa (tab. 7.1.4.1 & fig. 
7.1.4.9). Rotational speed and powder bed height variation seem to have little effect 
on angle of effective friction and angle of internal friction (approximately 40º±2º) 
which were significantly different to UCT obtained values (approximately 
1.5º±0.25º). In addition, cohesion values between the different Avicel grades 
contradict the manufacturer (FMC Biopolymer) data as PH-101 recommended for wet 
granulation due to its binding properties which has small particle size (50m) was 
found to be less cohesive irrespective of shear mechanism than the larger particle size 
PH-102 (100m) for direct compression and PH-200 (180m) for superior flow.  
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7.1.5 Conclusions 
 
An unconfined compression test (UCT) has been demonstrated to be capable 
of reliably measuring the cohesion of small amounts of cohesive pharmaceutical 
powders. These loose compacts can be easily made as long as the critical dimensions 
are met (height must be at least twice the diameter of the cylindrical sample) to ensure 
reproducible shear and yield. Unconfined yield strength and cohesion data was in 
good agreement with the industrially recognised role of the pharmaceutical excipient 
powders tested. This test has potential use in an industrial setting due to its 
measurement simplicity and reliability. Further work is required to compare UCT to 
other common techniques used with regard to understanding the true cohesiveness of 
powders as cohesion measurements should provide similar trends in terms of relative 
cohesion. 
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7.2 Effect of Surface Energy on Cohesion of Pharmaceutical Powders 
 
7.2.1 Dispersive Surface Energy 
 
 
The surface energy of a solid surface () is the energy or work required to 
create or form a new surface (per unit area - mJm
-2
) and is often described as the 
excess free energy at the surface of the solid compared to the bulk of the solid. It is 
also the energy required to maintain this surface. In terms of cohesion, surface energy 
is related to the thermodynamic work of adhesion and work of cohesion which exists 
between materials, so when work of adhesion is greater than the work of cohesion, 
adhesion between two surfaces will occur as it‘s the more thermodynamically 
favourable state. 
 
Fowkes proposed that surface energy consists of a number of components 
including dispersive, polar and hydrogen bonding, which can also be classified into 
the Lifshitz Van der Waals interactions (dispersive) and acid-base interactions (polar) 
[323]. The dispersive component is further subdivided into Keesom (two permanent 
dipoles), Debye (permanent-induced dipoles) and London (fluctuating-induced 
dipoles) interactions.  
 
7.2.2 Surface Energy Heterogeneity 
 
Pharmaceutical powders are usually crystalline particles with multiple facets 
of different shapes and sizes. Heng et al. have shown that these crystalline solids 
exhibit a wide range of surface energies, each of which are characteristic to a specific 
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crystal facet [79]. Therefore the surface energy of a crystalline powder should not be 
quantified by a single average value as is the case of most reported contact angle 
measurements on pharmaceutical powders. Similarly atomic force microscopy and 
infinite dilution inverse gas chromatography (IGC) which are also used to study 
surface energetics only sample a small amount of the true surface and therefore 
cannot provide a fully representative dataset of sample surface energies. A new 
approach utilising finite dilution IGC at intermediate surface adsorption coverages 
enables the mapping of the surface energies of bulk powders which takes into 
consideration their innate surface energy heterogeneity [324]. 
 
7.2.3 Materials and Methods 
 
7.2.3.1 Materials 
 
D-mannitol (PEARLITOL®C, Roquette Pharma, Lestrem, France) was sieved 
using a set of ASTM test sieves (Endecotts Ltd., London, UK) and two sets of 45μm 
to 63μm samples were prepared. One batch was treated by silanisation of surface 
hydrophilic hydroxyl groups with hydrophobic methyl functionalities by refluxing in 
a 5%v/v dichlorodimethylsilane (440272, Aldrich, Gillingham, UK) in 
trichloroethylene (251402, Sigma-Aldrich, Gillingham, UK) solution at 80°C for 3 
hours with continuous stirring. The other batch was also treated in the same way with 
the absence of the silanising agent (dichlorodimethylsilane). The samples were then 
filtered and dried at 80°C for one week. 
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7.2.3.2 Inverse Gas Chromatography 
 
Dispersive surface energy heterogeneity was determined using a Surface 
Energy Analyser (SEA, Surface Measurement Systems Ltd., London, U.K.). 45μm to 
63μm sieve fraction non-silanised and silanised D-mannitol powders were packed into 
silanised glass columns (300 mm × 3 mm inner diameter) with silanised glass wool at 
each end to constrain the powder bed and maintain pressure difference. Each column 
was filled with approximately 1.5g of D-mannitol and then conditioned in situ in the 
SEA with helium purge at 10 sccm for 5 minutes at 30C. Pulse injections using a 
timed valve gas injection manifold at 30C were performed with n-alkane probes 
(hexane, heptane, octane, nonane, decane and undecane) (HPLC grade, Sigma–
Aldrich, Gillingham, U.K.) were injected at 1%, 2%, 3%, 5%, 7%, 10%, 12%, 15% 
and 17% and 18% surface coverage to determine the adsorption isotherms, and net 
retention volumes. A short methane gas injection (3000ms) was performed to 
determine column dead time. Helium at 10sccm was used as the carrier gas for all 
injections. Dispersive surface energy as a function of probe surface coverage was 
calculated using SMS-SEA Analysis (version 1.1, Surface Measurement Systems 
Ltd., London, U.K.). 
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7.2.4 Results and Discussion 
 
7.2.4.1 Dispersive Surface Energy Heterogeneity 
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Fig. 7.2.1 – Dispersive surface energy heterogeneity of non-silanised treated D-
mannitol sieve fraction (45m - 63m) and silanised treated D-mannitol sieve 
fraction (45m - 63m) 
 
D-mannitol was chosen as the model compound due to large number of 
hydrophilic surface hydroxyl groups which could be easily silanised with hydrophobic 
methyl groups. Previous work by Ho et al. has shown that the silanisation process 
passivates the high surface energy sites on the surface, and thus reduces the intrinsic 
heterogeneity in surface energetics (silanised D-mannitol remained 34mJm
-2
, non-
silanised D-mannitol decreased with increasing surface coverage from 49mJm
-2
 – 
40mJm
-2
) [265]. This effect is clearly shown when the experiment was repeated with 
198 
 
specific treated sieve fractions in fig. 7.2.1 where d of silanised treated D-mannitol 
remained the same at approximately 34mJm
-2 
even with increasing surface coverage 
(n/nm), whereas d of non-silanised treated D-mannitol is initially approximately 46 
mJm
-2 
and gradually reduces to approximately 40 mJm
-2 
with increasing surface 
coverage up to 18%. These differences in surface energy heterogeneity should be 
reflected by differences in macroscopic physical properties of the powders such as 
cohesiveness. 
 
7.2.4.2 Yield Stress 
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Fig. 7.2.2 – Yield curves of non-silanised treated D-mannitol (45m - 63m) and 
silanised treated D-mannitol (45m - 63m) (n = 3) 
 
Utilising the same approach discussed above for as received pharmaceutical 
powders, unconfined uniaxial compression tests (fig. 7.2.2) clearly show that the yield 
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stress of non-silanised D-mannitol was roughly more than twice that of the silanised 
D-mannitol (both being the 45μm to 63μm sieve fractions). Silanised treated D-
mannitol compacts having lower elastic modulus (gradient) and earlier yield point 
(unconfined yield strength) is in agreement with the suggestion that silanisation 
minimises the higher surface energy sites and reduces the intermolecular interactions 
(converting polar hydroxyl surface functional groups to non-polar methyl surface 
functional groups) which manifests as the cohesion phenomenon. The use of sieved 
silanised treated and sieved treated D-mannitol provided samples with identical PSD, 
powder bulk densities and particle shapes for true comparison of surface energetics 
and cohesion. This in turn enabled a high degree of confidence that the differences in 
powder mechanical properties can be directly related to the powder surface properties.  
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Fig. 7.2.3 – Elastic moduli of non-silanised treated D-mannitol (45m - 63m) and 
silanised treated D-mannitol (45m - 63m) 
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Elastic moduli of silanised treated D-mannitol and non-silanised treated D-
mannitol powder compacts of different normal/consolidation stress were calculated 
(fig. 7.2.3), with non-silanised D-mannitol compacts having increasing elastic 
modulus with increasing consolidation stress from 129Pa to 252Pa, but no significant 
change with increasing consolidation stress for silanised D-mannitol compacts, 
indicating the impact of silanisation on lowering the elastic moduli of D-mannitol.  
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Fig. 7.2.4 – Elastic potential energy of non-silanised treated D-mannitol (45m - 
63m) and silanised treated D-mannitol (45m - 63m) 
 
Elastic potential energy of silanised treated D-mannitol and non-silanised 
treated D-mannitol powder compacts of different normal/consolidation stress were 
calculated (fig. 7.2.4), with non-silanised D-mannitol compacts having increasing 
elastic potential energy with increasing consolidation stress from 343J to 1863J, but 
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less prominently with increasing consolidation stress for silanised D-mannitol 
compacts from 276J to 768J. The decrease in elastic potential energy from 343J to 
276J (19.5%) at 127kPa is comparable to the decrease in dispersive surface energy 
(26%). 
 
7.2.4.3 Cohesion 
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Fig. 7.2.5 – Shear stress versus normal stress for non-silanised treated D-mannitol and 
silanised treated D-mannitol 
 
Cohesion based on Mohr-Coulomb theory (failure criterion) was determined 
by measuring maximum shear stress at different consolidation/normal stresses 
(127kPa, 255kPa and 382kPa) to generate the linear failure envelope for both types of 
D-mannitol, where the intercept at the y axis (Y0) is cohesion (c) and angle of internal 
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friction ().  Fig. 7.2.5 shows that silanised treated D-mannitol had a cohesion value -
45.3Pa and an angle of internal friction of 0.0344º and non-silanised treated D-
mannitol had a cohesion value of 113.3Pa and an angle of internal friction of 0.1318º. 
This confirms the hypothesis that silanisation reduces the dispersive surface energy of 
the bulk powder, which consequently also reduces the cohesion of the powder and 
increases flowability as cohesion decreased by 158.6Pa (139.9%) and angle of 
internal friction by 0.0974º (73.9%). Dispersive surface energy was only reduced by 
12mJm
-2
 (26%) from 46mJm
-2
 to 34mJm
-2
. If surface specific coverage silanisation 
can be achieved, an empirical relationship could be determined between dispersive 
surface energy and cohesion.  
 
Comparatively, the cohesion values for silanised and non-silanised treated D-
mannitol (-45.3Pa and 113.3Pa respectively) were much lower than the as received 
untreated and non-sieved pharmaceutical excipient powders studied previously 
(Avicel PH-101 – 2962Pa, Starch 1500 – 1255Pa, dicalcium phosphate dihydrate – 
24567Pa and Lactohale 210 – 20137Pa). Angles of internal friction however for 
silanised and non-silanised D-mannitol sieve fractions (0.0344º and 0.1318º 
respectively) were higher compared to magnesium stearate (0.004º). This is likely due 
to internal lubrication from magnesium stearate aiding dilatancy and shear in the loose 
compact which exceeds the contribution of surface energy to cohesion as the 
dispersive surface energy of magnesium stearate as measured by infinite dilution IGC 
was approximately 50mJm
-2 
[325]. These subtle differences are most likely due to the 
narrower particle size distribution achieved through sieving as well as the intrinsic 
low cohesion of D-mannitol. The greater cohesion for non-silanised D-mannitol 
confirms the hypothesis that surface energetics has a significant contribution towards 
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the cohesion phenomenon. Literature suggests negative cohesion values are common 
and the materials are typically assumed to have zero cohesion [326]. This zero 
cohesion effect occurs when dealing with low consolidation or normal stress, where 
angle of internal friction becomes proportional to consolidation or normal stress 
[327].  
 
7.2.5 Conclusions 
 
 
A simple test derived from soil mechanics has been utilised to measure the 
cohesion of weak pharmaceutical powder compacts. Using a silanisation reaction to 
manipulate the dispersive surface energy of a model powder, powder cohesion was 
directly related to dispersive surface energy of the powder. Silanised and non-
silanised powders showed significant reproducible difference in yield stress, shear 
moduli and cohesion from the UCT test results. It has been proven to be robust 
approach suitable for a number of different common used excipient powders. 
Dispersive surface energy was found to be proportional to cohesiveness with D-
mannitol. The greater cohesion for non-silanised D-mannitol confirms the hypothesis 
that surface energetics has a significant contribution towards the powder adhesion and 
cohesion phenomenon. Further study is required on active pharmaceutical ingredients 
powder blends and mixtures, as well as other variation in particle and surface 
properties. 
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Chapter 8 Quantifying the Amorphicity of Sub-Micron Particles in 
Micronised -Lactose Monohydrate 
 
8.1 Fractionation of Milled Pharmaceutical Powders 
 
Characterising pharmaceutical powders with low levels of amorphous content 
(<10%) remains a challenge due to the lack of understanding in terms of process 
induced structural disorder and stabilisation [40]. One school of thought has been that 
generation of amorphous fine particles by micronisation has a major contribution 
towards powder instability [150]. Pharmaceutical fines and ultrafines (sub-micron) 
have a significant effect to specific surface area, active-carrier adhesion, powder 
fluidisation and dispersion but are difficult to isolate and quantify [328]. Establishing 
their physicochemical properties could explain the problematic anomalous behaviour 
post-micronisation and upon storage [60]. 
 
Existing impactor based methods have proven to be robust at determining 
inhaled product performance and fulfilling regulatory requirements [329]. The 
approach presented here utilises a novel cascade impactor design, namely micro-
orifice uniform deposit impaction (MOUDI) which has been optimised for the 
collection of sub-micron particles through selective inertial impaction (fig. 4.2.11) as 
well as a novel dispersion system – vibrating turbine aerosol generator which provide 
the potential to separate and collect fractions of pharmaceutical fines in insolation to 
allow for further analysis to determine their relative physical stability compared to the 
bulk with conventional characterisation techniques [271, 330].  
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8.2 The Role of Fines 
 
Current inhaled formulations are normally classified into two categories – 
pressurised metered dose inhaler (pMDI) formulations which consists of the active 
pharmaceutical ingredient(s) (API) dispersed and an insoluble volatile propellant 
within a pressurised container and dry powder inhaler (DPI) formulations which 
consists of a physical mixture of smaller active pharmaceutical ingredient(s) (APIs) 
particles and larger carrier particles which are aerosolised through direct human 
inspiration, making particle size control key in DPI formulations.  
 
The API in both cases is normally micronised or jet-milled from the larger 
crystalline feed to achieve a particle size of approximately 3-5m for effective lung 
delivery in the treatment of asthma and chronic obstructive pulmonary disease (Berry 
2004). The DPI carrier of choice is -lactose monohydrate in the range of tens to 
hundreds of microns, provide surfaces with optimised adhesion and entrainment 
characteristics which are well-understood and designed in conjunction with the 
delivery device.  
 
Controlling behaviour of the smaller API particles post-micronisation is the 
most challenging as subsequent agglomeration and crack propagation can result in 
increases and decreases in particle size respectively. Micronisation as well as 
introducing amorphicity also has the tendency to generate low levels of very small 
particles, ‗fines‘ which are generally considered to be less than 5m and difficult to 
detect by conventional dry dispersion laser diffraction particle sizing. 
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8.3 Materials and Methods  
 
8.3.1 Materials 
 
Silicon (IV) oxide (CAS 7631-86-9) powders (nominal size 250nm - 44885, 
500nm – L16985, 1000nm – L16986, 1500nm – L16987, Alfa Aesar from VWR, 
Lutterworth, UK) were used as received (see fig. 8.3.1). 
 
  
250nm 500nm 
  
1000nm 1500nm 
 
Fig. 8.3.1 – Silicon (IV) Oxide Powders 
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8.3.2 Aerosol Generation 
 
 A manual aerosol generation system was setup using a 20L Pyrex glass 
bottle connected with 1/4in I.D. nylon reinforced tubing to the MOUDI entry port and 
~10mg of silicon (IV) oxide powder (all particle sizes physically mixed in equal 
portions) aliquots fed using a 60ml BD syringe and a 100l pipette tip (fig. X). 
 
 
Fig. 8.3.2 – Aerosol Generation Schematic 
 
8.3.3 MOUDI Fractionation 
 
The experimental setup as shown in fig. X, where a NanoMOUDI II 125B 
(MSP Corporation, Shoreview, MN, USA) was connected to a Copley HCP5 rotary 
vane vacuum pump which pulled air through the MOUDI at 10L per minute which is 
much lower than cascade impactors or NGIs which operate between 30L-60L per 
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minute. The 47mm aluminium foil substrate (0.05mm thickness) supplied was secured 
on each fractionation stage with the provided clamp ring with no silicone adhesive 
applied. Three aliquots of sample were fed in 5 minute intervals before turning off the 
pump and sample collection. 
 
8.3.4 Scanning Electron Microscopy 
 
 A TM-1000 tabletop scanning electron microscope (Hitachi High-
Technologies Corporation, Tokyo, Japan) with a 15 kV accelerating voltage electron 
gun and a solid state backscattered electron detector was used analyse the fractionated 
powder deposit directly on the aluminium substrates. Conductive gold coating of the 
particles was applied using a K550 sputter coater (Quorum Technologies, Ashford, 
UK) at 20mA deposition current for 2 minutes in argon at 1x10
-1
mbar to give an 
approximate coating of 13nm. 
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8.4 Results and Discussion 
 
 
8.4.1 MOUDI Validation 
 
 
  
S2 – 10m S3 – 5.6m  
  
S4 – 3.2m S5 – 1.8m 
  
S6 – 1.0m S7 – 0.56m 
 
 
Fig. 8.4.1 – MOUDI Fractions of Silicon (IV) Oxide Powder Mixtures 
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 Initial trials with the manual dispersion process provided poor results in terms 
of size specific fractionation. Agglomeration of silicon (IV) oxide particles (fig. 8.4.1) 
led to large porous aggregates being collected at upper MOUDI stages. Undesirable 
particle bouncing off initial deposition collection plates affected overall collection 
efficiency. Humidifying the feed air and application of adhesives to the substrate 
would have minimised these effects but would have altered the physical properties of 
the powder of interest. An improvement in dispersion system (Vilnius Aerosol 
Generator) made no positive impact on fractionation success of silicon (IV) oxide 
mixtures. 
 
8.4.2 Optimisation 
 
 Micronised crystalline -lactose monohydrate was used as alternative to 
silicon (IV) oxide as the model poly-dispersed fine powder. Crystalline -lactose 
monohydrate (L3625, Sigma-Aldrich, Gillingham, UK) was micronised using a lab-
scale jet-mill (Jetpharma MC One, Balerna, CH) using nitrogen as the process gas at 8 
bar venture pressure and 4 bar ring pressure.   
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S2 - 10m S3 – 5.6m 
  
S4 – 3.2m S5 – 1.8m 
  
S6 – 1.0m S7 – 0.56m 
 
Fig. 8.4.2 – MOUDI Fractions of Micronised -Lactose Monohydrate (20L spacer, 
1.5bar feed pressure) 
 
Micronised -lactose monohydrate provided much more consistent data in 
terms of fractionation as seen in fig. 8.4.2. Relative size classification was achieved 
but did not match nominal cut-off sizes of the MOUDI as fractionation is based on the 
mass median aerodynamic diameter (MMAD) which takes into consideration the 
particle density and shape, as well as the physical size. Although dispersion improved, 
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powder aerosol concentration proved too high at the minimum suggested feed air 
pressure of 1.5bar.  The two size fractions collected, a larger fraction from stage 2 to 
stage 5 (10m – 1.8m) and a smaller fraction from stage 6 onwards (<1.0m), all 
stages contained agglomerates due to the excess powder input feed, making it difficult 
to qualitatively quantify primary particle size of fractions. 
 
  
S2 – 10m S3 – 5.6m  
  
S4 – 3.2m  S5 – 1.8m  
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S6 – 1.0m  S7 – 0.56m 
  
S8 – 0.32m S9 – 0.18m 
 
Fig. 8.4.3 – MOUDI Fractions of Micronised -Lactose Monohydrate (100L spacer, 
1.0bar feed pressure, 10m cyclone) 
  
A larger ‗spacer‘ device (100L in volume) with lower input compressed air 
pressure (1 bar) was deployed to aid dispersion and fractionation further improved 
collection efficiency as shown in fig. 8.4.3. A 10m cyclone was added in line to 
remove particles >10m within the bulk powder. Once again only two fractions were 
generated, ‗bulk‘ fraction (S2 – S5, 10m – 1.8m) and ‗fine‘ fraction (S6 – S9, 
1.0m – 0.18m) which were ~5m and ~1m in primary particle size. Reduced 
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micronisation efficiency with lower fluidisation energy and feed rate explained the 
lack of sub-micron fines observed.  
  
S2 – 10m S3 – 5.6m 
  
S4 – 3.2m S5 – 1.8m 
  
S6 – 1.0m S7 – 0.56m 
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S8 – 0.32m S9 – 0.18m 
 
Fig. 8.4.4 – MOUDI Fractions of Friesland DOMO Micronised -Lactose 
Monohydrate (100L spacer, 1.0bar feed pressure, no cyclone) 
 
An industrial grade micronised -lactose monohydrate (kindly donated by 
Friesland DOMO) with estimated amorphous content of ~10% was fractionated (fig. 
8.4.4). Three well-defined fractions, bulk (S2 – S4, ~10m), fine (S5 – S6, ~2m) and 
ultrafine (S7 – S9, sub-micron) were observed. The presence of the 10m cyclone 
provided no additional benefit in aiding fractionation.  
 
The maximum deposition per stage suggested by the manufacturer is 
approximately 3mg with only passive collection at 10L/minute. With no adhesive and 
dry air feed, individual stage fractions need to be combined in order to meet sample 
size requirements for conventional amorphous content determination techniques. This 
matches well with micronised -lactose monohydrate fractionation which generated 
two distinct fractions of approximately 10mg, sufficient for organic vapour sorption 
with n-octane [236].  
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8.5 Conclusions 
 
 This study demonstrated the potential of using MOUDI with effective 
dispersion and aerosol generation to fractionate micronised pharmaceutical powders 
and collect sub-micron fine particles. For micronised -lactose monohydrate, the use 
of a vibrating turbine aerosol generator and large spacer device, aided dispersion, 
aerosolisation and fine particle entrainment. Results were confirmed by scanning 
electron microscopy.  
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8.6 Physicochemical Properties of Fine Particles from Micronised 
Pharmaceutical Powders 
 
8.6.1 Introduction 
 
Drug delivery to the lung is a fast growing area of pharmaceutical research, 
both in academia and industry, with the benefit of combining both formulation and 
device design in terms of intellectual property and patenting. Traditionally it has been 
focused on local delivery for the treatment of inflammatory conditions such as asthma 
and COPD but offers the potential for systemic delivery through alveolar exchange 
which bypasses gastrointestinal metabolism and increases bioavailability. An example 
of this has been the inhaled delivery of human insulin (Exubera). As eluded 
previously, current development pipelines focuses on DPIs, which have improved 
efficacy and compliance profiles for patients. The three key industrial advantages for 
DPIs are simplicity of design, lack of need for propellant and the relative solid state 
chemical stability. 
 
Physical properties including particle size, shape and surface properties play a 
major role in directly governing delivery performance, however physicochemical 
properties determine the stability of the formulation. Inhaled API is usually much 
more potent than the oral equivalent is normally prepared by initial batch 
crystallisation followed by micronisation (jet-milling) to achieve the appropriate 
particle size distribution. Micronisation being very energy intensive process involving 
high velocity particle-particle collisions which lead to process induced structural 
disorder, which often manifests in the form of amorphisation, the specific 
mechanism(s) of which is unknown and results in physical instability, anomalous 
behaviour post-micronisation and upon storage. 
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8.6.2 Materials and Methods  
 
8.6.2.1 Materials 
 
Micronised -lactose monohydrate with estimated amorphous content of 
~10% was kindly donated by Friesland DOMO (FD). 
 
8.2.6.2 Aerosol Generation 
 
 An automated aerosol generation system was setup using a 100L BIOEAZE 
polyethylene bag connected with 1/4in I.D. anti-static rubber tubing to the MOUDI 
entry port and ~1g of micronised -lactose monohydrate fed using Vilnius Aerosol 
Generator (CH Technologies-EMMS, Bordon, UK) at 1 bar dry compressed cylinder 
air. A Casella Microdust Pro (Casella, Kempston, UK) was fitted in line to measure 
the output aerosol concentration of the VAG before connection to ‗spacer‘ bag. 
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Fig. 8.6.1 – Aerosol Generation Schematic 
 
8.2.6.3 MOUDI Fractionation 
 
The experimental setup as shown in fig. X, where a NanoMOUDI II 125B 
(MSP Corporation, Shoreview, MN, USA) was connected to a Copley HCP5 rotary 
vane vacuum pump which pulled air through the MOUDI at 10L per minute. 47mm 
diameter circular aluminium foil substrate (0.05mm thickness) was used with no 
adhesive applied. VAG was only operated for 15 minutes initially whilst the MOUDI 
was run continuously for 1 hour after VAG was stopped. 
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8.6.2.4 Scanning Electron Microscopy 
 
 A TM-1000 tabletop scanning electron microscope (Hitachi High-
Technologies Corporation, Tokyo, Japan) with a 15kV accelerating voltage electron 
gun and a solid state backscattered electron detector was used analyse the fractionated 
powder deposit directly on the aluminium substrates. The SEM was operated in low 
vacuum charge-up reduction mode; therefore no coating was required or applied to 
allow for further characterisation. 
 
8.6.2.5 Dynamic Vapour Sorption 
 
Amorphous content of MOUDI fractions were determined by organic dynamic 
vapour sorption (DVS-Advantage, Surface Measurement Systems, London, UK). 
Organic vapour partial pressures (P/P0) were generated by mixing n-octane saturated 
vapour and dry air using mass flow controllers at a total gas flow rate of 100sccm at 
25ºC. ~10 mg of sample in an aluminium pan was run using a single step method at 
0%P/P0, 90%P/P0 and 0% P/P0 for 720 minutes at each step whilst the temperature 
was controlled (±0.1ºC). 
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8.6.3 Results and Discussion 
 
  
S2 – 10m  S3 – 5.6m 
  
S4 – 3.2m S5 – 1.8m 
  
S6 – 1.0m S7 – 0.56m 
Fig. 8.6.2 – MOUDI Fractions of Micronised -Lactose Monohydrate (FD) 
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Optimised MOUDI fractionation of industrial grade micronised -lactose 
monohydrate generated three fractions, ‗coarse‘ (S2-S3), ‗fine‘ (S4-S5), ‗ultrafine‘ 
(S6-S7) which had particle sizes approximately 10m, 5m and 1m respectively 
(fig. 8.6.2). Previous results indicating deposition in lower stages (S8-S9) were due to 
particle bounce from upper stages (S6-S7) and re-entrainment due to lack of adhesive. 
Organic vapour sorption measurements of the three fractions – coarse (2.7485mg), 
fine (2.3065mg) and ultrafine (1.1507mg) indicated increasing n-octane sorption with 
decreasing in micronised -lactose monohydrate particle size. At 90% P/P0 of n-
octane, the coarse fraction had a mass change of 0.89%, the fine fraction 2.01% and 
the ultrafine fraction 5.13% (fig. 8.6.4, fig. 8.6.5 and fig. 8.6.6). Young et al. have 
shown by calibration that mass change is proportional to the amorphous content of the 
lactose sample [236]. 
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Fig. 8.6.3 – Organic DVS measurement of bulk micronised -lactose monohydrate 
(90% P/P0 n-octane) 2.4627mg 
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Fig. 8.6.4 – Organic DVS measurement of ‗coarse‘ fraction (90% P/P0 n-octane) 
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Fig. 8.6.5 – Organic DVS measurement of ‗fine‘ fraction (90% P/P0 n-octane) 
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Fig. 8.6.6 – Organic DVS measurement of ‗ultrafine‘ fraction (90% P/P0 n-octane) 
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Fig. 8.6.7 – Organic DVS measurement of amorphous spray-dried lactose (90% P/P0 
n-octane) 2.6551mg 
225 
 
Amorphous Content (%)
0 20 40 60 80 100 120
d
m
 (
%
) 
- 
R
e
f
0
2
4
6
8
10
Amorphous Spray-Dried Lactose
Coarse Fraction
Bulk Micronised -Lactose Monohydrate
Fine Fraction
Ultrafine Fraction
 
Fig. 8.6.8 – Amorphous Content Calibration Curve for Organic DVS  
 
By comparing the equilibrium maximum n-octane uptake values from the 
organic vapour sorption results of the starting feed material (bulk micronised -
lactose monohydrate), the three MOUDI fractions and also an amorphous standard 
(amorphous spray-dried lactose). Fig. 8.6.3 shows that the micronised powder had an 
uptake of ~1.01% which is similar to the coarse fraction (~0.89%) but is much lower 
than the fine (2.01%) and ultrafine (5.13%) fractions. Based on the amorphous 
standard calibration curve which had 100% amorphous content equivalent to 8.71% 
uptake, it is clear that the fine and ultrafine are ‗more‘ amorphous compared to the 
larger fractions. This significantly greater amorphicity helps to explain the physical 
instability of micronised powders and the contribution of fines to anomalous 
behaviour in particle size and surface area post-milling and upon storage.   
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In order to confirm the difference in mass change between the size fractions 
was due to amorphous character rather than specific surface area contribution. 
Validation experiments using organic DVS were conducted using the same silicon 
(IV) oxide powder in the initial MOUDI fractionation optimisation experiment. Using 
the same methodology for micronised -lactose monohydrate, sorption measurements 
were made for 0.25m, 0.5m, 1.0m and 1.5m silicon (IV) oxide powders. 
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Fig. 8.6.9 – Mass Change of Silicon (IV) Oxide Powders and Micronised -Lactose 
Monohydrate MOUDI size fractions 
  
 As shown in fig. 8.6.9, the two different powders had very different sorption 
characteristics irrespective of particle size or surface area. Based on the average 
particle size (reported by the manufacturer and determined by SEM), the approximate 
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surface area of the powders (equ. 8.6.1) were estimated using the following equation 
which assumes spherical mono-dispersed particles. 
 
   
 
  
 
 
Where SA is the surface area in m
2
g
-1
, D is the average particle size in m and 
p is the density in gcm
-3
 (silicon (IV) oxide – 2.648gcm-3, -lactose monohydrate – 
1.54gcm
-3
). 
Equ. 8.6.1 – Estimated Surface Area of Spherical Powders 
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Fig. 8.6.10 – Estimated Surface Area of Silicon (IV) Oxide Powders and Micronised 
-Lactose Monohydrate MOUDI size fractions 
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By comparing the differences in mass change (fig. 8.6.9) and surface area (fig. 
8.6.10), it is clear that surface adsorption and bulk absorption into the amorphous 
phase must both occur in the MOUDI size fractions in order to achieve the 
significantly higher n-octane uptake, which is separate from the increased surface area 
contribution to surface adsorption [279]. Therefore confirming that fine particles 
generated during micronisation are ‗more‘ amorphous than the bulk micronised 
powder. 
 
8.6.4 Conclusions 
 
This is the first known study to characterise the physicochemical properties of 
fractionated fines from micronised bulk powders in isolation. Differences in 
amorphicity between fines and the bulk powder indicate the mechanism by which 
amorphisation occurs during micronisation. Process induced structural disorder 
initially occurs at the surface of particles, followed by disruption and breakage of 
amorphous surface layer resulting in the formation of highly amorphous fine particles 
compared to the predominantly crystalline bulk particles. These fine particles had a 
relative amorphous content of ~60% (ultrafines, 1m, ~5% n-octane uptake) 
compared to the 100% amorphous standard (amorphous spray-dried lactose, ~5-
10m, ~10% n-octane uptake) which confirms the hypothesis that they will contribute 
significantly to the physical instability of micronised pharmaceutical powders post-
processing and upon storage. Surface area contribution to relative n-octane sorption 
was also considered with higher uptake of ultrafines attributed to the addition of bulk 
absorption. Further work is required to fully characterise the MOUDI fractions as well 
as other model micronised pharmaceutical powders. 
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Chapter 9 Conclusions 
 
Summary 
 
The physical properties of milled or micronised pharmaceutical powders are 
crucial to product development and manufacturing. Current approaches are unable to 
establish the stability profile post-milling and upon storage. Amorphous spray-dried 
lactose compacts have been shown to have up to 15% dimensional changes, but only 
when RH was raised above 51% RH 25ºC. The complex compact volumetric 
behaviour during water sorption consists of both shrinkage and expansion events and 
can be attributed to water sorption into the glassy and rubbery phases and amorphous-
crystalline transformation. Optical dilatometry has also been demonstrated to be 
capable of assessing the physical stability of amorphous materials by measuring 
compact dimensions, in-situ under controlled environmental conditions with sub-
micron resolution. 
 
The underlying physical instability of milled or micronised powders can be 
attributed to viscoelastic behaviour of the partially amorphous phase. Direct stress 
relaxation measurements by uni-axial indentation of amorphous indomethacin and 
felodipine glasses over a range of temperatures generated master curves which were 
found to correlate well with the universal WLF model for viscoelasticity of polymers. 
The temperature dependent changes in mechanical properties observed were due to 
the existence of only local -relaxation processes. 
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A modified unconfined compression test was proven to be reliable at 
measuring cohesion of small weak pharmaceutical powder compacts. The higher 
surface energies of milled and amorphous powders are detrimental to processing and 
handling rendering them cohesive and poor flowing. A clear relationship between 
dispersive surface energy and cohesion was determined by IGC and UCT of silanised 
and non-silanised D-mannitol which confirms the role of milling in modification of 
surface properties and contribution to powder aggregation/agglomeration post-milling 
and upon storage.  
 
Whilst external surface changes in terms of roughness and topography are 
apparent, the mechanism(s) by which milling or micronisation creates low levels of 
amorphicity remains unclear. Sub-micron fractionation of bulk micronised -lactose 
monohydrate and proceeding dynamic vapour sorption has clearly shown that 
micronisation produces highly amorphous fine particles in small quantities within the 
predominantly crystalline bulk powder. Further investigation is required in order to 
establish the role of fines in the anomalous physical changes previously observed as 
they have significant contribution to the powder surface area and adhesion 
characteristics of lactose as an API carrier in dry powder inhaled formulations. 
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Future Work 
 
 
Positrons (e
+
) were first predicted by Paul A. M. Dirac in 1928 when 
describing the electron (e
-
) using quantum mechanics and relativity [331]. They are 
the anti-particle equivalent of the e
-
, with the same mass but opposite charge. 
Positronium atoms (Ps) are formed when a positron interacts with an electron within a 
material, eventually quenching i.e. annihilating to produce two 511keV -ray photons 
back-to-back (calculated using E=mc
2
) [332]. The characteristic lifetimes and 
intensity of these annihilations can provide information on intermolecular pore size 
and relative free volume [333]. Work has been carried in the characterisation of 
amorphous pharmaceutical polymers [334]. 
 
Digital Oscilloscope 
and LabView 
Windows PC
PMT2PMT1
Start Pulse Stop Pulse
Sample (Lactose Compacts)
Source 
(
22
Na)
Scintillator Crystals
 
 
Fig. 9.1 – Schematic diagram of a positron annihilation lifetime spectrometer (PMT = 
Photo-Multiplier Tube) 
  
  A digital PALS spectrometer was developed in house as part of an ongoing 
project (Fig. 9.1) [335]. The positron source was 
22
Na prepared from aqueous 
22
NaCl 
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enclosed in Kapton film. Sample compacts were prepared by manually compacting 
approx. 100mg of chosen form of lactose at 10kN using a 10mm evacuable die and 
manual press and placed either side of the source. Spectra were collected for 24 hours 
for each sample. Relative free volume and intermolecular pore size was calculated 
using equ. 9.1 [336]. 
 
Equ. 9.1 – Intermolecular pore size (rh - radius of the pore, r - positronium potential 
wall overlap layer. fi - fraction of positronium with spin i,  λi - corresponding 
annihilation rate in vacuum) 
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Fig. 9.2 – Lifetime spectra of the different forms of lactose (inset – comparison of 
pore size (lifetime) and relative free volume (intensity)  
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  Initial results (fig. 9.2) found that relative free volume measured correlated 
with variations in molecular packing in the different lactose forms. With spray dried 
amorphous lactose found to have the highest relative free volume of the three forms 
(13.3%), followed by -lactose monohydrate (7.7%) and re-crystallised lactose 
(7.4%). In terms of intermolecular pore size (rh), spray dried amorphous lactose had 
the smallest pore size (1.44nm), followed by -lactose monohydrate (2.8nm) and 
recrystallised lactose (2.3nm). This may be explained by localised short range order 
and higher electron density in the amorphous state, resulting in shorter lifetimes of 
higher intensity compared to the crystalline forms, which had minor variations due to 
the differences in anomeric composition.  PALS proved to be a novel method for the 
study of amorphous pharmaceutical solids, with data which can be complementary to 
conventional characterisation techniques. 
 
  Further characterisation of ultrafine particles post-fractionation has also been 
proposed. Physical instability of ultrafines has been hypothesized to be attributed to 
higher vapour pressure (Kelvin equation – size dependency).  
 
  
 
  
  
    
   
 
 
 where p is the actual vapour pressure, p0 is the saturated vapour pressure,  is the 
surface tension, Vm is the molar volume, r is the radius of the droplet, R is the 
universal gas constant and T is the temperature.  Utilising Knudsen cells which obey 
mean free path requirements and a vacuum microbalance to relate mass loss to 
sublimation, a physical stability relationship can be established between particle size 
and vapour pressure. 
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